TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS

Abstract: Tricyclic compound of general formula (I) as defined herein which exhibit antagonist activity at V1 and/or V2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and process for preparing such compounds.

Description: Title: TP.ICYCLIC BENZAZEPTNE VASOPRESSIN ANTAGONISTS 1. Field of the Invention This invention relates to new tricyclic non- peptide vasopressin antagonists which are useful in treating conditions where decreased vasopressin levels are desired, such as in congestive heart failure, in disease conditions with excess renal water reabsorption and in ccnditions with increased vascular resistance and coronary vasoconstriction. 2. Background of the Invent.ion Vasopressin is released from the posterior pituitary either in response to increased plasma os olarity detected by brain osmoreceptors cr decreased blood volume and blood pressure sensed by low-pressure volume receptors and arterial baroreceptors. The hormone exerts its action through two well defined receptor subtypes: vascular Vi and renal epithelial V2 receptors. Vasopressin-inauced antidiuresis, mediated by renal epithelial V2 receptors, helps to maintain normal plasma osmolarity, blood volume and blood pressure. Vasopressin is involved in some cases of congestive heart failure where peripheral resistance is increased. Vi antagonists may decrease systemic vascular resistance, increase cardiac output and prevent vasopressin induced coronary vasoconstriction. Thus, in conditions with vasopressin induce increases in total peripheral resistance and altered local blood flow, Vχ~ antagonists may be therapeutic agents. Vi antagonists may decrease blood pressure, induced hypotensive effects and thus be therapeutically useful in treatment of some types of hypertension. The blockage of V2 receptors is useful in treating diseases characterized by excess renal reabsorption of free water. Antidiuresis is regulated by the hypothalamic release of vasopressin (antidiuretic hormone) which binds to specific receptors on renal collecting tubule cells. This binding stimulates adenylyl cyclase and promotes the cAM?-mediated incorporation of water pores into the luminal surface of these cells. V2 antagonists may correct the fluid retention in congestive heart failure, liver cirrhosis, nephritic syndrome, central nervous system injuries, lung disease and hyponatremia. Elevated vasopressin levels occur in congestive heart failure which is more common in older patients with chronic heart failure. In patients with hyponatremic congestive heart failure and elevated vasopressin levels, a V2 antagonist may be beneficial in promoting free water excretion by antagonizing the action of antidiuretic hormone, On the basis of biochemical and pharmacological effects of the hormone, antagonists of vasopressin are expected to be therapeutically useful in the treatment and/or prevention of hypertension, cardiac insufficiency, coronary vasospasm, cardiac ischemia, renal vasospasm, liver cirrhosis, congestive heart failure, nephritic syndrome, brain edema, cerebral ischemia, cerebral hemorrhage-stroke, thrombosis-bleeding and abnormal states cf water retention. The following prior art references describe peptide vasopressin antagonists: M. Manning et al., J. Mad. ifim., 22, 382(1992); M. Manning et al. , J. Med. Chem.. 35. 3895(1992); K. Gavras and B. Lammek, U.S. Patent 5,070,187 (1991); M. Manning and W.H. Sawyer, U.S. Patent 5,055,448(1991) F.E. Ali, U.S. Patent 4,766,108(1988); R.R. Ruffolo et al. , Drug News and Perspective. 4(4), 217, (May) (1991) . P.D. Williams et al., have reported on potent hexapeptide oxytocin antagonists [J.. Med. Che .. 35 r 3905(1992)] which also exhibit weak vasopressin antagonist activity in binding to Vi and V2 receptors. Peptide vasopressin antagonists suffer from a lack of oral activity and many of these peptides are not selective antagonists since they also exhibit partial agonist activity. Non-peptide vasopressin antagonists have recently been disclosed, Y. Yamamura et al., Science. 211, 579(1991); Y. Yamamura et al . , fit. 1- Pharmacol. 105. 787(1992); Ogawa et al., (Otsuka Pharm Co., LTD.) EP 0514667-A1; EPO 382185-A2; WO9105549 and U.S.5, 258,510; WO 9404525 Yamanouchi Pharm.Co. ,Ltd. , WO 9420473; WO 9412476; WO 9414796; Fujisawa Co. Ltd., EP 620216-A1 Ogawa et al, (Otsuka Pharm. Co.) EP 470514A disclose carbostyril derivatives and pharmaceutical compositions containing the same. Non-peptide oxytocin and vasopressin antagonist have been disclosed by Merck and Co.; M.G. Bock and P.D. Williams, EP 0533242A; M.G. Bock et al., EP 0533244A; J.M. Erb, D.F. Verber, P.D. Williams, EP 0533240A; K. Gilbert et al., EP 0533243A. Premature birth can cause infant health problems and mortality and a key mediator in the mechanism of labor is the peptide hormone oxytocin. On the basis of the pharmacological action of oxytocin, antagonists of this hormone are useful in the prevention of preterm labor, B.Ξ. Evans et al. , - Ms...... Chem. 22., 3919(1992), ^. ≤ώ- Chem.. 36. 3993(1993) and references therein. The compounds of this invention are antagonists of the peptide hormone oxytocin and are useful in the control of premature birth. The present invention relates to novel tricyclic derivatives which exhibit antagonist activity at Vi and/or V2 receptors and exhibit in vivo vasopressin antagonist activity. The compounds also exhibit antagonist activity at oxytocin receptors. SUMMARY OF THE INVENTION This invention relates to new compounds selected from those of the general formula I: Formula I Wherein Y is (CH2)n. 0, S, NH, NCOCH3, N-lower alkyl (C1-C3), CH- lower alkyl (C1-C3) , CHNH- lower alkyl (C1-C3), CHNH2, CHN [lower alkyl (C1-C3H2, CHO-lower alkyl (C1-C3) , CHS-lower alkyl (C1-C3) , wherein n is an integer from 0-2: A-B is wherein m is an integer from 1-2, provided that when Y is -(CH2)n~ and n=2, m may also be zero and when n is zero, m may also be three, provided also that when y is -(CH2)n a n n is 2, may not also be two. Ri is hydrogen, halogen (chlorine, bromine, fluorine, iodine), OH, -S-lower alkyl (C1-C3) , -SH, -SO lower alkyl (C1-C3) , -Sθ2~lower alkyl (C1-C3) , -CO-lower alkyl (C1-C3) , -CF3; lower alkyl (C1-C3) ; O-lower alkyl (C1-C3) , -NO2, -NH2, -NHCO lower alkyl (C1-C3) , - N-[lower alkyl (C1-C3) ]2. -SO2NH2; -SO2NH lower alkyl (C1-C3) or -SO2N[lower alkyl (C1-C3) ] 2 ! R2 is hydrogen, Cl, Br, F, I. -OH, lower alkyl (C1-C3) , O-lower alkyl (C1-C3) , cr Ri and R2 taken together are methylenedioxy or ethylenedioxy; R3 is the moiety: O II -CAr wherein Ar is a moiety selected from the moiety R4 is hydrogen, lower alkyl (C1-C3) ; -CO-lower alkyl (C1-C3) ; R5 and R7 are selected from hydrogen, (C1-C3) lower alkyl, (C1-C3) lower alkoxy and halogen; R is selected from (a) moieties of the formula: -NCOAr', - NCON-Ar, -NCO(CH,, -cycloalkyl, i i I i i. V R R. R. R H -N50 2-bwe- a lkvl(C -,* π , a Ike iv * 1(C J, _ 0_ ) R. R. o -NH-C-O-lower alkyl(C -C straight or branched O II -NH-C-iovver alkyl(C 3 -C 8 )straight or branched, O II -NH-C-O-lower alkenyl(C 3 -C 8 )straight or branched, O II -NH-C-lower alkenyl(C 3 -C 8 )straight or branched, wherein cycloalkyl is defined as C3 to Cβ cycloalkyl, cyclohexenyl cr cyclopentenyl; R a is hydrogen, CH3 , C2H5, moieties of the formulae: -(CH j i-N^ - ( CH^-N^/ , \ X - (CH2) 2θ-lower alkyl (C1-C3) or -CH2CH2OH; q is one, two or three; R s hydrogen, CH3 or -C2H5; (b) a moiety of the formula: -X-Rχθ; wherein Rio s lower alkyl (C3-C8 ) , lower alkenyl (C3-C8) , - ( CH2 ) p-cycloalkyl ( C3-C6 ) , and p is zero to three: X is 0, S, NH, NCH3, C= O or a bond / and R5 and R7 are as previously defined (c) a moiety of the formula: R- - N- COJ wherein J is R a , lower alkyl (C3-C8) branched or unbranched, lower alkenyl (C3-C8) branched or unbranched, -lower alkyl (C3-C8) branched or unbranched, -O-lower alkenyl (C3-C8) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties or -CH2- ' wherein K' is halogen, -OH, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety: -N E \ / G=F wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen- (C1-C3) lower alkoxy, -CO-lower alkyl ( -C3) , CHO. (Cι~C3)lower alkoxy, -CO2-lower alkyl (C1-C3 ) , and F. a and Rfc, are as hereinbefore defined; (d) a moietv selected from those of the formulae: R N- COCIiΛr R O -O-C-lowe. nlkvKC.-C3) , -S-lower alk KC j -Cg) ■ R_ (CHΛ- N Λ NH.CH - CON X R_ R. HCH j ) N - 0- (CH J N \ R, X wherein F. is selected from halogen, (C1-C3) lower alkyl -O-lower alkyl (C1-C3) and OH, Rfc. iε as hereinbefore defined; Ar ' is a moietv selected from the orouo ■10- SUBSTΓΓUTE SHEET (RULE 26) R8 and R9 are independently hydrogen, lower alkyl (C1-C3); O-lower alkyl (C1-C3 X S-lov;er alkyl (C1-C3) , -CF3, -CN, -OH, -SCF3, -OCF3, halogen, O2, amino cr NH lower alkyl (C1-C3) , -N- [lower alkyl (C1-C3) ]2- -N ( Rb ) ( CH2 ) q-N ( Rb ) 2 ; W is 0, S NH, N-lower alkyl (C1-C3) , NCO-lower alkyl (C1-C3) or SO2-lower alkyl (C1-C3) or NS02lower alkyl ( C1-C3 ) R25 is selected from the moieties and the moiety represents: (1) phenyl or substituted phenyl optionally substituted by one or two substituents selected from (C1-C3) lower alkyl, halogen, amino, (C1-C3) lower alkoxy, cr (C1-C3) lower alkyl amino; (2) a 5-membered aromatic (unsaturated) heterocyclic ring having one heteroato selected from 0, N or S; (3) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom; (4) a 5 or 6-membered aromatic (unsaturated) heterocyclic ring having two nitrogen atoms; (5) a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom together with either one oxygen or one sulfur atom; wherein the 5 or 6-membered heterocyclic rings are optionally substituted by (C1-C3) lower alkyl, formyl, a moiety of the formula: - (CH 2 ) α N q \ halogen or (C1-C3) lower alkoxy. For example, the fused heterocyclic ring may be represented by furan, pyrrole, pyrazole, thiophene, thiazole, oxazole, imidazole, pyrimidine or pyridine ring which may be substituted or unsubstituted. DETAILED DESCRIPTION OF THE INVENTION Within the group of the compounds defined by Formula I, certain subgroups of compounds are broadly preferred. Broadly preferred are those compounds wherein R3 is a moiety: O II CAr and Ar is selected from the moiety: wherein R5, R6 and R7 are as hereinbefore defined. Especially preferred are compounds wherein R3 is the moiety: O II -CAr and Ar is selected from the moiety: R6 i s NHCOAr ' and Ar ' is wherein Rs. P-9, P25 and ' are as hereinbefore defined. Also especially broadly preferred are compounds wherein Y in Formula I is -(CH2)n _ and n is zero or one; A-B is and R4 , R5 , R6- P-7 « F-8. R9 and Rio are as hereinbefore defined; and m is an integer from 1-2. The most broadly preferred of the compounds of Formula I are tliose wherein Y is -(CH2)n~ an n is one; A-B is -(CH 2 ) m " ( CH 2) m ' m is one or two R3 is the moiety: O II -CAr Ar is NHCOR jj and R6 is -NCOΛr ' , or -NCOCH, Λr ' , -NCON -Ar' R. R. R *b -NCO(CH ) „ -cycloalkyl, -X-R 10 R and Ar ' is a moiety Cycloalkyl R a . R and W are as previously defined and R8 and R9 are preferably ortho CF3, Cl, OCH3, CH3, SCH3 or OCF3 substituents or Ar' is a disubstituted derivative wherein R8 and R9 are independently Cl, OCH3 , CH3 and F. The most highly broadly preferred of the compounds of Formula I are those wherein Y is -(CH2)n~/ n is zero or one and the moietv Z represents a phenyl, substituted phenyl, thiophene, furan, pyrrole or a pyridine ring; A-B is m is one when n is one and m is two when n is zero; R3 is the moiety: O II - CAr wherein Ar is NHCOR B and and R6 is selected f rom the group R -N COAr', - 3XH 2 Ar where Ar' is selected from the moieties: and R a , Rb- Rl , R2. &4 , R5. R 6- R7- R8- R°, R25 and W are as previously defined. Most particularly preferred are compounds of the formulae: wherein m is an integer one or two; Ri and R2 are as previously defined; P,3 is the moiety: O II -CAr wherein Ar is selected from moieties of the formulae: R6 is -NCOAr', NCO(CH 2 ) n cycloalkyl, R R - OCH 2 Ar', -X-R ]0 wherein cycloalkyl is defined as C3-C6 cycloalkyl, cyclohexenyl or cyclopentenyl and wherein Ar' is selected from the moieties: R„ R a is independently selected from hydrogen, CH3 or -C2H5; and R5, R7, R8< R 9- Rl0< R 25- X and W are as hereinbefore defined. Also particularly preferred are compounds of the formulae: wherein m is an integer one or two; Ri and R2 are as previously defined; R3 is the moiety: O II -CAr wherein Ar is selected from moieties of the formulae: 6 is NCOΛr', NCO(CH 2 ) n cycloalkyl, R. R. NCONΛr ' , NCOCH 2 Ar', -X-R 10 - R. R.. R. o II -NH-C-O-lower alkyl(C 3 -C 8 )straight or branched O II -NH-C-lower alkyl (C 3 -C 8 )straight or branched, O II -NH-C-O-lower alkenyl(C 3 -C 8 )straight or branched, O II -NH-C-loweralkenyl(C 3 -C 8 )straightorbranched, wherein cycloalkyl is defined as C3 to Cg cycloalkyl, cyclohexenyl or cyclopentenyl and wherein Ar' is selected from the moieties: R„ Ra is independently selected from hydrogen, CH3 or - C2H5; and R5, R7 , Rζ , R9» l0» R 25> x and W are as hereinbefore defined. Compounds of this invention may be prepared as shown in Scheme I by reaction of tricyclic derivatives of Formula 2a and 2h with a substituted or unsubstituted 6-nitropyridine-3-carbonyl chloride to give the intermediates 2a. and 2 . Reduction of the nitro group in intermediates 2a and 2 gives the β-amino-3- pyridinylcarbonyi derivatives a and £ . The reduction of the nitro group in intermediates a. and 2 may be carried out under catalytic reduction conditions (hydrogen-Pd/C; Pd/C-hydrazine-ethanol) or under chemical reduction conditions (SnCl2~ethanol; Zn-acetic acid; TiClβ) and related reduction conditions known in the art for converting a nitro group to an amino group. The conditions for conversion of the nitro group to the amino group are chosen on the basis of compatibility with the preservation of other functional groups in the molecule. Reaction of compounds of Formula £a and Jab. with aroyl chlorides, heteroaroyl chlorides, aryisulfonyl chlorides, diarylphosphinyl chlorides, diphenoxyphosphinyl chlorides, alkyl (C3-C8) carbonyl chlorides, alkenyl (C3-C8) carbonyl chlorides, alkoxy (C3-C8) carbonyl chlorides, alkenyloxy (C3-C8) car¬ bonyl chlorides, alkyl (C3-C8) sulfonyl chlorides, alkenyl (C3-C8) sulfonyl chlorides cycloalkylcarbonyl chlorides, arylcarbamoyl chlorides or heteroaryl- carbamoyl chlorides as illustrated in Scheme 1, gives the novel compounds 2 and £b_ of this invention. The reactions may be carried out in solvents such as chloroform, dichloromethane, dioxane, tetrahydrofuran, toluene and the like in the presence of a tertiary base such as triethylamine, diisopropylethylamine or pyridine at 0°C tc 50°C. If more than one aroyl, heteroaroyl or aryisulfonyl group, etc. is introduced during the reaction, mild base treatment (NaOH, KOH etc.) in a lower alkancl removes the second such group to give the products 2a and ≤b_. Scheme 1 20 NO, NO„ 5a 5b Scheme 1 (Cont'd.) OCI as fib -NHCOAr'; -NHCONAr'; -NHCO(CH 2 ) n cycloalkyl; ft -NHCOCHgAr' Scheme 1 (Cont'd.) 6a £b fia fib Scheme 1 (Cont'd.) Rg = -NHCOalkenyl(C 3 -C 8 ), -NHCOalkyl(C 3 -C 8 ) , - NHC0 2 alkyl(C 3 -C 8 ). - NHS0 2 alkyl(C 3 -C 8 ) , -NHC0 2 alkeπyl(C 3 -C 8 ) -NHS0 2 alkenyl(C 3 -C 8 ) Reaction of tricyclic derivatives of Formula 6a and £b_ with either a carbamoyl derivative 2 or a isocyanate derivative lϋ gives compounds (Scheme 2) of Formula 11a and lib which are vasopressin antagonists and/or oxytocin antagonists of Formula I wherein Rg is -NHCONAr' and Rb is H, CH3 or C2H5 . Scheme 2 fib Reaction of tricyclic derivatives of Formula 3a and h with a 6-chloro or a 6-f luoropyridinine-3- carbonyl chloride 12 gives intermediates 13a and 13b (Scheme 3 ) . Scheme 3 12 The intermediates 13a and 13b may be reacted with RioX- ( 4.) wherein Rio is as previously defined and X is 0, S, NH or NCH3 to give derivatives of 15a and 15b as shown in Scheme 4. Scheme 4 13A ιab 0 15a 15b The compounds of Formula I wherein Y, A-B, Z, Rl , R2 and R3 are as defined and the R3 (-COAr) aryl group is wherein Rg is as previously defined may be prepared as shown in Scheme 5 by first synthesizing the pyridinyl moieties 22 which are to be attached to the tricyclic benzazepine units. 16 The preformed pyridinyl moieties 22 may be activated for coupling by reaction with peptide coupling reagents or preferably activated by conversion to the pyridine-3-carbonyl chlorides 12. The coupling may be carried out in inert solvents such as chloroform, dichloromethane, tetrahydrofuran, dioxane, toluene and the like in the presence of a tertiary amine such as triethylamine. The reactions may also be carried out in pyridine and related alkyl pyridines. Scheme 5 3a 2b The starting materials 3_a and 2 in Scheme 1 can be made by literature methods. For example, intermediate 6, ll-dihydro-5H-dibenz [b, ejazepines and substituted derivatives are prepared according to literature procedures: L.H. Werner, et al., J. ϋfid. Chem..8.74-80 (1965); A. .H. Wardrop et al . , J. Chem. Soc. Perkins Trans I. 1279-1285 (1976) . Substituted 5, 11-dihydrodibenz[b,e]azepin-6- one are prepared by literature procedures: J. Schmutz et al., Helv. Chi . Acta., 4J 336 (1965); and reduced to substituted 6, il-dihydro-5H-dibenz [b,e] azepines with lithium aluminum hydride, borane, borane-dimethylsulfide and agents know to reduce an amide carbonyl to a methylene group. Intermediate 10,11- dihydrodibenz [b, f] [1, 4 ] thiazepines are prepared by literature procedures - for example, see K. Brewster et al., il_ Chem. Soc. Perkin I, 1286 (1976) . Reduction of either dibenz [b, f] [1, ] oxazepines [A.W.H. Wardrop et al., J. Chem. Soc. Perkin Trans. I, 1279 (1976)] and dibenz [b,f] [l,4]oxazepin-li(10H) -ones and diben [b, f] [1, ]thiazepin-li (10K) -ones - J . Schmutz et al., Helv. Chim. Acta..48, 336 (1965); may be carried cut with lithium aluminum hydride in inert solvents such as dioxane and the like. The tricyclic 6, 7-dihydro-5H- dibenz [b,d] azepine intermediates of Formula 22 . may be prepared by the literature procedures: T. Ohta et al., Tetrahedron Lett.. 22, 5811 (1985); Wiesner et al. , J. Amer. Chem. Soc.. 22, 675 (1955) ; or derivatives may be prepared by coupling procedures illustrated in Scheme 7. The reduction of nitro compounds of structure type 22 followed by ring closure, affords iactams .3.2 which are reduced to give tricyclic azepines of Formula 33. 5, ll-Dihydrc-6H-pyrido [3, 2-c [1]beπzazepines are prepared by literature procedures - J. Firl et al., liebiσs Ann. Che . 469, (1989) . llfi-Pyrido [2, 3- b] [1, ]benzoaiazepin-β (5H) ones have been reported by J.F.F. Liegeois et al. , 2 - Mad- Chem 36. 2107 (1993) and these derivatives are reduced to llϋ-pyrido[ [2, 3- b] [1, 4]benzodiazepines. The synthesis of tricyclic 1,4,5, 10-tetrahydropyrazolo- [4, 3-c] [1]benzodiazepine and the 3-chloro derivative have been reported - G. Palazzinc, et al., 2- Heterocyclic Che .. 22, 71 (1989) . 4, 10-Dihydro-5H-thieno [3, 2-£j [1]ben∑azepine 21a and 9, 10-dihydro-4H-thieno [2, 3-cJ [ 1]benzazepine 2_1____ may be prepared by coupling tributyltin derivatives 1_9_ and 20 with 2-nitrobenzyl bromide in the presence of tetrakis (triphenylphosphine) palladium(0) as shown in Scheme 6. Following coupling cf intermediate 4 to give the tricyclic azepine 22, the nitro group is reduced to give the 6-aminonicotinoyl derivative 2 ' The derivative 2 is then reacted with the appropriate acid chlorides as illustrated in Scheme 2 to give the products 22 and 27a. Also depicted in Scheme 7 is the synthesis of intermediate tricyclic azepine 22 and 22 - The tricyclic lactam derivatives 22 and 22 may be prepared by reduction of nitro intermediates 22 and 22, followed by ring closure of the corresponding amino derivatives. These tricyclic lactam intermediates 22 and 22 may be reduced with lithium aluminum hydride (LAH) or borane to give the tricyclic azepines 22 and 33. Scheme 6 H + Zn: HOAc 21a 21b Scheme 7 BHLS(CHL 3)' 2 23 22 2£ Scheme 7 (Continued) Scheme 7 (Continued) a = NHR 11a O 27a II alkyl(C 3 -C 8 )0-C- alkenyl(C 3 -C 8 )CO- alkenyl(C 3 -C 8 )COCO- alkyl(C 3 -C 8 )S0 2 - alkenyl(C 3 -C 8 )S0 2 - Scheme 7 (Continued) ure 32 32 2 24 Tricyclic intermediates 42 for the synthesis of selected vasopressin antagonists of this invention wherein Y in Formula I is -CH2- and m is one, may be prepared as shown in Scheme 8. Suitable l-nitro-2- chloro or l-nitro-2-bromo heterocycles 22 undergo halogen exchange when reacted with a alkyllithium reagent such as t-butyllithiuin, s-butyllithium or n- butyllithiu to give intermediates 22. which react with anhydrides of Formula 22 - Rl2 i s £_£-____.-butyl, secondary butyl, n-butyl, 2, 6-dimethylpiperidine or a hindered non-nucleophilic dialkylamine. The nitro products 3_£ are reduced with hydrogen and a suitable catalyst or chemically reduced (Zn-acetic acid, TiCl3 etc.) to the amino intermediates 1Q.. Ring closure to the cyclic lactams 41 is conveniently carried out by heating in xylene or an inert solvent at 100 C C to 200°C. The cyclic lactams of structure type 4 are readily reduced by borane in tetrahydrofuran, borane-dimethylsulfide in tetrahydrofuran or lithium aluminum hydride in a suitable solvent such as dioxane to give the tricyclic compounds 42.• Alternatively phenyllithium derivatives 37b. which are prepared by lithiation of protected benzaldehyde derivatives or by lithiation of 2-chloro or 2-bromo protected benzaldehyde derivatives, are reacted with derivatives 38b wherein 2 is as previously defined. Derivatives 38b are prepared by standard procedures such as ring closure of l-amino-2-carbcxy heteroaromatic compounds or l-amino-2-benzoic acid derivatives, with acetic anhydride (Scheme 8) . Scheme 8 4(3 4β 41 42 Alternatively, as shown in Scheme 9, some of the tricyclic derivatives of structural type 42. may be prepared by "palladium" type coupling or "copper" induced coupling of halogenated derivatives 4 . to give tricylic lactams L . Reduction of the lactam carbonyl group gives the intermediates 42- Coupling of halogen derivatives 45 to effect ring closure with activated copper or "palladium' type reagents which induce aryl coupling gives lactams 42.. Borane reduction of lactams 46 gives derivatives 42- Ull ann cross couplings of halogenated hetterocycleε and 2-bromonitrobenzenes and related cross couplings by low valent palladium species such as [Pd(PPh3)4] and PdCl2(PP 3)2 are known synethetic procedures; N. Shi izu et al . , Tetrahedron Lett. 34, 3421 (1993) and references therein; N. M. Ali et al . , Tetrahedron, 37, 8117 (1992) and references therein; J. Stavenuiter et al., Heterocycles, 2£ 2711 (1987) and references therein. Scheme 9 45 Tetrahydro-lH-l-benzazepin-5-ones 21 and the tetrahydro-lH-l-benzazepin-2, 5-diones 22 . are useful compounds for the synthesis of intermediate tricyclic heterocyclic structures 22 and 1 (Scheme 10) . The tetrahydrobenzazepin-5-σnes 51 and 5 may be formulated to give hydroxymethylene derivatives or reacted with either the Vils eier reagent or the N, N- dimethylformamide dimethyl acetal to give the dimethylaminomethylene derivatives. The construction of heterocyclic rings from a-hydroxymethyleneketones by reactions with hydrazine, N-methylhydrazine, hydroxylamine or formamidine to give pyrazoles, N- methylpyrazoles, oxazoles or pyrimidines respectively, is a standard literature procedure. See Vilsmeier formylation - Tetrahedron. 1, 4015-4034 (1993) and references therein and ring formations - J.Heterocyclic Che . , 29. 1214 (1992) and references therein. Substituted and unsubstituted tetrahydrobenzazepin-2-ones are known compounds which are prepared by reaction of a-tetralones with sodium azide under acidic conditions. [^2. Chem. Soc. 456 (1937); Tetrahedron 49. 1807 (1993) ] (Schmidt reaction) . Reduction of tetrahydro-lH-benzazepin-2-ones gives the tetrahydro-lH-ben∑azepines 4U which acylation gives compounds 2 - Oxidation of N-acyl tetrahydro-lH- benzapines of type to give the 5-one derivatives is a known oxiaative procedure; R. L. Augustine and W. G. Piersoπ, 2 - ∑α. Chem.. 2A, 1070 (1969) . The synthesis of 3, 4-dihydro-lϋ-l-benzazepine- 2,5-diones (5_2:Ri5=H) has been reported as well as the conversion cf 3, 4-dihydro-l£-l-benzazepine-2, 5-diones to 4- [ (dimethylamino)methylene] -3, 4-dihydro-lϋ-l- benzazepine-2, 5-diones with ., N-dimethylformamide, dimethylacetal : [VI.-Y. Chen and N. W. Gilman, J.. Heterocyclic Chem., 20. 663 (1983)] . The preceding reference describes the synthesis of 2-methyl-5, 7- dihydropyrimido [5, 4-d [1]benzazepir.-6 (6ϋ) -ones which may be reduced tc remove the lactam carbonyl group to give tricyclic derivatives cf structural type 2A wherein Z is a pyrimidine ring. Scheme 10 KMnO, (Continued) Scheme 10 (Cont'd.) 10 2 (R 15 = H) 51 30 53 54 Scheme 11 2a 2b 5£h 35 Scheme 11 (Cont'd.. 35 The compounds wherein the aryl group in the R3 moiety -COAr is are prepared as shown in Scheme 11. The tircyclic derivatives 2a and 2h are reacted with a substituted or unsubstituted 4-nitrobenzoyl chloride 22 to give the derivatives 56a and 5 b. Reductions of the nitro group in derivatives 56a and 56b gives the 4-aminobenzoyl intermedites 5 " ?3 and 57b which are then reacted with an acid chloride represented by formula 22 to give the products 59a and 59b. The compounds wherein the aryl group in the R3 moiety -COAr is are prepared by reactin of tricyclic azepines 2a and 2 with a substituted benzoyl chloride illustrated by- structural formula 2 (Scheme 12) to give the products 61a and 61b. In a similar manner reaction of heteroaroyl chlorides 22, 22, or 2A. with the tricyclic azepines 2a and gives the products 65a and 65b wherein the aryl groups are as illustrated in Scheme 13. Scheme 12 2a 2b 60 61a 61b Scheme 13 ££s 65b Reference Example 1 6. ll-Dihvdro-5H-dibenz.b.e)azepine A mixture of 48.52 g (0.20 mol) of 2- aminobenzophenone-2 ' -carboxylic acid and 500 ml of xylene is refluxed for 67 hours, cooled to room temperature and filtered. The solid is washed with xylene to give 43.3 g (97.8%) of Stf-dibenz[Ja,≤)azepine- 6,11-dione as light tan crystals, m.p. 245-248°C. To 4.46 g (0.020 mol) of the preceding compound in 25 ml of tetrahydrofuran is added 12 ml (0.12 mol) of a 10 molar solution of boron-dimethylsulfide in tetrahydrofuran. An additional 10 ml of tetrahydrofuran is added and the mixture is stirred overnight and then is refluxed (solids dissolve) for 4 hours. The solution is cooled and 15 ml of methanol added dropwise. The mixture is concentrated under vacuum, 50 ml of 2H sodium hydroxide is added and the mixture refluxed for 2 hours. The solid is filtered, washed with water, air dried and extracted with dichloromethane. The extract is dried (Na2Sθ4) and the solvent removed to give 3.25 g (83%) of crystals, m.p. 117-122°C. Peference E a pl 2 2-Chloro-5H-diber.z fb. l azepine-6.11-dione Chlorine gas is bubbled into a mixture (partial suspension) cf 1.0 g (450 mmol) of 5H- dibenz [b, e] -azepine-6, 11-dione in 50 ml of glacial acetic acid. The temperature cf the mixture rises to 38°C. On standing, as the temperature of the solutions decreases, a white solid precipitates. The mixture is filtered to give 0.40 g of solid (mixture of starting material and product in ratio of 1:8) . The filtrate on standing gives 0.10 g cf product as crystals, m.p. 289- 293°C. Reference Example 3 10.11-Dihvriro-N.M-dimethvldibenzrb. fl r1.41 o.xa2epine-2- sulfonamide To 5.88 g of 10, 11-dihydro-N,N-dimethyl-11- oxodibenz [b, f] [1, 4] oxazepine-2-sulfonamide in 5 ml of tetrahydrofuran is added 20 ml of a molar solution of borane-dimethylsulfide in tetrahydrofuran. The mixture is stirred overnight and then refluxed for 2 hours. The mixture is chilled, diluted with 10 ml of methanol and then concentrated, methanol added again and the mixture concentrated. To the mixture is added 20 ml of 2N NaOH and the mixture refluxed for 2 hours. The mixture is extracted with dichloromethane, the extract dried (MgSO_5) and filtered. The filtrate is passed through a thin pad of hydrous magnesium silicate and the pad washed with dichloromethane. The filtrate is concentrated to give 4.8 g of crystals, m.p. 99-102°C. Recrystallization from diisopropylether-dichloromethane gives 3.96 g of crystals, m.p. 109-110°C. Mass Spectrum (FAB) 305 (M + H) .Anal.Calc'd. for Ci5Hi6N2θ3S:C,59.2; H,5.3; N,9.2; S,10.6. Found: C,57.6; H,5.2; N,8.9; S,10.1. Reference Example 4 2-Chloro-5. -dihvdrophenanthridine To a hot (70°C) solution cf 2.62 g (17 mmol) of 6 (5K) -phenanthridinone in 120 ml of acetic acid is added chlorine gas for 10 minutes. The solution is allowed to cool to room temperature and the mixture filtered. The crystals are filtered to give 1.35 g of crystals, m.p. 310-318°C. To the preceding compound (1.57 g) in 25 ml of tetrahydrofuran is added 12 ml of a 10 molar solution of boron-dimethylsulfide in tetrahydrofuran. The mixture is refluxed for 18 hours, cooled and 15 ml of methanol is added. The mixture is concentrated under vacuum and 50 ml of 2 N sodium hydroxide added. The mixture is refluxed for 2 hours and the solid filtered off and washed with water and air dried to give the product as a solid. Reference Example 5 Q -Chloro-5H-dibenzfb.eiazepir.-6.11-dione A mixture of 11.15 g of 5ϋ-dibenz [b,e] ∑epin- 6,11-dione and 600 mi of glacial acetic acid is heated on a steam bath until the solid dissolves. To the solution (70°C) is added chlorine gas. Chlorine is bubbled throughout the solution until a precipitate begins tc form. The mixture is allowed to cool to room temperature and is filtered to give 7.3 g of product, m.p. 290°C to 295°C. Reference Examc.g 6 Q -Chloro-6.ll-dihvdrc-5H-dibep.zrb, el azepine To a mixture of 7.28 g 9-chloro-5ϋ-dibenz- [b,e]azeρin-6, il-dione in 25 mi cf tetrahydrofuran under argon is added 8.5 ml of 10 molar boron-dimethylsulfide in tetrahydrofuran. The mixture s stirred 18 hours at room temperature, 30 ml of tetrahydrofuran added and the mixture refluxed for 3 hours (solids dissolved) . The solution is cooled to room temperature and 25 ml of methanol added dropwise. The volatiles are removed under vacuum. To the residue is added 100 ml cf 2 N NaOH. The mixture is refluxed overnight and filtered. The solid is extracted with dichloromethane and the extract is washed with 2- N citric acid, water and dried (Na2Sθ ) . The solvent is removed to give 4.2 g of solid which is triturated with ethyl acetate-hexane (1:2) to give crystals, m.p. 137°C to 141°C. Reference Example To a mixture of 3.3 g cf 1C, 11-dihydro-ll- oxodibenz [b, f] [1, 4]t iazepine in 25 ml of tetrahydrofuran is added 4.0 mi cf 10 molar borane- dimethylsulfide in tetrahydrofuran. The mixture is stirred at room temperature for 18 hours, 50 ml of anhydrous methanol added and the solvent removed. An additional 30 ml of methanol is added and the solvent removed to give white crystals. A sample is purified by chromatography on silica gel with hexane-chloroform- ethyl acetate (2:1:1) as solvent to give white crystals, m.p. 145-148°C. The following compounds are prepared as described in Reference Example 7. Reference Example 8 4-Me hvl-lQ.1l-dihvdrodibenzfb.fi fl . . hiazeoine Reference Example 9 4-C _oro-10.::-dihvdrodibenzfb. fi '1. λthiazeoine Reference 10 Reference Example 11 2-^hlorc-10.11-dihvdrodibenzrb. fl fl. 1thiazeoine Reference Example 12 2-Me hoxvl .11-dihvdrodibenz fb.fl r1.41 hiazeoine Reference Example 13 fi-Chloro- 0.11-dihvdrodibenz fb. fi r l . 1 hiazepine Reference Example 14 4.8-Dichloro-l n .1 -dihvdrodibenz fb. fl fl.41 hiazepine Re_.erenς? Example 15 fl- hloro-4-methvl-10.11-dihvdrodibenz fb.fl r 1.4i- t-iiazepjp.e Reference Example 16 B-Methoxv- . ll-dihvdrcdibenz fb. f '1. 1 hiazepine Reference Example 1 7-Chloro-4-methyl-10.11- riihvrirodibenz fb. f " .41thiazepine The following compounds are prepared as described in Reference Example 3. Ref rence, Example 18 7-C .nro-1 .1 -dihvdrcdibenz fb. '1. 1 -oxazeoine Reference Example 19 2-Met.hv]-10.1 l-dihvdrodibenzfb.fi f1.41 -oxazepine Reference Example 20 4-Chloro- .11-dihvdrodibenz fb. fl fl. 1 -oxazepine Reference Example 21 3-Methvl- .11-dihvdrodibenzfb. fl f1.4i-oxazepiΠP Reference Example 22 7-Chlorn-lO. l-dihvdrodi.benzfb. fl fl.4 -oxazepine Reference Example 23 8-Chlcrc-10. 1-dihvdrodibenz fb. f1 f1.4^ -oxazepine Reference Example 24 2. -Dichloro-lO.11-dihvrirodibenz fb. fl fl. i-oxazepine Reference Example 25 4.8-Dic loro-lO. ll-dihvdrodibe z F b. fl ■" 1.41 -oxazepine Reference Example 26 4-Chloro-S-methyl-lC. ll-dihvdrodibenz fb. f^ Q.41- oxazepine Reference Example 27 4-Met.hvl-T-__hloro-10.ll-riihvdrodibenzrb.fi f .41- oxazepine Reference Example 28 l -Chloro-4-methvl- 10. l l-dihydrodibenz i b . f i f l . 4 1 - oxazepine Reference Example 29 2-Fluoro-10. ll-dihvdrodibenz fb. f1 r l. * -oxazepine Reference Example 30 N- (2-Iodophenvl ) -2-iodophenvlacetamide A solution of 13.32 g (0.05 mol) of 2- iodophenylacetic acid in 75 ml thionyl chloride is refluxed for 2 hours, and the volatiles removed under vacuum. Toluene is added (3 times) and the solvent removed under vacuum after each addition to give 2- iodophenylacetyl chloride as a gum. To the preceding compound (0.05 mol) in a mixture cf 100 mi cf toluene- dichloromethane (1:1) is added 11 g (0.05 mol) of 2- iodoaniline and (0.10 mol) of diisopropylethylamine. The mixture is stirred at room temperature overnight and the solvent removed. The residue is dissolved in dichloromethane and the solution washed with IN HCI, saturated sodium bicarbonate, brine and dried (Na2Sθ ) . The solvent is removed and the residue recrystallized from methanol-ether to give 16.0 g of light brown crystals, m.p. 160°-163°C. Reference Example 31 2-Iodo-N- (2-iodophenvl.benzeneethanamine To a suspension of 1.39 g (3 mmol) of 2-iodo- N- (2-iodophenyl)benzeneacetamide in 30 ml of tetrahydrofuran-dichloromethane (1:1) is added 3.75 ml of 2.0 molar borane-dimethylsulfide in tetrahydrofuran. The solution is stirred 1 hour at room temperature and then relfuxed for 16 hours. The mixture is cooled and water slowly added dropwise until gas evolution ceases. The volatile are removed under vacuum and the aqueous residue made alkaline with 2N sodium hydroxide. The mixture is extracted with ether (50 ml) and the extract is washed with brine and dried (Na2Sθ ) . The solution is filtered through a thin pad of hydrous magnesium silicate and the filter pad is washed with ether and the filtrate evaporated. The residual solid is washed with isooctane to give 1.20 g of white solid. Recrystallization from diethylether/hexane gives white crystals. Reference Example 32 N- -N- robenzovl-N-f2-ioriophenvl)-2- iod__ber.zeneet.hvlamine To a solution cf 0.90 g of 2-iodo-N- (2- iodophenyl)benzeneethanamine in 4 ml cf tetrahydrofuran is added C.41 g of triethylamine, and 0.57 g of 4- nitrobenzoyl chloride. The mixture is stirred at room temperature for 2 hours and the solvent removed under vacuum. The residue is dissolved in ethyl acetate- dichloromethane (5:1) and the solution washed with IN HCI, saturated NaHCθ3, brine and dried (Na2Sθ4) . The solution is filtered through a thin pad of hydrous magnesium silicate. The filtrate is evaporated and the residual solid triturated with diethyl ether and hexane to give 1.10 g of product as a white solid. Reference Example 33 2 .4-Dihydro-lH-l-benzazeρine-2. -dione To a solution of 225 ml of glacial acid and 8.5 ml of concentrated sulfuric acid is added 49.54 g (0.30 mol) cf 2 '-nitroacetophenone and 47.02 g (0.50 mol) of glyoxylic acid (hydrated) . The mixture is heated at 100°C for 16 hours. The mixture is cooled and poured over crushed ice. After the ice melts, the mixture is filtered and the solid washed with cold water. The solid is dried and recrystallized from dichloromethane-hexane to give 20.1 g of 3- (2- nitrobenzoyl) acrylic acid as white crystals, m.p. 153- 158°C. A solution of the proceeding compound (9.0 g) in 80 ml of ethanol and 1.6 g of palladium-on-carbon is hydrogenated in a Parr hydrogenator under 30 pounds per square inch cf hydrogen for 20 hours. The mixture is filtered through diatomaceous earth and the solvent is removed. The residue (7.0 g) is chromatographed on silica gel with hexane-ethyl acetate (1:1) as solvent to give 4.0 g cf 3- (2-aminobenzoyl)propionic acid as an orange solid, m.p. 103°-107°C. A 0.50 g sample of the preceding compound, 0.36 ml of triethylamine and 0.43 ml cf diethoxyphosphinyi cyanide in 20 ml of dichloromethane is stirred at room temperature for 5 days. The solvent is removed, ethyl acetate is added and the mixture washed with water, 2 M citric acid, 1M NaHCθ3, brine and dried ( a2S04) . The solvent is removed and the residue purified by chromatography over silica gel with ethyl acetate-hexane (1:1) as solvent to give C.190 g of light brown crystals, m.p. 168°-170°C. Reference Example 34 4-f (Dimethvlamino)methvlene1- .4-riihydro-lH-l- benzazepine-2.5-dione A mixture of 0.250 g (1.43 mmol) of 3,4- dihydro-lϋ-l-benzazepine-2, 5-dione and 5.5 ml (4.93 g, 41.5 mmol) of ϋ,M-dimethylformamide, dimethylacetal is heated at 90°C for 1.5 hour. The mixture is cooled, diluted with diethyl ether and filtered. The solid is washed well with diethyl ether and dried to give 0.26 g of tan crystals, m.p. 203°-205°C. Reference Example 35 2-Methvl-6.7-dihvdrc-5H-Pvrimidof5.4-dl benzazeoine To a solution of 0.308 g (3.26 mmol) of acetamidine hydrochloride in 15 ml of methanol under argon is added 0.176 g of (3.26 mmol) of sodium methoxide and the mixture stirred for 5 minutes. To the mixture is added 0.50 g (2.17 mmol) of 4- [ (dimethylamino)methylene] -1,2, 3, -tetrahydro-5ϋ _ l- benzazepine-2, 5-dione and the mixture stirred at room temperature overnight. The mixture (containing thick precipitate) is diluted with 3 ml of methanol, chilled and filtered. The filtrate is concentrated to dryness. The residue and original solid are combined and chloroform added. The mixture is washed with water, the organic layer is treated with activated carbon and then filtered through a thin pad of hydrous magnesium silicate. The filtrate is evaporated to give 0.41 g of crystals, m.p. 257°-258°C. The preceding compound is heated with 5 equivalents of lithium hydride in dioxane for 24 hours to give the product as a solid. Reference Example 36 5. -Dihvdropvridof2.3-bl f1. Ibenzothiazepine To a suspension of 11.67 g of 2-thiobenzoic acid in a mixture of 32 ml of ethanol and 11 ml is added portion wise 12.72 g of solid sodium bicarbonate. After the complete addition, the mixture is stirred for 15 minutes and 10.0 g of 2-chloro-3- nitropyridine added portionwise. The mixture is refluxed for 2 hours, cooled and then concentrated 2R vacuo. The residual aqueous solution is diluted with 15 ml of water, acidified with 2N HCI and extracted twice with 250 mi of ethyl acetate. The extract is concentrated under vacuum to give a yellow solid residue. The residue is dissolved in a minimum of ethyl acetate by heating on a steam bath. The solution is cooled overnight and filtered to give 2.5 g of starting material. The filtrate is concentrated, chilled and filtered to give 12.5 g of 2- (3-nitro-2- pyridinylthio)benzole acid as a yellow solid. The preceding compound (5.0 g) and 0.75 g of Pd/C in 60 ml of ethanol is shaken in a Parr hydrogenator under 45 psi cf hydrogen for 18 hours. The mixture is filtered through diatomaceous earth and the filter cake washed with 200 ml of dichloromethane. The combined filtrate is evaporated in vacuo to give a solid. The solid is triturated with ethanol and filtered to give 3.6 g of yellow solid. This solid (3.0 g) is again hydrogenated with Pd/C (0.50 g) in 50 ml cf ethanol and 30 ml of acetic acid under 45 psi of hydrogen for 18 hours. The mixture is filtered through diatomaceous earth and the filter cake washed with methanol. The combined filtrate is concentrated in vacuo to give 1.6 g cf solid. This solid in 25 mi cf N,N-dimethylformamide is again reduced with 0.80 g of Pd/C under 45 psi of hydrogen to give C.57 g of solid. Recrystallization from ethyl acetate gives C.28 g of 2- (3-amino-2-pyridinylthio)benzoic acid. The preceding compound (0.20 g) is heated in 2- hyarcxypyridine at 170°C to give 5, 6-dihyaropyrido [2, 3- b [1, 4]benzothiazepine as a yellow solid. The preceding compound is reacted with borane-dimethylsulfide as described for Reference Example 3 to give the product as a solid. Reference Example 37 2-Nitro-2 '-carboxy-diohenvlamine A stirred solid mixture of 13.7 g of anthranilic acid, 20.2 g of o_-bromonitrobenzene, 13.8 g of anhydrous potassium carbonate and 0.1 g of copper metal is heated at 200°C in an oil bath. The reaction mixture is heated for 2 hours, cooled and the solid washed with ether (3 X 100 ml) . The solid is dissolved in hot water and filtered. The filtrate is acidified with 40 ml of HCI and the resulting solid is collected and dried to give 2C.5 g cf the desired product as a solid, m.p. 262-265°C. Reference Example 38 2-Amino-2'-carboxy-diphenylamine A solution of 7.3 g of 2-nitro-2 *-carboxy- diphenylamine in 50 ml of methanol containing 10% palladium-on-carbon is hydrogenated under 42 pounds of pressure for 24 hours. The reaction mixture is filtered through diatomaceous earth. The filtrate is evaporated to dryness in vacuo to give 6.6 g of the desired product as a solid, m.p. 72-75°C. Peferenc° Example 39 5. ll-Dihvdro-10H-dibenz fh.e f1.41riiazeoine-Ll-one A mixture of 6.6 g of 2-amino-2'- carboxydiphenylamine in 300 ml of xylene is heated at reflux fcr 20 hours. The xylene is evaporated in vacuo to a residue which is evaporated from 210 ml of toluene in vacuo to a residue which is evaporated from 50 ml of chloroform to give a residue. The residue is dissolved in 10 ml of tetrahydrofuran and added to 400 ml of ice- cold hexane. The resulting solid is collected, to give 4.3 g of the desired product as a solid, m.p. 121-123°C. Reference Example 40 5. 1-Dihvdro-lOH-dibenzfb.el r l .41diazeoine To a stirred solution of 4.3 g of 5,11- dihydro-10ϋ-dibenz [b,e] [1, 4]diazepin-11-one in 50 ml of tetrahydrofuran, under nitrogen and cooled to 0°C is added 4.0 ml of a 10 molar solution of dimethyl sulfide- borane complex in tetrahydrofuran. The ice bath is removed after 30 minutes and the reaction mixture stirred at room for 18 hours. The reaction mixture is cooled in an ice bath and 30 ml cf anhydrous methanol added dropwise and evaporated to dryness in vacuo. Another 30 ml of methanol is added and evaporated to a residue. The residue is quenched with 30 ml of 40% sodium hydroxide followed by heating at 110°C for 45 minutes and cooling to room temperature. The reaction mixture is diluted with 200 ml of water and extracted with methylene chloride (3 x 100ml) . The combined extracts are washed with IN HCI, water and 0.5 N NaOH. The organic layer is dried and evaporated in vacuo to give 3.2 g of the desired product, m.p. 114-116°C. Reference Example 41 SH-Diber.zfb, el azepine-6. ll-dione A mixture of 2.50 g of 2-aminobenzophenone-2 '- carboxylic acid in 50 ml of xylene is stirred at reflux for 23 hours. The mixture is filtered to give 1.82 g of the desired product as a solid. Reference Example 42 2-Chlorc-5H-dibenzfb.e azepine-6. ll-dione A mixture of 1.0 g of 5ϋ~aibenz [b,e] azepine- 6, ll-dione in 50 ml of acetic acid is stirred while chlorine is bubbled into the reaction mixture until saturated. The temperature increases to 38°C. After standing, a precipitate forms and is filtered, washed with hexane and air dried to give 0.62 g of solid which is purified by chromatography to give the desired product as a solid, m.p. 289°-293°C. Reference Example 43 ?-Chloro-6. l-Dihvdro-5H-dibenzfb. el zepine To a mixture of 7.28 g of 2-chloro-5ϋ~ dibenz [b,e]azepine-6, ll-dione in 25 ml of anhydrous tetrahydrofuran, under argon, is added dropwise 8.5 ml of (10 M) boron-dimethyl sulfide in tetrahydrofuran. The reaction mixture is stirred at room temperature for 18 hours. The reaction mixture is heated at reflux for 3 hours and cooled to room temperature. While stirring, 25 ml of methyl alcohol is carefully added, followed by 100 ml of 2 N NaOH. The reaction mixture is heated at reflux for 24 hours and the solid collected. The solid is dissolved in methylene chloride and washed with 2 N citric acid, water and dried (Na2≤θ ) . The volatiles are evaporated in vacuo to give 4.16 g of a residue which is crystallized from ethyl acetate-hexane to give 2.05 g of the desired product as a crystalline solid, m.p. 137-141°C. Reference Example 44 2- ( 7- (Tributvlstannvl) -3-thienvl1 -1.3-dioxolane To a stirred solution of 15.6 g (0.10 mol) of 2- (3-thienyl) -1, 3-dioxolane in 100 ml of anhydrous ether, n-butyl-lithium (1.48N, in hexane, 74.3 ml) is added dropwise under nitrogen at room temperature. After being refluxed for 15 minutes, the reaction mixture is cooled to -78°C and tri-n-butyltin chloride (34.18 g, 0.105 mol) in 100 ml of dry tetrahydrofuran is added dropwise. After the addition is complete, the mixture is warmed to room temperature and the solvent evaporated. To the oily residue 100 ml of hexane is added, and the resulting precipitate ( iCl) is filtered off. The filtrate is evaporated and the residue distilled at reduced pressure, given 34.16 g (77%) of the desired product. Reference Example 45 2-f2-r (2-Nitrophenvl)methvli-3-thienvli-l. -dioxolane A mixture of 2- [2- (tributylstannyl) -3- thienyl]-1, 3-dioxolane (8.8 gms, 20 mmols) , 2- nitrobenzyl bromide (4.5 gms, 22 mmol) and tetrakis (triphenylphosphine) -palladium (0) (200 mg) is refluxed in degassed toluene for 16 hours under a nitrogen atmosphere. At the end, the reaction mixture is cooled to room temperature and filtered through diatomaceous earth. The toluene is removed by concentrating at reduced pressure and the product isolated by silica gel column chromatography by elution with 30% ethyl acetate: hexane to give 4.5 gms of the desired product as viscous liquid. Mass Spectrum; M + 292 Reference Example 46 4 . lP-Dihvdro-5H-thien.of3.2-c 1 fπbenzazepine A stirred solution of 4 gms of 2- [2- [ (2— nitrophenyl)methyl] -3-thienyl]-1, 3-dioxolane in acetone (50 ml) and acetic acid (90% 50 ml) is heated to 60°C. Zinc dust (10 gms) is slowly added and after the addition, reaction mixture is stirred for 6 hours. At the end, reaction mixture is filtered and the residue washed with acetone and concentrated. The brown residue is extracted with chloroform and washed well with water. The organic layer is dried (Na2Sθ4) and filtered and concentrated. The product is isolated by silica gel column chromatography by eluting with 20% ethyl acetate: hexane to give 2.0 g cf the desired product as a pale yellow crystalline solid, m.p. 86°C. Mass Spectrum; M + 202. Reference Example 7 4.5-Dihyrir ^ -4.4-dimethyl-2- f 3- f (2-r.ι roohenyl) ethyl 1 -?- thienyl 1 oxazole To a solution of 4 , 5-dihydro-4, 4-dimethyl-2- (2-thienyl) -oxazole (4.5 gms 25 m ol) in anhydrous ether at -70°C, n-butyl-iithium (2.5 molar solution in hexane, 11 ml) is added drop by drop under N2 atmosphere. The reaction mixture is stirred at -78°C for 45 minutes and tri-n-butyltin chloride (8.3 gms 25 mmol) in dry ether is added drop by drop. The reaction mixture is stirred at room temperature for 1 hour and quenched with water. The reaction mixture is extracted with ether, washed well with water, dried and concentrated. The product obtained is pure enough for further transformation. The oil product, 4, 5-dihydro-4, 4-dimethyl-2- [3- (tributylstannyl) -2-thienyl] -oxazole is mixed with 2- nitrobenzyi bromide (5.5 g 25 mmol) in toluene and refluxed in the presence of tetrakis (triphenylphoshine) -palladium (0) 200 mg) fcr 16 hours. At the end reaction mixture is cooled to room temperature and filtered. Toluene is removed under reduced pressure and the product is isolated as brown oil by silica gel column chromatography by eluting it with 30% ethyl acetate:hexane to give 5.7 g of the desired product. Mass Spectrum; M + 316. Refe nc Example 48 9.1 -Dihyriro-4H-thieno f3.2-cl fllber.zazepin-10-one A solution of 4, 5-dihydro-4, 4-dimethyl-2- [3- [ (2-nitrophenyl)methyl] -2-thienyl]oxazole 5 gms is refluxed in acetone/water (3:1 100 ml) containing 1 N HCI (30 ml) for 24 hours. The reaction mixture is concentrated and the residue is dissolved in glacial acetic acid (100 ml) . The acetic acid is stirred at 70°C and zinc dust (10 gm) is slowly added. Stirring is continued at 70°C for 6 hours. At the end, the reaction mixture is cooled to room temperature and filtered. Acetic acid is removed under reduced pressure and the residue is extracted with chloroform. The chloroform layer is dried and concentrated to give 2.9 gms of the desired product as a brown solid. Mass Spectrum: M + 215. Reference Example 49 9. -!P-Dihvdro-4H-thienof2.3-cl f11benzazep ne A stirred solution of 2.0 g of 9, 10-dihydro- 4ϋ _ thieno[2, 3-c] [1]benzazepin-10-one and lithium aluminum hydride (500 mg) in tetrahydrofuran is refluxed for 4 hours. At the end, reaction mixture is carefully quenched with ice cold water and extracted with chloroform. The organic layer is washed well with water and dried over anhydrous Na2S04, filtered and concentrated. The product is purified by silica gel column chromatography by eiuting it with 30% ethyl acetate:hexane to give 1.2 g of the desired product as a bright yellow solid. Mass Spectrum M + 202. Reference Example 50 2-Methvlf rane-3-carbonvl chloride A mixture of 4.0 g of methyi-2-methylfurane-3- carboxylate, 30 ml of 2 N NaOH and 15 ml methanol is refluxed for 1.5 hours. The solvent is removed under vacuum to give a solid. The solid is extracted with dichloromethane (discarded) . The solid is dissolved in water and the solution acidified with 2 N citric acid to give a solid. The solid is washed with water and dried to give crystals 1.05 g of crystals of 2-methylfuran-3- carboxyiic acid. The preceding compound (0.95 g) and 3 ml of thionyi chloride is refluxed fcr 1 hour. The solvent is removed, toluene added (20 ml, three times) and the solvent removed to give the product as an oil. Reference Example 51 2- r -(Tr:hutvlsr.annvl)-3-thie.vll-l.3-dioxolane To a stirred solution of 15.6 g (0.10 mol) of 2- (3-thienyl) -1, 3-dioxciane in 100 ml cf anhydrous ether, n-b tyl-lithium (1.48 N, in hexane, 74.3 ml) is added dropwise under nitrogen at room temperature. After being refluxed for 15 minutes, the reaction mixture is cooled to -78°C and tri-n-butyltin chloride (34.18 g, C.1C5 mol) in 100 ml of dry tetrahydrofuran is added dropwise. After the addition is complete, the mixture is warmed to room temperature and the solvent evaporated. To the oily residue 100 ml of hexane is added, and the resulting precipitate (LiCl) is filtered off. The filtrate is evaporated and the residue dis¬ tilled at reduced pressure, giving 34.16 g (77%) of the desired product. Reference Example 52 Methvl 6-aminopvridine-3-carboxvlate Dry methanol (400 ml) is cooled in an ice bath and HCI gas is bubbled into the mixture for 25 minutes. To the MeOH-HCl is added 30 g of 6-aminopyridine-3- carboxylic acid and then the mixture is stirred and heated at 90°C for 2 hours (all the solid dissolved) . The solvent is removed under vacuum and the residual solid dissolved in 100 ml of water. The acidic solution is neutralized with saturated sodium bicarbonate (solid separated) and the mixture chilled and filtered to give 30 g of white crystals, m.p. 150°-154°C. Reference Example 53 6- f (5-fluoro-2-methvlbenzovl) aminolPvridine-3-carboxylic acid To a mixture of 4.5 g of methyl 6-amino- pyridine-3-carooxylate and 5.53 ml cf triethylamine in 40 ml of dichloromethane (cooled in an ice bath) is added 6.38 g of 5-fluoro-2-methylbenzoyl chloride in 10 ml of dichloromethane. The mixture is stirred at room temperature under argon for 18 hours and an additional 3.4 g of 5-fluoro-2-methylbenzoyl chloride added. After stirring at room temperature fcr 3 hours, the mixture is filtered to give 3.0 g of methyl 6- [ [bis (5-fluoro-2- methylbenzoyl) ] amino]pyridine-3-carboxylate. The filtrate is concentrated to dryness and the residue triturated with hexane and ethyl acetate to give an additional 9.0 g of bis acylated compound. A mixture of 12.0 g of methyl 6- [ [bis (5- fluoro-2-methylbenzoyl) ]amino]pyridine-3-carboxylate, 60 ml of methanol-tetrahydrofuran (1:1) and 23 ml of 5 ϋ NaOH is stirred at room temperature for 16 hours. The mixture is concentrated under vacuum, diluted with 25 ml of water, cooled and acidified with 1 N HCI. The mix¬ ture is filtered and the solid washed with water to give 6.3 g of the product as a white solid. As described for Reference Example 53, but substituting the appropriate aroyl chloride, heteroaroyl chloride, cycloalkanoyl chlorides, phenylacetyl chlorides and related appropriate acid chlorides, the following 6- [ (aroylamino]pyridine-3-carboxylic acids, 6- [ (hetero-aroyi) amino]pyridine-3-carboxylic acids and related 6- [ (acylateα) amino]pyridine-3-carboxylic acids are prepared. Reference Example 54 6- ' (3-Methvl-2-thienvlcarbonyi) aminoloyridine-3- carboxvlic acid Reference Example 55 6- ' (2-Methvl-?-thienvlcarbonvl) amino 1 pvridine-3- carboxvlic acid Reference Example 56 6- : (3-Methvl-2-furanvlcarbonvl)aminoiovridine-3- carboxylic ac d Reference Example 57 6- r (2-Methvl-3-f---ranylcarbonvl) aminolovridine-3- carboxvlic acid Reference Example 58 acid Re ference Example 59 6- f (?-Met hvlbenzovl ) amino i ρyridine- 3-carboxvlic aci d Reference Example 60 6- f (2-ch . -rober.zovl ) amino l oyridine-3-carboxvl i c aci d Reference Example 61 6-f (2-Fluorobenzovl)aminolpvridine-3-carboxvlic acid Reference Example 62 6- f (2-Chloro-4-fluoroben2oyl) aminolpyridine-3-carbnyyl . r acid Reference Example 63 6- r (2 .4-Dichlorobenzovl) aminolpyridine-3-carboxyl ir ar Reference Example 64 6- f (4-Chloro-2-fluoroben2oyl) aminolovridine-3-carhoxvl . c acid Reference Example 65 6- r (3.4.5-Trimethoxvbenzoyl) aminolPvridine-3-carboxyl \ r. acid Reference Example 6? 6- ' (2. -Difluorobenzovl) aminolpvridine-3-carboxylic acid Reference Example 67 6-f (2-3rπmobenzovl) aminol vridine-3-carboxvlic acid Reference Example 68 6- r (2-Chlorc-4-nitrobenzovl) amirnlpvridine-3-carboxyl io 2£id Reference Example 69 6- r (Tetrahvdrof ranyl-2-carbonyl) a ino ovridine-3- carboxylic acid Reference Example 7Q 6- r (Tetra vdrcthienvl-2-carbonvl) amino Pvridine-3- carkcxylic acid Reference Example "?! 6- r (Cvclohevvlcarbonvl) aminolPvridine-3-carboxvlic acid Reference Example 72 6- f (cyclo ex-3-enecarbonvl) amino^ovridine-S-carboxvlic acid Reference Example 3 6- r ( 5-Fl-joro-2-methvlbenzeneacetv1 . amino l Pvridine- 3- cargcxylic acid Reference Example 74 6- f (2- hlorobenzeneacetvl) aminolpvridine-3-carboxvl ic acid Reference Example 75 6- f (cvclopentvlcarbonvl) aminolpvridine-3-carboxvlic acid Reference Example ~>6 6-f (cvclohexvlacetvllaminolpvridine-^-carboxv ic arid Reference Example 77 6-r f3-Methvl-2-thienvlacetvl) aminolovridine-3-carboxvlic acid Reference Example 7R 6- f (2- ethvl-3-thienvlac.er.vl)am2nolPvriri ne-3-carboxv1 ic acid Reference Example 79 6- ' (3- e^hvl-?-furanvlacetyl) aminolpyridine-3-carboxvlic acid, m.p. 28δ-290°C Example 80 6- f f 2- ethv l- ?-furanvlacetyl ) ammo i pvridine- 3-carboxyli c acid Reference Example 81 6- r (3-Methvi-2-tetrahvdrothienγlacetvl) amino 1 ovridine-3- carboxylic acid Reference Example 82 6-f f?- f .t-. n V ι-- a -rιetrahvdrs hienvlacetvl)ar.inc i pvridine-3- carboxylic acid Reference Example 83 6- r (2 , F-Dichlorobenzovl) aminol vridine-?-carboxvlic acid Reference Example 84 Reference Example 85 6- ' (2-Methvl-4-chlcrcbenzoyl) ammo 1 pvridine-3-carboxyl i r. acid Peference Example 86 6- f ( 2 . -Dimerhvlbenzovl) aminolpvridine-3-carboxvlic acid Reference Example 87 6- f (2-Methcxybenzoyl) aminolpyridine-3-carboxylic acid Reference Example 88 6-f (2-Tr. f ■■ir.rnmethoxvbenzovl. aminol pvridine-3- carboxylic acid Reference Example 89 6-f (4-Chinro-?-methoxvbenzovl)aminolpvridine-3- carboKylic acid Reference Example 90 6-r ?2- (Tri f..:r;roπethvll benzovl! aminolpvridine-:*- carboxvlic acid Reference Example 91 6-f (2.6- ich ornbenzovl) aminolPvridine-3-carboxvlic ari Reference Example 92 6- r (2.6-Dimer.hvlbenzovl) aminolPvridine-3-carboxvlic arid Peference Example 93 6- r (2-Methvlthiobenzovl)amino1ovridine-3-carboxvlic arid Reference Example 94 6- r -Fl'. oro-2- (trifluoromethvl)benzovl) aminolovridine- 3-carbnxvlic acid Reference Example 95 6- f (2.3-Dichlorobenzovl) aminolovridine-3-carboxvl ic arid Reference Example 96 6- r -"luoro-2-methvlbenzovl) aminolPvridine-3-carboxylir acid Reference Example 97 6- r (2. .--Trichlorcbenzcvl)amino1pvridine-3-carboxvlir acid Reference Example 98 6- f (5-~iuoro-2-chlcrobenzovl) aminol vridine-3-carboxyl it. azlύ Reference Example 99 6- r (2-r-luor - K - (tri fluoromethvl) benzovl> aminolovririine- :arboxvlic acid Reference Example 100 6- f (5-Fluoro-2-methvlbenzovl) aminolpvridine-3-carbonvl chloride A mixture of 6.2 g of 6- [ (5-fluoro-2-methyl- benzoyl) amino]pyridine-3-carboxylic acid and 23 ml of thionyl chloride is refluxed for 1 hour. An additional 12 ml of thionyl chloride is added and the mixture refluxed for 0.5 hour. The mixture is concentrated to dryness under vacuum and 30 ml of toluene added to the residue. The toluene is removed under vacuum and the process (add toluene and remove) is repeated to give 7.7 g of crude product as a solid. As described for Reference Example 100, the following 6- (acyl) amino)pyridine-3-carbonyl chlorides are prepared. Reference Example 101 6-f (3-Methvl-2-thienvlcarbonyl) amino1ovridine-3-carbonyl chloride Reference Example 102 6-f (2-Methvl-3-thienvlcarbonvl)aminolpvridine-3-carbonvl chloride Reference Example 103 6- r .3-Methyl -2-f ranvlcarbonyl) aminolpvridine-3-carbonyl chloride Reference Example 104 6-f (2-Methv 1 -^-f^ranvlcarbonvl)amir.olpvridine-3-carbonvl chloride Reference Example 105 6-f (3-Fluor -2-met vlbenzovl)ami .olpvridine-3-carbonvl chloride Reference Example 106 Cr— F I " - o<- V " l V>pr >-;i' 1 ) ar 1 ^ Π Λ 1 DV ' ' " θ- ^- <~? rhn n v 1 r-V> 1 o i- i i Reference Example 107 6- r (2- hlorcbenzovl) ami olPvridine-3-carbonvl chloride. white crystals Reference Example 1Q8 6- f ( 2-Fluomhenzovl ) amino 1 pvridine- 3-carbonvl ch l ori de Reference Example 109 6- f ( 2-Chloro-4-f luorobenzovl ) amino l Pvridine-3-carbony l chloride Reference Example 110 6-r (2.4-Dichlorobenzovl) aminolPvridine-3-carbonvl chloride Reference Example 11 6- r (4-Chloro-2-fluorobenzoyl) aminol yridine-3-carbonyl chloride Reference Example 112 6-f (3. .5-Trimethoxvbenzovl)aminolpvridine-3-carbonγ1 chlori e Reference Example 113 6- r (?.4-Pi.fI' orcbenzovl) aminolovridine-3-carbonγl chloride Reference Example 114 6-r (2-Promobenzovl) aminolpvridine-3-carbonvl chloride Reference Example 115 6-r (2-?hloro-4-nitrobenzovl)aminolPvririine-3-carbonv1 chloride Reference Example 116 6- r (Terrahvdrofuranvl-2-carbonvl) aminolovridine-3- carbonvl chloride Reference Example 117 -r (Tetra yrirothienvl-2-carbonvl) aminoiPvridine-3- carbonvl chloride Reference Example 118 6- r fCvclohexvlcarbonvl) aminolPvridine-3-carbonyl chloride Reference Example 119 6- r (Cv lohe. y -3-enecarbonvl) aminolpyridine-3-carbonvl chloride Reference Example 120 6- r (2-Methvlbenzeneacetvl) aminolPvridine-3-carbonyl chloride Reference Example 121 6-r (2-Ch.iorobenzeneacetvl)aminolpvridine-3-carbonyl chloride Reference Example 12? 6- r (Cvclopentvlcarbonvl) aminol pvridine-3-carbπnvl chloride Reference Example 123 - r (Cyclohexvlacetvl)amino1ovridine-3-carbonyl chloride Reference Example 124 6- r (?-Met vl-2-thienvlacetvl) amir.o 1 ovridine-3-carbonyl chloride Reference Example 125 6-r (2-Mer. vl-3-thienvlacetvl)amir.olpvridine-3-carbonyl chloride Reference Example 126 6-r (3-Mer vl-2-furanvlacetvl) aminol pvridine-3-carbonyl chloride Reference Example 127 6- ' (2-Methvl-3-f rar.vlacetvl) aminolovridine-3-carbonyl chloride Reference Example 128 6- r (2-Me*-hvl-.^-fl- orobenzene5ce-.vl) aminolpyridine-3- carbonyl chloride Reference Example 129 - r .3-Methy -2-tetrahydrothienvlacetvl) aminol vridine-3- carbonyl chlori e Reference Example 130 - f (2-Methy.-3-tetrahydrothienvlacetyl) aminolpvridine-3- carbonvl chloride Reference Example 131 6-r (2. -n:chl-rcbenzovl) aminolpyridine-3-carbonyl chloride Reference Example 132 6-r (3.5-Dichlorobenzovl)aminolpvridine-3-carbonvl chloride Reference Example 133 6- r (2-N!ethvl-4-chlorobenzovl) aminolPvridine-3-carbonvl chloride Reference Example 134 6- r (2. -Dimethvlbenzovl) aminolpvridine-3-carbonyl chloride Reference Example 135 - f (2-Methoxvbenzovl) aminolPvridine-3-carbonvl chloride Reference Example 136 - '■ (2-Trifluoromethoxvbenzovl) aminolovridine-3-carbonvl chloride Reference Example 137 - '■ (4-Chlorc-2-merhoxvbenzovl) aminolρyridine-3-carbonvl chloride Reference Example 138 -r f2- (Trifluoromethvl)benzovl 1 minolpyridine-3-carbonvl chloride Reference Example 139 6-r (2.6-Dichlorobenzovl) amindpyridine-3-carbonvl chloride Reference Example 140 6- r (2.6-Dimethvlbenzovl) aminolovridine-3-carbonvl chloride Reference Example 141 6-r (2-Methvlthiobenzovl) aminoloyr ine-3-carbonvl chloride Reference Example 142 - r (_.— lucro-2- (trifluoromethyl)benzoyl ) aminolpvridine- 3-carbonyl chloride Reference Example 143 6-r (2. -Dichlorobenzovl) aminolpvridine-3-carbonvl chloride Reference Example 144 6- f (4-Fluoro-2-methvlbenzoyl) aminolpvridine-3-carbonvl chloride Reference Exam p e 145 6-r (2.3. -Trichlorobenzovl)amiPQ pvridine-3-carbonγ1 chloride Reference SKaπpig ^§ 6-r (5-Fluoro-2-chlorobenzoyl) aminolpyridine-3-carbonyl chloride Reference Example 147 6- r (2-F :oro-5- ftrifluoromethvl) benzovl) aminolpvrid ne- 3-carbonvl chloride As described for Reference Example 53, the following bis acylated products (Table A) are prepared and purified by silica gel chromatography. These compounds are then hydrolysed to the acids (Table B) as described in Reference Example 53. Table + is molecular ion found from FAB mass spectrum Table R M + is molecular ion found from FAB mass spectrum. Reference Example 172 6-Am.ino-5-bromopyridine-3-carboxylic acid To a stirred solution of 6-aminonicotinic acid (13.8 g, 0.1 mole) in glacial acetic acid (100 ml), bromine (16 g, 5 ml, 0.1 mole) in acetic acid (20 ml) is added slowly. The reaction mixture is stirred for 8 hours at room temperature and the acetic acid is removed under reduced pressure. The yellow solid residue is dissolved in water and carefully neutralized with 30% NH4OH. The separated solid is filtered and washed with water to give 18 g of solid; mass spectrum: 218 (M + ) . Reference Example 173 Mot- yl 6-amino-5-bromopvri ine-3-carboxvlate 6-Amino-5-bromopyridine-3-carboxylic acid (10 g, 50 mmol) is dissolved in saturated methanolic HCI (100 ml) and refluxed for 24 hours. The solvent, methanol, is re-moved under reduced pressure and the residue is dis-solved in ice cold water. The aqueous solution is neutralized with 0.1 N NaOH and the solid which separates is filtered; washed well with water and air dried to yield 10 g of product as a solid: mass spectrum 231 (M + ) . Reference Example 174 6-f (2- ethvlbenzeneacetvl) aminolpvridine-3-carboxvl \ r. a LU To a cooled (0°C) mixture of 5.0 g methyl 6- aminopyridine-3-carboxylate, 12.6 ml of N,N-diisopropyl- ethylamine in 40 ml of dichloromethane is added a solution of 12.2 g of 2-methylbenzeneacetyl chloride in 10 ml of dichloromethane. The mixture is stirred under argon at room temperature overnight. The mixture is diluted with 200 ml of dichloromethane and 50 ml of water and the organic layer separated. The organic layer is washed with 50 ml each of 1 M NaHCθ3, brine and dried ( a2Sθ ) . The solution is filtered through a thin pad of hydrous magnesium silicate and the filtrate con¬ centrated to dryness. The residue (9.0 g) is chromato- graphed on a silica gel column with hexane-ethyl acetate (3:1) as eluent to give 8.6 g of solid. This solid, mainly methyl 6- [ [bis (2-methylbenzeneacetyl) ]- amino]pyridine-3-carboxylate, is dissolved in 60 ml of tetrahydrofuran- ethanol (1:1) and 23 ml of 5 N NaOH added to the solution. The mixture is stirred at room temperature overnight and the mixture concentrated under vacuum. Water (25 ml) is added and the mixture is stirred and acidified with cold 1 N HCI. The mixture is chilled and the solid filtered and washed with water to give 5.9 g of off-white solid. Reference Example 175 6-f (?-Methvlbenzeneacetyl) aminolpvridine-3-carbonyl chloride A mixture of 4.5 g of 6- [ (2-methylbenzene- acetyl) amino]pyridine-3-carboxylic acid and 25 ml of thionyl chloride is refluxed for 1 hour and then con- centrated to dryness under vacuum. To the residue is added 20 ml of toluene and the solvent removed under vacuum. The addition and removal of toluene is repeated and the residual solid dried at room temperature under vacuum to give 5.3 g of dark brown solid. Reference Example 176 f1.1 '-Biphenvl -2-Biphenvlcarbonvl chloride A mixture of 5.6 g of [1, 1 • -biphenyl]-2- carboxylic acid and 29 ml of thionyl chloride is heated on a steam bath for C.5 hour and the volatiles removed under vacuum. Toluene (40 ml) is added (twice) and the solvent removed under vacuum to give 6.8 g of a yellow oil. Reference Example 177 ethvl 6- f fbis ( rl . ■ -biphenyl1-2- • . -carbonvl) 1 aminolpvridine-3-carboxvlate To a chilled (0°C) solution of 2.64 g of methyl 6- aminopyridine-3-carboxylate and 5.5 ml of diisopropylethylamine in 30 ml of dichloromethane under argon is added 6.8 g of [1, 1 '-biphenyl]-2-carbonyl chloride in 10 ml of dichloromethane. The mixture is stirred at room temperature 2 days and then diluted with 120 ml of dichloromethane and 50 ml of water. The organic layer is separated, washed with 50 ml each cf 1 M NaHC03 and brine and dried (Na2Sθ4) . The solution is filtered through a thin pad cf hydrous magnesium silicate and the filtrate concentrated under vacuum to give a solid. Crystallization from ethyl acetate gives 6.2 g of white crystals, m.p. 180-188°C. Reference Example 178 f- π . l '-biphenvli-2-vlcarbonvl) amino 1 pvridine-3- carbc ylic acid To a chilled (0°C) mixture of 6.0 g of methyl 6- [ [bis [(!,!' -biphenyl] -2-yicarbonyl) ] amino]pyridine-3- carboxylate in 40 ml of methanol and 30 ml of tetrahydrofuran is added slowly IS ml of 2 N NaOH. The mixture is stirred at room temperature overnight and brought to pH 5 with glacial acetic acid. The mixture is concentrated, acidified to pH 2-3 with 1 N HCI and extracted with 250 ml of ethyl acetate. The extract is washed with 50 ml of brine, dried (Na2Sθ4) and the solvent removed under vacuum. The residual white solid is triturated with 15 ml of ethyl acetate to give 3.35 g of white crystals, m.p. 215-217°C. Reference Example 179 6- r1.1 '-biphenvlι -?-vlcarbonyl ) amino1ovridine-3-carbony1 chloride A mixture of 1.9 g of 6- [( [1, 1 '-biphenyl] -2- ylcarbonyl) amino]pyridine-3-carboxylic acid and 9 ml of thionyl chloride is refluxed for 1 hour and then con- centrated to dryness under vacuum. Toluene (15 ml) is added (twice) to the residue and the solvent removed under vacuum to give 2.1 g of a light brown oil. Reference Example IRQ 6- f (Cvclohexvlcarbonvl)aminolpvridine-3-carboxylic acid To a chilled <0°C) solution of 5.0 g of methyl 6-aminopyridine-3-carboxylate and 12.6 ml of diiso¬ propylethylamine in 50 ml of dichloromethane under argon is added a solution of 9.7 ml of cyclohexylcarbonyl chloride in 10 ml of dichloromethane. The mixture is stirred at room temperature overnight and diluted with 200 ml of dichloromethane and 60 ml of water. The organic layer is separated, washed with 60 ml of brine and dried (Na2Sθ ) . The solution is filtered through a thin pad of hydrous magnesium silicate and the filtrate concentrated under vacuum to give 12.8 g of a solid. The above solid (12.0 g) in a mixture of 150 ml of tetrahydrofuran-methanol (1:1) is chilled (0°C) and 62 ml of 2 N sodium hydroxide added. The mixture is stirred at room temperature for 3 hours, neutralized with 10 ml of glacial acetic acid and concentrated under vacuum. The mixture (containing solid) is acidified to pH 1 with 1 N HCI and extracted with 250 ml of ethyl acetate and twice with 100 ml of ethyl acetate. The combined extract is washed with 100 ml of brine, dried (Na2S04) and concentrated to a white solid. Trituration with hexane gives 6.5 g of product as a white solid. Reference Example 181 Me*- v1-2- r (4-ethoxv-oxob\:tvl)aminc1benzoate A mixture of 19.2 g of methyl 2-aminobenzoate and 9.6 g of ethyl g-bromobutyrate is heated at 80-85°C for 24 hours, cooled to room temperature and filtered. The solid is washed with CH2CI2 and the filtrate washed with 1NHC1, H2O, !NNaHC03 and brine. The solvent is removed to give an oil. The oil is distilled and the fraction boiling at 45-75°C and 13C-160°C were collected and discarded. The residue is the product (55.4 g of oil) Reference Example 182 Met vl ?-rN-(4-ethoxy-4-oxobutvl)-N-(2- methylphenvlsulfonyl) aminolbenzoate A mixture of 2.65 g of methyl 2- [ (4-ethoxy-4- oxobutyl) amino]benzoate, 2.0 g of 2-methylphenylsulfonyl chloride and pyridine is heated on a steam bath for 16 hours. The mixture is concentrated under a vacuum (remove pyridine) and IN HCI added. The mixture is extracted with dichloromethane and the extract washed with 1NHC1, H2O, 1 M NaHC03, brine and dried (Na2S04). The solution is filtered through a thin pad of hydrons magnesium silicate and the filtrate evaporated to give 3.8 g of solid which is crystallized from ethanol to give crystals, m.p. 100-102°C. Reference Example ifi3 of yi and Ethvl .2-Dihvdro-5-hvdroxv-l- r (4- ethylphenyl sulfonvl i -3H-l-benzazepine-4-carboxvlate To a mixture of 0.448 g of potassium tert- butoride in 2 ml of tetrahydrofuran; cooled to 0°C is added 0.838 g of methyl 2- [N- (4-ethoxy-4-oxobutyl) -N- (2- methylphenylsulfonyl) amino]benzoate in 12 ml of tetrahydrofuran. The mixture is stirred at 0°C for 4 hours (under argon) , poured into water and neutralized with 2N citric acid. The mixture is extracted with dichloromethane and the extract washed with H20, brine and dried (Mg SO4) . The extract is filtered through a thin pad of hydrous magnesium silicate and the filtrate concentrated to dryness to give 0.59 g of product (a mixture of methyl and ethyl esters) . Reference Example 184 1.2.3.4-tetrahvdro-l- f (2-methvlphenvl) sulfonvl i -5H-1 - benzazepin-5-one A 30 g sample of a mixture of methyl and ethyl 1, 2-dihydro-5-hydroxy-l- [ (4-methylphenyl) sulfonyl]-3H-1- benzazepine-4-carboxylate in a mixture of 171 ml of concentrated hydrochloric acid and 171 ml of glacial acetic acid is refluxed 24 hours. An additional 170 ml of concentrated hydrochloric acid is added and the mixture refluxed for 24 hours. The mixture is concentrated under vacuum to near dryness, diluted with water and the solution brought to pH 8 with saturated NaHC03. The mixture is extracted with dichloromethane and the extracted washed with H2O, brine and dried (Na2Sθ4) . The solution is filtered through a thin pad of hydrous magnesium silicate and the filtrate evaporated to give 12.0 g of a brown oil. Reference Example 185 4-r (Dimer.hvlamino)methvlenel-1.2.3.4-tetrahvdro-l-r (2- mefbylphenvl) sulfony 1 -5H-l-benzazepin-5-one A mixture of 1.89 g of 1, 2 , 3, 4-tetrahydro-l- [ (2-methylphenyl) sulfonyl] -5H-l-benzazepin-5-one and 2.47 ml of tert-butoxy-bis (dimethvla ino)methane (Bredericks reagent) in 10 ml of dichloromethane is heated under argon on a steam bath for 16 hours. The mixture is concentrated to dryness under vacuum and the residue dissolved in CH2C12- The solution is filtered through a thin pad of hydrous magnesium silicate and the pad washed with 5% ethyl acetate in CH2CI2. The filtrate is concentrated to dryness and the residue (1.96 g) crystallized from CH2Cl2~hexane to give 0.85 g of crystals, m.p. 180-185°C. A second crop of crystals (0.85 g) is recovered from the mother liquors and an additional 0.30 g is recovered from washing the pad of hydrous magnesium silicate with ethyl acetate. Reference Example 186 l, ,5,6.-ιe-.ranydro-'-[ (2- methvlphenvl) sulfonvllpvrazolof4.3-dl fllber.zazepine A mixture of 1.55 g of 4- [ (dimethylamino) - methylene] -1,2,3, 4-tetrahydro-l- [ (2-methylphenyl) - sulfonyl] -5ϋ-l-benzazepin-5-one, 0.25 ml of hydrazine and 60 ml of ethanol is refluxed on a steam bath under argon for 2 hours. After standing overnight at room temperature, the solvent is removed under vacuum. The residue is dissolved in CH2CI2 and the solution washed with water, brine and dried ( (Na2Sθ4) . The solution is filtered through a thin pad of hydrous magnesium silicate and the filtrate evaporated to give 1.4 g of crystals, m.p. 76-79°C. On a larger scale reaction with 18.29 g of 4- [ (dimethylamino)methylene]-1, 2,3, 4-tetrahydro-l- [ (2- methylphenyl) sulfonyl]-5H-i-benzazepin-5-one the product in CH2CI2 is filtered through a thin pad of hydrous magnesium silicate and the filter pad washed with ethyl acetate. The filtrate is concentrated to give 16.5 g of product (one spot by thin layer chromatography (silica gel) with hexane-ethyl acetate (1:2) . Reference Example 187 1.4.5. £-Tetra ydrcpyrazolo-f4.3-dl f1Ibenzazepine A mixture of 1.0 g cf 1, , 5, 6-tetrahydro-6- [ (2-methylphenyl) sulfonyl]pyrazolo [4, 3-d] [1Ibenzazepine in 60 ml of 40% (V/v)H2S04 in glacial acetic acid is heated at 60°C for 12 hours or until the tosyl group is removed. The mixture is poured into 100 ml ice and water with cooling. Solid NaOH is added portionwise (temperature kept below 30°C) with efficient stirring and the pH brought to 8. The mixture is extracted with ethyl acetate and the extract dried (Na2Sθ4) and the solvent removed to give a solid. Peference Example 188 1 . ll-Dihvdroben? fb. fl r1.41 oxazepine To a slurry of 7.35 g of lithium aluminum hydride 100 ml of tetrahydrofuran is added in portions 10.0 g of dibenz [b, f] [1, ] oxazepin-10 (11H) -one. An additional 100 ml of tetrahydrofuran is added and the mixture is refluxed for 6 hours and then stirred at room temperature overnight. To the chilled mixture is added dropwise 7.5 ml of H2θ, 7.5 ml cf 15% NaOH and three 7.5 ml portions of H2O. The mixture is filtered and the filter cake washed with tetrahydrofuran and dichloromethane. The filtrate is concentrated to dryness under vacuum to give 10.1 g of solid. The solid is dissolved in dichloromethane and the solution filtered through a thin pad of hydrous magnesium silicate. The filter cake is washed with dichloromethane and the filtrate concentrated to dryness to give 8.9 g of solid. Crystallization from dichloromethane-hexane gives 7.5 g crystals, m.p. 69- Reference Example 1B9 Pvr-i of2.3-bl f1.41benzoxazepin-6 (5H) -one A mixture of 21.4 g of phenyl salicylate, 25.71 g 3-amino-2-chloropyridine and 20 ml of 1,2,4- trichlorobenzene is refluxed for 1 hour under argon and the liberated phenol and HCI simultaneously distilled (from the refluxing mixture) and collected in a solution of IN NaOH. The hot mixture is poured into 200 ml of ethanol and the precipitated solid collected by filtration. The solid is washed with ethanol and dried. Recrystallization from methanol - DMF (6:1) gives 6.0 g of product, m.p. 268-270°C. Reference Example 190 5. -DihvdroPvrido f2.3-b 1 f1. 1benzoxazeoine A mixture of 2.8 g of pyrido [2, 3-b] [1, 4] benzoxazepin-6 (5 ) -one, 10 ml of tetrahydrofuran and 3 ml of 10M borane-dimethylsulfide in tetrahydrofuran is stirred at room temperature overnight and then refluxed for 3 hours. To the mixture is added dropwise under argon, 5 mi of methanol. The solvent is removed under vacuum and methanol added. The solvent is removed under vacuum and 12 ml of 2£J NaOH added tc the residue. The mixture is refluxed for 2 hours ana extracted with ethyl acetate. The extract is washed with 2H citric acid, H2θ, brine and dried ( a2SO_5) . The solution is filtered through a thin pad cf hydrous magnesium silicate and the filtrate concentrated to dryness under vacuum. The residue is chromatographed on a column (2" x 18") of silica gel (32° g) with hexane-ethyl acetate (1:1) as solvent to give 0.78 g of crystals, m.p. 172-174°C. Reference Example 191 N- (2-Hydrovyphenvl) -2-chloro-3-Pvridinecarboxamide As described in J. Med. Chem.. 37. 519 (1994), a solution cf 1.09 g cf 2-aminophencl in 15 ml of tetrahydrofuran is added dropwise to a mixture of 2.1 g cf triethylamine and 2.33 g cf 2-c loropyridine-3- carbonyl chloride hydrochloride in 10 ml of tetrahydrofuran. The mixture is stirred at room temperature for one hour under argon and then refluxed for one hour. The solvent is removed under vacuum and the residue triturated with water: The solid is filtered off and washed with water to give 1.02 g of solid. Recrystalii∑aticn from 2-prcpancl gives crystals, m.p. 145-146°C. Reference Example 192 Pvridof2.3-bl f1.51benzoxazepin-5 (6H)one A mixture of 13.0 g of ϋ- (2-hydroxyphenyl) -2- chloro-3-pyridinecarboxamide and 2.82 g of sodium methoxide in 100 ml of N, N-dimethylformamide is refluxed under argon for 3 hours . Sodium methoxide (0.50 g) is added and the mixture refluxed 2 hours and then stirred at room temperature for 2 days. The solvent is removed under high vacuum and the red-brown residue triturated with cold methanol. The mixture is filtered and the solid washed with chilled methanol to give 5.0 g of white solid, m.p. 250-253°C. Reference Example 193 5, -rihvdropvridor2.2-k 1 fl,Slfrenzoxazepine To a stirred slurry of 0.886 g of lithium aluminum hydride in 20 ml of tetrahydrofuran is added 1.65 g cf pyrido[2, 3-b] [1, 5] benzoxazepin-5 (6H) -one in portions. The mixture is diluted with 30 ml of tetrahydrofuran and refluxed under argon for 18 hours. To the mixture is added 1 ml of water, 1 ml of 15% NaOH and three one-ml portions of H2O and the mixture is filtered. The solid is extracted with dichloromethane and the solution passed through a thin pad of hydrous magnesium silicate. The filtrate is concentrated to dryness to give crystals, m.p. 125-129°C. Reference Example 194 9.10-r hvdrc-4H-thienof2,3-c1 f 1benzazeoine To a solution of 9.0 g at 4, 5-dihydro-4, 4- dimethyl-2- (2-thienyl) oxazole in 200 ml of tetrahydrofuran, cooled to -78°C, is added 20 ml of a 2.5 molar solution of n-butyl lithium in hexane. The mixture is stirred -78°C for 15 minutes and at 0°C for 30 minutes. To the stirred solution is added 6.0 g of 2-methylbenzoxazepine-4-one. The mixture is stirred at room temperature for 16 hours quenched with ice cold water and extracted with chloroform. The extract is concentrated to dryness and 100 ml of 40% H2SO4 is added. The mixture is refluxed for 4 hours, cooled to room temperature and filtered to give 9, 10-dihydro-4, 10- dioxo-4ϋ-thieno [2, 3-£] [1]benzazeρine. The solid is washed with water to give 2.5 g of crystals. The solid is dissolved in 100 ml of dry tetrahydrofuran and 1.0 g of lithium aluminum hydride added. The mixture is refluxed for 16 hours, chilled and ice cold water is added dropwise. The mixture after dilution with water is extracted with chioroform-methanol (3:1) and the extract dried (MgSO.?) . The solvent is removed and the residue chromatographed over silica gel with ethyl acetate-hexane (1:1) as solvent to give 1.8 g of solid; Mass spectrum (CD 202 (M + H) . Reference Example 195 thyl 4- r ( H, 1 ' -Biphenyl1 -2-carhonyl ) aminr. -3- methoxybenzoate A mixture of 10.0 g of [1, 1 '-biphenyl] -2- carboxylic acid in 75 ml of methylene chloride and 12.52 g of oxalyl chloride is stirred at room temperature for 15 hours. The volatiles are evaporated in vacuo to give 11.06 g of an oil. A 2.16 g portion of the above oil in 25 ml of methylene chloride is reacted with 1.81 g of methyl 4-amino-3-methoxybenzoate and 1.30 g of N,N- diisopropylethylamine by stirring at room temperature for 18 hours. The reaction mixture is washed with water, saturated aqueous NaHCθ3 and the organic layer dried( a2S0 ) . The organic layer is passed through hydrous magnesium silicate and hexane added to the filtrate at the boil to give 3.20 g of the desired product as a crystalline solid, m.p. 115-117°C. 2 Reference Example 196 Methvl 4- f ( f1.1 '-Biphenvl1-2-carbonyl) mino1-2- chlorobenzoate A solution of 2.37 g of [1, 1 '-biphenyl]-2- carbonyl chloride in 10 ml of methylene chloride is added dropwise to an ice cold solution of 1.84 g of methyl 4-amino-2-chlorobenzoate and 1.49 g of N,N- diisopropylethylamine in 50 ml of methylene chloride. The reaction mixture is stirred at room temperature for 18 hours and washed with water, saturated aqueous NaHCθ3 and the organic layer dried( a2Sθ4) . The organic layer is passed through a pad of hydrous magnesium silicate and hexane added at the boil to give 1.1 g of the desired product as a crystalline solid, m.p. 132-134°C. M + H=365 Reference Example 197 4-f (fl.1 '-Biphenvl1-2-carbonyl) aminol-2-chlorobenzoic Acid A mixture of 3.0 g of methyl 4- [([1,1*- biphenyl]-2-carbonyl) amino]-2-chlorobenzoate in 75 ml of absolute ethanol and 2.0 ml of 10 N sodium hydroxide is heated on a steam bath for 3 hours. Water is added to obtain a solution which is extracted with methylene chloride. The aqueous phase is acidified with acetic acid and the resulting solid collected and dried 2Ά vacuo at 80°C to give 0.1 g of the desired product as a crystalline solid, m.p. 217-219°C Reference Example 198 4-f ( ri, '-Biphenvlι-2-carbonyl) -aminol-3-methoxvbenzovl Chloride A solution of 2.69 g of 4- [([1, 1 '-biphenyl]-2- carbonyl]amino]-3-methoxy benzoic acid in 5 ml of thionyl chloride is heated on a steam bath for 1 hour under Argon. The volatiles are removed in vacuo to give a residue which is stirred with hexane to give 2.58 g of crystalline solid, m.p. 121-123°C. +=361. Reference Example 199 er.hvl 4-r (H.l '-BiPhenvl i -2-carbonvl) aminolbenzoare A mixture of 10.0 g of [1, 1 '-biphenyl]-2- carboxylic acid in 75 ml of methylene chloride and 12.52 g cf oxalyl chloride is stirred at room temperature for 18 hours. The volatiles are evaporated i vacuo to give 11.66 g cf an oil. A 7.5 g portion of the above oil in 25 ml of methylene chloride is added dropwise to a solution of 4.53 g cf methyl-4-aminobenzoate and 4.3 g cf N,N-diisopropylethylamine in 100 ml of methylene chloride at 0°C. The reaction mixture is stirred at room temperature for 18 hours and washed with water, and saturated aqueous NaHC03 and the organic layer dried(Na2≤θ ) . The organic layer is passed through hydrous magnesium silicate and hexane added to the filtrate at the boil to give 8.38 g of the desired product as a crystalline solid, m.p. 163-165°C. Reference Example 200 4- r ( M . : ■ -Biphenvli-2-carbonvl) aminolbenzoin Acid A 3.15 g sample of methyl 4- [( [1, 1 '-biphenyl] - 2-carbonyl) amino]benzoate is refluxed for 8 hours in 100 ml of ethyl alcohol and 2.5 ml of ION sodium hydroxide. The cooled reaction mixture is acidified with [[? acid]] and the desired product collected and dried to give 2.9 g of the desired product as a solid m.p. 246-249°C. M+H=318. Reference Example 201 4-f ( ri. '-Pjphenyli-2-carbonyl) aminolbenzoyl Chloride A mixture of 1.39 g cf 4-[ ([l, 1 '-biphenyl] -2- carbonyl) amino]benzoic acid in 2.0 ml of thionyl chloride is heated on a steam bath for 1 hour. Cold hexane is added and the crystalline solid collected and dried to give 1.34 g of the desired product, m.p. 118- 120°C. Reference Example 202 2- (Phenvlmethvl)benzovl Chloride A mixture of 5.0 g of 2- (phenylmethyl)benzoic acid in 5.0 ml of thionyl chloride is heated on a steam bath for 1 hour. The volatiles are evaporated in vacuo to give 5.74 g of the desired product as an oil. M + =227 as methyl ester. Reference Example 203 Methvl 4- r T2- (Phenvlmethvl)benzovl1 aminolbenzoate To 3.03 g of methyl 4-aminobenzoate and 3.12 g of N,N-diisopropylethylamine in 75 ml of methylene chloride is added 5.54 g of 2- (phenylmethyl)benzoyl chloride and the reactants stirred at room temperature for 18 hours. The reaction mixture is washed with water, saturated aqueous NaHCθ3 and the organic layer dried(Na2Sθ4) . The organic layer is passed through hydrous magnesium silicate two times and hexane added to the filtrate at the boil to give 5.04 g of the desired product as a crystalline solid, m.p. 138-139°C. Reference Example 204 Sodium 4- r f2- (Phenylmethyl)benzovll aminolbenzoate A mixture of 4.90 g of methyl 4-[[2- (phenylmethyl)benzoyl] amino]benzoate in 100 ml of absolute ethanol and 3.50 ml of 10 N sodium hydroxide is heated on a steam bath for 3 hours. The aqueous phase is filtered and the resulting solid collected and dried to give 4.25 g of the desired product m.p. 340-346°C. Reference Example 205 4- r f - (Phenvlmethvl) benzovl1 aminolbenzoin Aci A mixture of 4.0 g sodium 4- [ [2- (phenylmethyl)benzoyl] amino]benzoate is suspended in water and the pH adjusted to 5 with acetic acid. The solid is collected by filtration and dried at 80°C in vacuo to give 3.75 g of the desired product, 246-247°C, M^=332. Reference Example 206 4-r r 2- (Phenylmethyl) benzoyllamir.o 1 benzoyl Chloride A mixture of 2.0 g cf 4- [ [2- (phenylmethyl) benzoyl] amino]benzoio acid in 2.0 ml of thionyl chloride is heated on a steam bath for 1 hour. The volatiles are evaporated in vacuo to give 1.53 g of the desired product as an oil. M + =346 as methyl ester. Reference Example 207 Methyl 4-r f (2-Phenvlmethyl)benzov 1 aminol -2-chloro- benzoate A mixture of 5.0 g of 2- (phenylmethyl)benzoic acid in 5.0 ml of thionyl chloride is heated on a steam bath for 1 hour. The volatiles are evaporated in vacuo to give 5.70 g cf an oil. A 2.85 g portion of the above oil in 25 ml of methylene chloride is added to a solution of 50 ml of methylene chloride containing 1.85 g of methyl 4-amino-2-chlorobenzoate and 1.65 g of N,N- diisopropylethylamine by stirring at room temperature for 18 hours. The reaction mixture is washed with water, saturated aqueous NaHCθ3 and the organic layer dried (Na2Sθ4) . The organic layer is passed through hydrous magnesium silicate two times and hexane added to the filtrate at the boil to give 2.96 g of the desired product as a crystalline solid, m.p. 133-135°C. M + =380. Reference Example 2Q8 Me hvl 4-f r (2-Phenvlmethvl)benzov laminol-3- methoxvbenzoate A solution of 2.85 g of 2- (phenylmethyl)benzoyl chloride in 25 ml of methylene chloride is added dropwise to an ice cold solution of 1.84 g of methyl 4-amino-3-methoxybenzoate and 1.61 g of N,N-diisopropylethylamine in 50 ml of methylene chloride. The reaction mixture is stirred at room temperature for 18 hours and washed with water, saturated aqueous NaHCθ3 and the organic layer dried( a2Sθ4) . The organic layer is passed through a pad of hydrous magnesium silicate and hexane added at the boil to give 2.2 g of the desired product as a crystalline solid, m.p. 129-131°C. M + =376. Reference Example 209 2-Chloro-4- r r (2-Phenvlmethvl)benzovl1aminolbenzoic Acid A mixture of 2.8 g of methyl 2-chloro-4- [ [ (2- phenylmethyl) benzoyl] aminobenzoate in 75 ml of absolute ethanol and 1.84 ml of 10 N sodium hydroxide is heated on a steam bath for 3 hours. Water is added to obtain a solution which is extracted with methylene chloride. The aqueous phase is acidified with acetic acid and the resulting solid collected and dried in vacuo at 80°C to give 2.6 g of the desired product as a crystalline solid, m.p. 184-187°C. M + H=366. Reference Example 210 3-Methoxy-4-r f (?-phenvlmethvl) benzovll aminolbenzoi r. Acid A mixture of 2.05 g of methyl 4- [ [ (2- phenylmethyl)benzoyl]amino]-3-methoxybenzoate in 75 ml of absolute ethanol and 1.4 ml of 10 N sodium hydroxide is heated on a steam bath for 3 hours. Water is added to obtain a solution which is extracted with methylene chloride. The aqueous phase is acidified with acetic acid and the resulting solid collected and dried ip vacuo at 80°C to give 1.87 g of the desired product as a crystalline solid, m.p. 176-178°C. M + H=362. Reference Example 211 3-Methoxv-4-f r (2-phenvlmethvl)benzovl 1 aminolbenzovl Chloride A mixture of 1.71 g of 3-methoxy-4- [ [ (2- phenylmethyl) benzoyl] amino]benzoic acid in 2.0 ml of thionyl chloride is heated on a steam bath under Argon for 1 hour and hexane added. The resulting solid is collected and dried to give 1.71 g of the desired product as a crystalline solid, m.p. 130-135°C. M + =376 as the methyl ester. Reference Example 212 f4 '- (Trifluoromethvl) -1.1 '-biphenvl < -2-carbonvl Chloride A mixture of 5.0 g of 4'- (trifluoromethyl) [1, 1 '-biphenyl] -2-carboxylic acid in 5.0 ml of thionyl chloride is heated on a steam bath under Argon for 1 hour and hexane added. The resulting solid is collected and dried to give 5.36 g of the desired product as a colorless oil. M + =280 as methyl ester. Reference Example 213 Mer.hvl 4-f (f4'-(trifluoromethvl) fl.l'- biphenyll carbonyl) aminolbenzoate A solution of 3.13 g of [4'- (trifluoromethyl) [1, 1 '-biphenyl] -2-carbonyl chloride in 25 ml cf methylene chloride is added dropwise to an ice cold solution of 1.84 g of methyl 4-aminoben∑oate and 1.43 g of N,N-diisopropylethylamine in 50 ml of methylene chloride. The reaction mixture is stirred at room temperature fcr 18 hours and washed with water, saturated aqueous NaHCθ3 and the organic layer dried(Na2Sθ4) . The organic layer is passed through a pad of hydrous magnesium silicate and hexane added at the boil to give 3.36 g of the desired product as a crystalline solid, m.p. 164-165°C. M + =396. Reference Example 214 3-Methoxy-4-f ( r '- (trifluoromethvl ) M X '-biphenyH -7- carbonyl) ami olbenzoyl Chloride A mixture of 2.0 g of 3-methoxy-4- [ ( [ ' - (trifluoromethyl) [1, 1 '-biphenyl] -2- carbonyl) amino]benzoic acid in 20 ml of thionyl chloride is heated on a steam bath under Argon for 1 hour and hexane added. The resulting solid is collected and dried to give 1.92 g of the desired product as a crystalline solid, m.p. 136-138°C. Reference Example 215 carbonyl) aminolbenzoic Acid A mixture of 3.78 g of methyl 3-methoxy-4- [ ( [ '-trifluoromethyl) [1, 1 '-biphenyl] -2- carbonyl) amino]benzoate in 75 ml of absolute ethanol and 2.20 ml of 10 N sodium hydroxide is heated on a steam bath for 3 hours. Water is added to obtain a solution which is extracted with methylene chloride. The aqueous phase is acidified with acetic acid and the resulting solid collected and dried in vacuo at 80°C to give 3.49 g of the desired product as a crystalline solid, m.p. 213-215°C. R fgr p.c Example 71 Moi-hyl 3-Mefhnχv-4-r f '-trif.nnrp- pr.hyl) fl.l'- h-iphenyl 1-2-carbonvl) amino1hen?nate A solution of 3.56 g of [4'- (trifluoromethyl) [1, 1 '-biphenyl] -2-carbonyl chloride in 25 ml of methylene chloride is added dropwise to an ice cold solution of 1.81 g of methyl 4-amino-3- methoxybenzoate and 1.62 g of N,N-diisopropylethylamine in 50 ml of methylene chloride. The reaction mixture is stirred at room temperature for 18 hours and washed with water, saturated aqueous NaHCθ3 and the organic layer dried(Na2Sθ ) . The organic layer is passed through a pad of hydrous magnesium silicate and hexane added at the boil to give 3.9 g of the desired product as a crystalline solid, m.p. 112-113°C. Reference Example 217 2-Chloro-4- r ( J Δ '- (trifluoromethyl) fl.1 '-biphenyl1-2- carbonvl) aminolbenzovl Chloride A mixture of 1.39 g of 2-chloro-4- [ ( [4 '- (trifluoromethyl) [1,1 '-biphenyl] -2- carbonyl) amino]benzoic acid in 2.0 ml of thionyl chloride is heated on a steam bath for 1 hour. The reaction mixture is concentrated to a residue in vacuo to a residue. Cold hexane is added to the residue and the solid collected and dried to give 1.39 g of the desired product. Reference Example 21B 7-Chloro-4-r ( r '- (trifluoromethyl) r 1.1 '-biphenyl1-2- carbonyl) aminolbenzoic acid A mixture of 3.83 g of methyl 2-chloro-4- [ ( [4 '- (trifluoromethyl) [1,1 '-biphenyl] -2- carbonyl) amino]benzoate in 75 ml of absolute ethanol and 2.20 ml of 10 N sodium hydroxide is heated on a steam bath for 3 hours. Water is added to obtain a solution which is extracted with methylene chloride. The aqueous phase is acidified with acetic acid and the resulting solid collected and dried in vacuc at 80°C to give 3.42 g of the desired product as a crystalline solid, m.p. 187-189°C. Reference Example 219 Methyl 2-Chloro-4-f(f4'- (trifluoromethyl) fl. '- biphenvl1-2-carbonyl)aminolbenzoate A solution of 3.56 g of [4'- (trifluoromethyl) [1, 1 '-biphenyl] -2-carbonyl chloride in 10 ml of methylene chloride is added dropwise to an ice cold solution of 1.86 g of methyl 2-chloro-4- aminobenzoate and 1.6 g of N,N-diisopropylethylamine in 50 ml of methylene chloride. The reaction mixture is stirred at room temperature for 18 hours and washed with water, saturated aqueous NaHCθ3 and the organic layer dried(Na2Sθ ) . The organic layer is passed through a pad of hydrous magnesium silicate (3X) and hexane added to the filtrate at the boil to give 4.0 g of the desired product as a crystalline solid, m.p. 130-132°C. Reference Example 22Q 4-r fH'- (Trifluoromethyl. [1,1'- biphenvl! carbonvl) aminolbenzoic Acid A mixture of 3.0 g of methyl 4-[([4'- (trifluoromethyl) [1,1 '-biphenyl]-2- carbonyl) amino]benzoate in 75 ml cf absolute ethanol and 2.0 ml of 10 N sodium hydroxide is heated on a steam bath for 3 hours. Water is added to obtain a solution which is extracted with methylene chloride. The aqueous phase is acidified with acetic acid and the resulting solid collected and dried in vacuo at 80°C to give 2.93 g of the desired product as a crystalline solid, m.p. 243-245°C. M + =385. Reference Example 221 Methvl 6-r - 3- (2-MethvlPvridinvl) carbonvll aminolpvr. ine- 3-carboxvl te To a stirred solution of 3 g of methyl 6- aminopyridine-3-carboxylate and 4 ml of N,N- diisopropylethylamine in 100 ml of methylene chloride is added dropwise a solution of 6.4 g of 2-methylpyridine- 3-carbonyl chloride in 25 ml of methylene chloride. The reaction mixture is stirred at room temperature for 2 hours and quenched with water. The organic layer is washed with water, dried(MgS04) , filtered and evaporated in vacuo to a residue which is stirred with ether and the resulting solid collected and air dried to give 6.8 g of the desired product. M + =390. Reference Example 222 6- r ΓT - (2-methvlPvridinvl) carbonvllaminolpvridine-3- carboxvlic Acid To a solution of 6.5 g of methyl 6- [[3- (2- methylpyridinyl) carbonyl]amino]pyridine-3-carboxylate in 100 ml of 1:1 tetrahydrofuran:methyl alcohol is added 20 ml of 5N NaOH. The reaction mixture is stirred overnight and evaporated in vacuo to a residue. The residue is dissolved in water and neutralized with acetic acid. The separated solid is filtered and air- dried to give 3.0 g of the desired product. M + =257. Reference Example 223 Methyl 6- r ( π . '-Biphenvl1 -2-carbonvl) amino1 -pyridine-3- carboxylate To a solution of 1.5 g of methyl 6- aminopyridine-3-carboxylate in 100 ml of methylene chloride is added 3 ml of N,N-diisopropylethylamine at room temperature. To the stirred reaction mixture is slowly added a solution of 2.5 g cf [1, 1 '-biphenyl] -2- carbonyl chloride. The reaction mixture is stirred at room temperature for 4 hours and then quenched with water. The organic layer is washed well with water and dried over anhydrous MgSθ4, filtered and evaporated in vacuo to a solid residue. The residue is stirred with ether, filtered and dried to give 3.0 g of the desired product:M + =332. Reference Example 224 6-f (fl.1 '-Biphenvl1-2--^rbonvl)aminolPvridine-3- carboxylic Acid To a stirred solution of 2.5 g of methyl 6- [([1,1'-Biphenyl] -2-carbonyl) amino]-pyridine-3- carboxylate in 50 ml of 1:1 tetrahydrofuran:methanol is added 10 ml of 5N sodium hydroxide and the mixture stirred at room temperature for 16 hours. The reaction mixture is concentrated in vacuo to a residue which is dissolved in water and neutralized with acetic acid. The separated colorless solid is filtered and air dried to give 2.0 g of the desired product:M + =318. Reference Example 225 Methvl 2- (2-Pyridinvl)benzoate A mixture of 12 g of methyl 2- (iodomethyl)benzoate, 20 g of n-butyl stannane and 2 g of tetrakis (triphenylphosphine)palladium (0) are refluxed in degassed toluene for 48 hours. The reaction mixture is concentrated in vacuo to a residue which is purified by column chromatography on silica gel by elution with 1:1 ethyl acetate:hexane to give 5.5 g of the desired product as an oil. M " =213. Reference Example 226 2- (2-Pvridinvl Ibenzoic Acid A mixture of 3.0 g of methyl 2- (2- pyridinyl)benzoate and 600 mg of sodium hydroxide in 50 ml of 9:1 methanol:water is refluxed for 4 hours. The reaction mixture is concentrated in vacuo and the residue dissolved in 50 ml of cold water. The solution is neutralized with glacial acetic acid and the resulting product filtered, washed with water, and dried to give 2.5 g of the desired product:M+1=200. Example 1 N-f - (Diben fb.fl f1.41oxazeoi -10 (11H1 -yl carbonyl ) -7- pvridinvl i -5-fluoro-2-methylbenzamide To a stirred solution of 0.39 g cf 10,11- dihydrodibenz [b, f] [1, 4] -oxazepine, 1.1 ml of triethyl- amine in 5 ml of dichloromethane is added 1.17 g of 6- [ (5-flucro-2-methylbenzoyl) amino] -pyridine-3-carbonyl chloride. The mixture is stirred under argon at room temperature for 16 hours, and diluted with 50 ml of dichloromethane and 20 mi cf water. The organic layer is separated, washed with 20 ml each of IM NaHC03, brine and dried (Na2S0 ) . The solution is filtered through a thin pad of hydrous magnesium silicate and the filtrate is concentrated to dryness under vacuum. The residue is chromatographed on silica gel with ethyl acetate-hexane (1:1) as solvent to give a solid. Crystallization from ethyl acetate gives 0.335 g cf off-white crystals, m.p. 180-186°C. Example 2 -r5-r (9.10-Dihvdro-4H-thie no r2.3-ci r_Xber.zazepir.-9- yl) carbonyl . -2-pyridinvl -5- luoro-2-methylbenzanide As described for Example 1, 9, iO-dihydro-4-ϋ- thieno [2, 3-c] [1]benzazepine in dichloromethane, in the presence of triethylamine is reacted with 6- [ (5-fluoro- 2-methylbenzoyl) amino]pyridine-3-carbonyl chloride to give the product as a non-crystalline yellow solid. Example 3 N-r.5-r (4.10-Dihvdro-5H-thienof3.2-cl fllbenzazep ne-5- ylcarbonvl -2-ovridinvll-5-fluoro-2-methylbenzamide As described for Example 1, a mixture of 4,10- dihydro-5H-thieno [3, 2-c] [1]benzazepine and triethylamine in dichloromethane is reacted with 6- [ (5-fluoro-2- methylbenzoyl)amine]pyridine-3-carbonyl chloride to give the product as a solid. Example 4 N-r5-(Pyridor2.3-bll. 1benzoxazepin-5(6H)-ylcarbonyl)-2- pyridinvl -5-fluoro-2-mer-hvlbenzamide As described for Example 1, 5, 6-dihydro- pyrido[2, 3-b] [1, 4]benzoxazepine is reacted in dichloromethane, in the presence of triethylamine, with 6- [ (5-fluoro-2-methylbenzoyl) amino]pyridine-3-carbonyl chloride to give the product as white crystals, m.p. 187-189°C. Example 5 N-r.5-(Pvridor2.3-bl r1, 51benzoxazepin-6 (5H) -vlcarbonyl) - 2-pvridinvl -5-fluoro-2-methvlben7.amide As described for Example 1, 5, 6-dihydro [2, 3- b] [1, Sjbenzoxazepine reacted with 6- [ (5-fluoro-2- methylbenzoyl) amino]dichloromethane in the presence of triethylamine to give the product as a non-crystalline solid. Example 6 N- r - r ( . -Dihvdro-5H-dibenz fb. l azeoin-5-vl) carbonvl1 - 2-pyridinvl -5-fluoro-2-methvlbenzamide As described for Example 1, 6, ll-dihydro-5H- dibenz [b,e] azepine is reacted in dichloromethane in the presence of triethylamine, with 6- [ (5-fluoro-2- methylbenzoyl)aminojpyridine-3-carbonyl chloride to give the product as a solid. Example N- f5- f4.5-Dihvdro-2-methylpyrazolo f4. -dl f11benzazepi - 6 (2H) -vll carbonvl-2-pvridinvll -5-fluoro-2-methyl- benzamide As described for Example 1, 2, 4, 5, 6-tetra- hydro-2-methylpyrazolo [4, 3-d] [1]benzazepine is reacted in dichloromethane, in the presence of triethylamine, with 6- [ (5-fluoro-2-methylbenzoyl) amino]pyridine-3- carbonyl chloride to give the product as a solid. Example 8 N- X- r (6. ~-Dihvdro-5H-diber.z fb.dl azepin-5-yl) carbonyl1 - 2-pyridinvl1 -5-fluoro-2-methylbenzamide As describe for Example 1, 6, 7-dihydro-5H- dibenz [b, ] azepine is reaction in dichloromethane in the presence cf triethylamine, with 6- [ (5-fluoro-2-methyl- benzoyl) amino]pyridine-3-carbonyl chloride to give the product as a solid. Example 9 N-fή-r (4.5-Dihvdro-6H-thienof3.2-dl f11benzazeoin-6- yl) carbonvll -2-pyridinvl -5- luoro-2-methvlbenzamide As described fcr Example 1, 4, 5-dihydro-6ϋ- thieno [3, 2-d] [1]benzazepine is reacted in dichloromethane, in the presence cf triethylamine, with 6- [ (5-flucro-2-methylbenzoyl) amino]pyridine-3-carbonyl chloride to give the product as a solid. Example 10 N-r (5.10-Dihydro-4H-thieno r 3.2-c i f21benzazepin-4- yl) carbonyl 1 -2-pyridinyl ι -5-fluoro-2-methylbenzamide As described for Example 1, 5, 10-dihydro-4fi- thieno [3, 2-c [2]benzazepine in dichloromethane in the presence of triethylamine is reacted with 6- [ (5-fluoro- 2-methylbenzoyl) amino]pyridine-3-carbonyl chloride to give the product as a solid. Example 11 N-f f (4.5-Dihvdropvrazolof4.3-dl mbenzazep n- flH - yll carbonvll -2-Pvridinvll-5-fluoro-2-methylbenzamide To a solution of 0.20 mol of 1,4,5,6- tetrahydropyrazolo[4, 3-d] [l]benzazepine, 0.80 mol of triethylamine is added 0.42 mol of 6- [ (5-fluoro-2- methylbenzoyl) amino]pyridine-3-carbonyl chloride in 15 ml cf dichloromethane. The mixture is stirred under argon for 16 hours and diluted with dichloromethane (25 ml) . The mixture is washed with H2θ) , lMNaHC03, brine and dried ( a2S0 ) . The solvent is removed and the residue in methanol-tetrahydrofurane (1: 1) stirred with INNaOH for 5 hours. The mixture is neutralized with acetic acid and the solvent removed. To the residue is added H2O and the mixture extracted with ethyl acetate. The extract is washed with H2O, 1NHC1, lMNaHCC3 and dried ( a2S0 ) . The solvent removed under vacuum and the residue chromatographed on silica gel with ethyl acetate-hexane as solvent to give the product as a solid. Example 12 N-f5- r (6.11-Dihvdro-5H-dibenz fb.el azepin-5-yl. carbonyl1 - 7-pvridinvll fl. '-biphenvl1 -2-carboxamide To a chilled (0°C) solution of 0.293 g of 6, li-dihydro-5ϋ-dibenz [b, e] azepine and 625 L triethyl¬ amine in 3.5 ml of dichloromethane is added a solution of 0.657 g cf 6- [( [1, 1 '-biphenyl] -2-ylcarbonyl) amino] -3- pyridinecarbonyl chloride in 1.5 ml of dichloromethane. The mixture is stirred under argon at room temperature for 16 hours and diluted with 40 ml of dichloromethane and 20 ml of water. The organic layer is separated and washed with 20 mi each of IM NaHC03, brine and dried ( a2S0 ) . The solution is filtered through a thin pad of hydrous magnesium silicate and the filtrate con- centrated to dryness under vacuum. The residual solid is chromatographed on silica gel with ethyl acetate- hexane (1:1) as solvent to give the product as a glass. Crystallization from ethyl acetate gives 0.395 g of white crystals, m.p. 134-142°C. Example 13 N-T - f (4.5-Dihvdro-2-methvlPvrazolof4.3-dl r11benzazepi - 6 (7H) -vl) carbonvli -2-pvridinvl 1 r 1.1 ' -biphenyl -2- carboxamide As described for Example 12,2,4,5,6- tetrahydro-2-methylpyrazolo[4, 3-d] [1]benzazepine is reacted with 6- [( [1, 'biphenyl]-2-ylcarbonyl) amino] -3- pyridinecarbonyl chloride to give the product as a solid. Example 14 N- f^- r (6. ~7 -Dihycro-5H-dibenz fb.dl azepin-5-vl) carbonvl i- 2-Pvridir.vl . r l.1 '-biphenvl 1 -2-carboxamide As described for Example 12, 6, 7-dihydro-5H- dibenz [b, d] azepine is reacted with 6- [ ( [1, 1 '-biphenyl]- 2-ylcarbonyl) amino] -3-pyridinecarbonyl chloride to give the product as a solid. Example 15 N-rF-f (4.5-Dihvdro-6H-thienor3.2-d 1 riibenzazepin-6- yl ) carbonvl 1 -2-pyridinvll fl.1 '-biphenvli -2-carboxamide As described for Example 12, 4, 5-dihydro-6H- thieno [3, 2-d] [1]benzazepine is reacted with 6-[ ([l,l'- biphenyl] -2-yicarbonyi) amino] -3-pyridinecarbonyl chloride to give the product as a solid. Example 16 -f -r (5.10-Di ydrc-4H-thienof3.2-c i f21benzazepin-4- yl ) carbonyl ■ -2-pyridinvll n. l '-biohenvl i -2-carboxamide As described for Example 12, 5, 10-dihydro-4H- thienc [3, 2-c] [2]benzazepine is reacted with 6-[([l,l'- biphenyl] -2-yicarbonyi) amino] -3-pyridinecarbonyl chloride o give the product as a solid. Example 17 N-rS-r (9.10-Dihvdro-4H-thienof2.3-cl f 1benzazepin-9- vl) carbonvl1-2-pvridinvl1 f1.1 '-biphenvl1-2-carboxamide As described for Example 12, 9, 10-dihydro-4H- thieno[2, 3-c.] [1]benzazepine is reacted with 6-[([l,l'- biphenyl]-2-ylcarbonyl) amino]-3-ρyridinecarbonyl chloride to give the product as a solid. Example 18 N- f5- r (4.10-Dihvdro-5H-thieno f3.2-cl f11benzazepin-5- vl) carbonvll-2-pvridinvll ri. 'biphenvli-2-carboxamide As described for Example 12, 4, 10-dihydro-5fi- thieno[3,2-£] [1]benzazepine is reacted with 6-[([l,l'- biphenyl]-2-ylcarbonyl) amino] -3-pyridinecarbonyl chloride to give the product as a solid. Example 19 N-f5-r (4.5-Pihvdrcpvra?.olpr4.3-dl rπbenzazepin-6 (1H1 - vl) carbonvl < -2-pvridinvl1 f1.1 '-biphenvl1 -2-carboxamide As described for Example 11, 1,4,5,6- tetrahydropyrazolo[4, 3-d.] [l]benzazepine is reacted with 6- [ ( [1, 1 '-biphenyl] -2-ylcarbonyl) mino-3-pyridine- carbonyl chloride to give the product as a solid. Example 20 N- r - f (6.11-Dihvdro-5H-pvridof2.3-bl f1.51benzodiazepin- 6-yl) carbonvl -2-pvridinvl 1 -2-methvlfurane-3-carboxamide To a cooled (0°C) solution of 0.296 g of 6,11- dihydro-5ϋ-pyrido [2, 3-b] [1, 5]benzodiazepine and 624 mL cf triethylamine in 3 ml of dichloromethane is added a solution of 6- [ (2-methyi-3-furanyicarbonyl)amino]-3- pyridinecarbonyl chloride in 4 ml of dichloromethane. The mixture is stirred at room temperature for 16 hours and the solvent removed under vacuum. To the residue is added IM NaHCOs and the mixture extracted with ethyl acetate. The extract is washed with H2θ, IM NaHCθ3 brine and dried (Na2S0 ) . The solvent is removed under vacuum and the residue chromatographed on silica gel with ethyl acetate-hexane as solvent to give the product as a solid. Example 21 N- f5- r (6H) -ohenanthridinvl) carbonvl1 -2-pvridinyl 1 -2- methy yrane-?-carboxamide As described for Example 20, 5, 6-dihydro- phenanthridine is reacted with 6- [ (2-methyl-3-furanyl- carbonyl) amino] -3-pyridinecarbonyl chloride to give the product as a solid. Example 22 N-f5-r (5.1 -Dihvdro-lQH-dibenzfb.e i f1.41 diazepin-10- vll carbonvl ι -2-pyridinvl i -2-methylfurane-3-carboxamide As described fcr Example 20, 5, ll-dihydro-10ϋ- dibenz [b, e] [1, ] diazepine is reacted with 6- [ (2-methyl- 3-furanylcarbonyi) amino] -3-pyridinecarbonyl chloride to give the product as a solid. Example 23 N-f5-r (5.11-Dihvdro-lOH-dibenzfb.el r1.41 diazepin-10- yl) carbonvl -2-ovridinyll f1.1 '-biphenvl1 -2-carboxamide As described for example 12, 5, il-dihydro-lOfi- dibenz [b,e] [1, 4]diazepine is reacted with 6- [ ([1,1'- biphenyi] -2-yicarbcnyl) amino] -3-pyridinecarbonyl chloride to give the product as a solid. Example 24 5- (4- H-3ut.vlo>:vϊbenzovl-6. ll-dihvdro-5H- i ' pgp∑ b,el zepine To a solution of 6, ll-dihydro-5H-dihydro-5H- dibenz [b,e] azepine (0.12 g, 0.6 mmol) in methylene chloride (2 mi) is added triethylamine (0.12 g, 1.2 mmol), followed by 4-butoxybenzoyl chloride ( (0.15 g, 0.72 mmol) . The resulting mixture is stirred at room temperature for 2 hours, and then treated with 4 ml of IN NaOH. The mixture is extracted with ethyl acetate (10 ml) , and the extract is washed with IN sodium hydroxide and brine (5 ml) , dried over anhydrous sodium sulfate, and filtered through hydrous magnesium silicate. The fitrate is evaporated, and the crude material is triturated with isoctane to give 0.24 g of white solid; Mass spectrum (CD, 372 (MH+) Example 25 10- ( fl.1 'BiphenvH- -vlcarbonvl) -5. ll-dihvdro-10H- difrenzo-fb.el fl. 1 iazepine To a cooled (0°C) solution of 0.5 g of 5,11- dihydro-10ϋ-dibenzo [b,e] [1, 4]diazepine in 50 ml of CH2CI2 and 12 ml of disopropylethylamine is added dropwise a solution of 0.67 g of [1, 1 '-biphenyl]-4- carbonyl chloride in 50 ml of CH2C12- The mixture is stirred at room temperature for 16 hours. An additional 0.3 g cf [1, 1 ]-biphenyl] -4-carbonyi chloride in 30 ml of CH2CI2 is added and the mixture stirred at room temperature 16 hours. The volatiles are removed under vacuum and the residue dissolved in 150 ml of CHCI3. The solution is washed with 50 ml of H2O, dried (Na2Sθ4) and the solvent removed. The residue is chromatographed on silica gel with ethyl acetate-hexane (1:5) and ethyl acetate-hexane (1:3) as solvent to give 0.86 g of solid, m.p. 152°-154°C; Mass spectrum (CD, 377 (MH + ) . Example 26 .0- m .1 '-Biphenv 1 -4-v carbonyl ) -10.11- dihvorodibenz fb. f1 r l.41 oxazepine To a cooled (0°C) solution of 1.0 g of 10,11- dihydrodibenz [b, f] [1, 4] oxazepine and 7 mi of triethylamine in 30 ml of CH2C12 under argon is added dropwise 2.0 g cf [1, 1 '-biphenyl] -4-carbonyl chloride. The mixture is stirred at room temperature for 16 hours and diluted with 50 ml of CHCI3. The mixture is washed with 30 mi each of H2O, 2NHC1, H2O, saturated NaHC03, H2θ, and dried (Na2S04) . Solvent is removed under vacuum to give 1.6 g cf a yellow solid, m.p. 93°-95°C; Mass soectrum (CD, 3 "? 8 (MHD . Example 2 9- . '-Biphenvll -4-vlcarbonvl1-9.10-dihvdrr>-4H- thienor2.3-cl r11benzazepine As described for Example 26, 9, 10-dihydro-4ϋ~ thieno[2, 3-c] [l]benzazepine is reacted with [1,1'- biphenyl] -4-carbonyl chloride to give the product as a yellow solid; Mass spectrum (CD 381 (MT) . Example 8 5-(n.l '-Biphenvll-4-vlcarbonvl)-6.7-dihvdro-5H- dibenz fb. diazepine As described for Example 26, 6, 7-dihydro-5H- dibenz [b, d] azepine is reacted with [1, 1 '-biphenyl] -4- carbonyl chloride to give the proαuct as a solid. Example 29 6- ( r1. '-Biphenvl > -4-vlcarbonvl) 5. l-dihvdro-6H- pyridof2. -el r 1 benzazeoine As described for Example 26, 5, lll-dihydro-6H- pyrido[2, 3-e] [1]benzazepine is reacted with [1,1'- biphenyl] -4-carbonyl chloride to give the product as a solid. Example 30 5- ( r .1 ' -Biphenvli-4-vlcarbonvl) -5.6-dihvdropyrido f2.3- bl r .41benzothiazepine As described for Example 26, 5,6- dihydropyrido [2, 3-b] [1, 4]benzothiazepine is reacted with [1, 1 '-biphenyl] -4-carbonyl chloride to give the product as a solid. Example 31 10-ff 1 ..1 ' -Biohenyl > -4-ylcarbonyl) -10.11- dihvdro fb.fi '1. 1 hiazepine As described fcr Example 26, 10,11- dihydro [b, f] [1, 4] -thiazepine is reacted with [1,1'- biphenyl] -4-carbonyi chloride to give the product as a solid. Example 32 10- (4-Benzovlbenzovl) -10.11- dihydrodibenz fb.fl f1.41oxazepine As described for Example 26, 10,11- dihydrodibenz [b, f] [1, 4]oxazepine is reacted with 4- (benzoyl)benzoyl chloride to give the product as an off- white, m.p. 103° - 106°C; Mass spectrum (CD, 406 (MH + ) . Example 33 5-(4-Benzovlbenzoyl)5.6.11.12- tetrahvdrodibenz fb. f1 azocine As described for Example 26, 5,6,11,12- tetrahydrodibenz [b, f]azocine is reacted with 4- (benzoyl)benzoyl chloride to give the product as a solid, m.p. 89°-92°C, Mass spectrum (CD, 418 (MHD Example 34 10-f4- (Benzovlbenzovl)-lO. 1-dihvdro fb. fi f1. HIthiazepine As described for Example 26, 10,11- dihydro[b, f] [1, ]thiazepine is reacted with 4-(benzoyl chloride to give the product as a solid. Example 35 5- r_- (Benzovlbenzovl) -5.6-dihydropvridor2.3- fc 1 r l, 1benzothiazepine As described for Example 26, 5,6- dihydropyrido [2, 3-b] [1, 4]benzothiazepine is reacted with 4- (benzoyl)benzoyl chloride to give the product as a solid. Example 36 6-r (4-BenzoylbenzovD 15.11-dihvdro- 6H-pyridof2.3-el f11benzazepine As described for Example 26, 5, 11-dihydro-6&- pyrido [2, 3-eJ [1]benzazepine is reacted with 4- (benzoyl)benzoyl chloride to give the product as a solid. Example 37 5-r (4-Benzovlbenzovl) 13-6. -dihvdro-5H- dibenz fb. dl azepine As described for Example 26, 6, 7-dihydro-5ϋ- dibenz [b, d]azepine is reacted with 4- (benzoyl)benzoyl chloride to give the product as a solid. Example 38 Q -r (4-Benzovlbenzcvl) -9.10-dihvdro-4H- thienof2.3-ci fl1benzazepine As described for Example 26, 9, 10-dihydro-4£i- thieno [2, 3-c] [1]benzazepine is reacted with 4- (benzoyl)benzoyl chloride to give the product as a solid. Example 39 5- r (4-3enzoylbenzovD 1 - .10-dihyoro-5H-thieno r 3.2- cl f11benzazepine As described for Example 26, 4, 10dihydro-5H- thieno[3, 2-c] [1]benzazepine is reacted with 4- (benzoyl)benzoyl chloride to give the product as a solid. Example 40 5- X X : '-Biphenvlι-4-vlcarbonlv) -4.10-dihvdro-5H- thieno .2-d '11benzazepine As described fo Example 26, , 10-dihydro-5H- thieno [3, 2-c] [1]benzazepine is reacted with [1, 1 'biphenyl] -4-carbonyl chloride to give the product as a solid. Example 41 6-( f .l '-Biphenvli-4-vlcarbonyli-1.4.5.6- tetrahydropyrazolc r 4.3-dl ' 1benzazepine As described fcr Example 26, 2 mmol of 1,4,5, 6-tetrahydropyrazolo [4, 3-d] [11benzazepine is reacted with 5 mmol of [1, 1 '-biphenyl] -4-carbonyl chloride. The product is stirred in methanol with 2N NaOH fcr 16 hours and the mixture concentrated and extracted with ethyl acetate. The extract is washed with 1 M citric acid, NaHCOβ, H2O, dried (Na2Sθ ) and the solvent removed to give the product of the example as a solid. Example 47 - r - ' (5.6-nihydropyra7.nl o- (4.3-dl fl 1benzazepin-6 (1H - yi carbonvl ι-3-chlornphenyll M, .1 '-biphenvl 1-2- carfto ami . As described for Example 11, 6- (2-chloro-4- aminobenzoyl) -1,4,5, 6-tetrahydropyrazolo[4,3- d] [l]benzazepine is reacted with [1, 1 ' -biphenyl] -4- carbonyl chloride to give the product as a solid. Example 43 N-π-r f c , g- n ihvdrnpvra7.nl nf4.3-di r1.benzazepi n-6 (1HI - ylcarbonyl' -3-chlcrophenyl -2- (d ethyla ino) yridine-3- carbcxamid As described for Example 11, 6- (2-chloro-4- aminobenzoyl) -1,4,5, 6-tetrahydropyrazolo [4,3- d]benzazepine is reacted with 2- (dimethlamino)pyridine- 3-carbonyl chloride to give the product of the example as a solid. Example 44 N-f<_- r (5.6-dihvdropyrazolnf4.3-dl f11ben-azepin- (1H. - yi ) carbonvllPhenyl1-2- (dimethylaminn)pyridine-3- carboxamido As described for Example 11, 6- (4- aminobenzoyl) -1, 4, 5, 6-tetrahydropyrazolo- [4, 3- d]benzazepine is reacted with 2- (dimethylaminopyridine- 3-carbonyl chloride to give the product as a solid. Example 45 _r^- r - 6 "i "" 1 ?-r-o-ra h v , "^dibor 7 fb * 1 a^n^-t - -^.- v "1 . '-?> y- ' i- r m ' " > "• — 9 — JV'"' H ' P l 1 - " - f 1 'i <-' - '? — τιρt- 1-ι y l Kon ? aηι rip To a cooled (0°C) and stirred solution of 0.246 g of 5, 6, 11, 12-tetrahydrodibenz [b, f]azocine 695 mL of triethylamine in 5 ml of dichloromethane is added 0.586 g cf 6- [ (5-fluoro-2-methylbenzoyl) aminopyridine-3- carbonyl chloride. The mixture is stirred 16 hours - Ill - under argon, diluted with 50 ml of dichloromethane and 20 ml of water, and the organic layer separated. The organic layer is washed with 20 ml each of NaHCθ3, brine and dried (Na2Sθ4) . The solution is passed through a thin pad of hydrous magnesium silicate and the filtrate concentrated to dryness under vacuum. The residue (450 mg) is chromatographed on silica gel preparative plates to give a solid. Crystallization from ethyl acetate gives C.20 g of white crystals, m.p. 198° - 200°C. Example 46 N-r4- (Dibenz fb.fl fi , i oxazepin-10 (11H) -ylcarbonyl ) - phenvli ri. : ' -biphenyl 1 -2-carboxamide To a mixture of 0.197 g of 10,11- dihydroaibenz [b, f] [1, ] oxazepine and 0.402 g of 4- [( [1, 1 ' -biphenyl] -2-carbonyl) amino]benzoyl chloride in 5 ml of dichloromethane (cooled in ice bath) is added dropwise 0.154 g of N,N-diisopropylethylamine in 2 ml of dichloromethane. The mixture is stirred at room temperature under argon for 2 hours. The mixture is poured into water and the organic layer separated. The organic extract is washed with 2N a2Cθ3, water, brine and dried (Na2Sθ ) . The solution is filtered through a thin pad of hydrous magnesium silicate and the filter cake washed with dichloromethane. The filtrate is concentrated to dryness to give 0.65 g cf solid. The solid is purified by thick layer chromatography on silica gel with hexane-ethyl acetate (2:1) as solvent to give 0.110 g of a glass, m.p. 107°C-122°C. Anal. Found: C, 80.8; H, 4.9; N,6.0. Example 47 N- J - (Diben? rb. f 1 fl .41 oxazeoin-l0 (11H. -vlcarbonvl) -3- chl orophenyl 1 fl.1 'biphenyl 1 -2-carboxamide A mixture of 0.263 g of 10, ll-dihydro-10 (4- amino-2-chlorobenzoyl) ibenz [b, f] [1, 4] oxazepine, 0.195 g of [1, 1 '-bipheny] -2-carbonyl chloride and 0.116 g of M / ϋ-diisopropylethylamine in 7 ml of dichloromethane is stirred at room temperature for 3 hours. The mixture is poured into water and extracted with dichloromethane. The extract is washed with 2ϋ Na2Cθ3, water, brine and dried (Na2Sθ ) . The solution is filtered through a thin pad of hydrous magnesium silicate (pad washed with dichloromethane) . The filtrate is concentrated to dryness to give a yellow solid. The solid is purified by chromatography on thick layer silica gel plates with hexane-ethyl acetate (1:1) as solvent to give 0.12 g of a yellow glass, m.p. 145°C-188°C: Anal. found: C, 73.6; H, 4.6; N,5.0; Cl, 6.4. Example 48 N- r - (Dibenz fb. f1 fl .41 oxazepi n-1 nπiHIyl rarbnnvl ) -7- pyridinylι -5-fluoro-7-mei-hylbenzami e As described for Example 46, 10,11- dihydrodibenz [b, f] [1, 4 ] oxazepine is reacted in dichloromethane with 2- [ (2-methyl-5- fluorobenzoyl) amino] -5-pyridinylcarbonyl chloride in the presence of N, -diisopropylethylamine to give the product as crystals, m.p. 180°C-186°C. As described for Example 46 the following compounds can be prepared. Example 49 N-f4- (Dibenz fb. f 1 f 1.41 oxazepin- 0 (1 H1 - l carbonvl ) - phenyl1-2- (2-pyridinyl) benzamide Example 50 N- f4- (Diben fb.f 1 r .41 oxazepin-10 f11HI -yl carbonyl ) - phenyl1 -2- (3-pyridiny benzamide Example 51 N- r - (Dibenz fb.f 1 fi. 1 oxazepin-10 f H) -yl carbonyl ) - phenyl 1 -2- (4-pyridinyl ) benzamide Example 52 N- H- (Dibenz fb. fl fl .4 1 oxazepin-10 ( 1H -vlcarbonvl ) -3- rh1orophenyl 1 -2- (2-thienvl) benzamide Example 53 N-f4-Dlben7rb. 1 f 1.41 oxazepin- 0 ( 1H) -v.! carhonyl ) -3- chlorophenyl ' -2- (3-thienyl) benzamide As described for Example 48 the following compounds can be prepared. Example 54 N- f5- (Dibenz f fb. f1 f1.41oxazeoin-lO (11H) -vlcarbonyl ) -7- pvridinvl 1 -2-chloro-5-fl\-iorobenzamide Example 55 N- f5- (Dibenz rb. f1 ri .4!oxazeoin-lO (11H) -vlcarbonyl ) -7- pvridinv 1 -2-methvl-3-fluorobenzamide Example 56 N- f - (D ibenz rb . 1 f 1 . 4 i oxazepin-10 ( 11H) -vl carbonyl ) -7- pvri dinvn -2-methvl benzami de Example 57 N- f - (Dibenz fb. f 1 f1 ■ 41 oxazeoin-10 (11H) -ylcarbonyl) -2- pvridinvl!-2-chloro-3-pyridinvlcarboxamidP Example 5R N- f - (Dibenz rb. fi '1.41 oxazeoin-10 (11H) -vlcarbonyl ) -7- pvridinvl1 -2-hvdroxvbenzamide Example 59 N- f - (Dibenz fb. fi f1.41oxazepJn-10 (11H -vlcarbonyl) -2- pvridinvll-2- (dimethylamino)benzamide Example $Q N- f5- (Dibenz fb. fi f1■ 41 oxazeoin-lO (11H) -ylcarbonyl) -2- pvridinv] 1-7- (dimethylamino) -3-pvridinvlcarboxamide Example 61 N- f5- (Dibenz fb. f1 f1.41oxazeoin-lO (11H) -v carbonyl) -2- pyridinvl 1 -2-fluoro-5-chlorobenzamide Example 62 N- r.5- (Dibenz fb. f1 r 1.41oxazeoin-lO (11H) -vlcarbonvl) -2- pvr invll fl.1-biPhenvl1 -2-carboxami e Example 63 N-rS- (Dibenz fb.fl fl .41-oxazeoin-lO (11H) -vlcarbnnyll-2- pyr--:dinvll -2- (3-ovridinvl)benzamide Example 64 N- f - (Dibenz fb. f 1 f1.4l oxazeoin-10 (11H) -vlcarbonvl) -2- pvnidinvli -2- (2-Pvridinvl)benzamide Example 65 N- f5- (Dibenz fb. f 1. 1oxazeoin-l ( 1H) -vlcarbonvl 7- pvridinvll -2- (4-ovridinyl)benzamide Example 66 N- f5- (Pvrido f2.3-bl f1.51benzoxazepin-6 (5H) -vlcarbonyl ) - 2-Pvridinvli fl.1 'biphenyl i -2-carboxamide A mixture of 0.198 g of 5, 6-dihydropyrido[2, 3- fc] [1/ 5]benzoxazepine, 0.155 g of H ϋ- diisopropylethylamine and 0.404 g of 6- [( [1, 1 'biphenyl]- 2-carbonyl) amino]pyridine-3-carbonyl chloride in 12 ml of dichloromethane is stirred at room temperature for 3.5 hours. The mixture is poured into water and extracted with dichloromethane. The extract is washed with 2N Na2Cθ3,H2θ, brine and dried (Na2S04) . The solution is passed through a thin pad of hydrous magnesium silicate and the filtrate concentrated to dryness. The solid is dissolved hexane-ethyl acetate (1:2) and the solution filtered through a thin pad of hydrous magnesium silicate. The pad is washed with hexane-ethyl acetate (1:2) and the filtrate concentrated to dryness to give a glass, m.p.107°C-114°C Anal. Found: C, 74.4; H, 5.7; N, 8.8 Example 67 N-f4- (Pvrido f2.3-b1 f1.51benzoxazepin-6 (5H) -vlcarbonvl ) - 3-chlcrophen l rι, i ■ -biphenvli -2-carboxamide A mixture of 0.198 g of 5, 6-dihydropyrido [ 2 , 3- b] [1, 5]benzoxazepine, 0.155 g of H,H- diisopropylethylamine and 0.444 g of 4- [ ( [1, 1-biphenyl] - 2-carbonyl) amino] -2-chlorobenzoyl chloride in 12 ml of dichloromethane is stirred at room temperature for 2.5 hours. The mixture is poured into water and extracted with dichloromethane. The extract is washed with 2£J Na2Cθ3, H20, brine and dried (Na2S04) . The solution is passed through a thin pad of hydrous magnesium silicate. The filter pad is washed with 50 ml of hexane-ethyl acetate (1:2) and the filtrate concentrated to dryness. The residue is triturated with ether to give a solid, m.p. 205-217°C Anal. Found: C, 72.3; H, 4.2; N, 7.9; Cl, 6.7. As described for Example 66, the following compounds can be prepared. Example 68 N-r5-(Pyridof2.3-bl f1.51benzoxazepin-6 (5H) -ylcarbonyl)- 3-Pvridinvli fl.1 'biphenvli -2-carboxamide Example 69 N- f - (Pvrido f2.3-bl f1.51benzoxazepin-6 (5H) -vlcarbonyl) - 2-pvridinvl1 -2-chlorobenzamide Example 70 N- r5- (Pyrido f2.3-bl f1.51benzoxazepin-6 (5H) -ylcarbonyl . - 2-pvridinvli-2-chloro-5-fluorobenzamide Example ~ ?1 N-X - (Pvrido f2.3-b1 f1.51benzoxazeoin-6 (5H) -vlcarbonyl) - 2-pvridinvn-2-hvdroxvbenzamide Example 72 N- f5- (Pvridor2. -bi f1.51benzoxazepin-6 (5H) -vlcarbonvl) - 2-pyridinvl 1 -2.5-difluorobenzamide Example 73 N-f - (Pyridof2. -b 1 f1.51benzoxazepin-6 (5H) -vlcarbonyl) - 2-pvridinvl1-2-methvlbenzamide Example 74 N- ffi- (Pyrido r2.3-bi r1.51benzoxazepin-6 (5H) -vlcarbonyl) - 7-pvridinvl i -2- (dimethylamino)benzamide Example 75 N- f5- (Pyridor2.3-b! '1.5!benzoxazepin-6 (5H) -vlcarbonvl) - 7-pyridinvll -2- (methvlamino)benzamide Example 76 N-ffi- (Pyrido f?. -bl Q.51benzoxazeoin-6 (5H) -vlcarbonvl) - 7-pyridinvll-2- (aminomethvl)benzamide Example 77 N- f5- (Pvrido r2.3-bl f1.51benzoxazepin- (5H) -vlcarbonyl ) - 2-Pvridinvl1 -2-methoxvbenzamide Example 78 N-f5- (Pvridof2.3-bl f1.51benzoxazeoin-6 (5H) -vlcarbonvl . - 2-Pvridinvli-2-chloro-5-fluorobenzamide Example 79 N- f5- (Pvrido f2.3-b 1 f1.51benzoxazeoin- (5H) -ylcarbonyl) - 2-pvridinvl1 -2-methvl-3-fluorobenzamide Example 80 N- rg- (Pvridof2, -bl f1.51benzoxazepin- (5H) -ylcarbonyl ) - 2-ovridinvll -2-fluoro-6-chlorobenzamide Example 81 N- f - (Pvrido f2. -b 1 f1.51benzoxazepin- (5H) -ylcarbonyl ) - 2-ovridinvli -2.6-dichlorobenzamide Example 82 N- r 5- (Pvrido f2.3-bl f1.51benzoxazeoin-6 (5H) -vlcarbonyl) - 2-pyridinyl1-2,5-dimethylbenzamide Example 83 N- r5- (Pyrido f2.3-bl f1.51benzoxazepJ.n-6 (5H) -ylcarbonyl) - 7-pvridinvl 1 -2-chloro-3-Pvridinvlcarboxamide Example 84 N-r5- (Pyrido f2. -bl f1.51benzoxazep n-6 ( H) -vlcarbonvl) - 2-pvridinvl -2- (methvlamino) -3-ovridinvlcarboxamide Example 85 N- f5- (Pyrido f2. -bi fl.51benzoxazepjn-6 (5H) -vlcarbonvl) - 2-Pyridinvl i -2 (dimethylamino) -3-Pvridinvlcarboxamide Example 86 N-f5- (Pyrido f2. -bl fl, 51benzoxazerin- (5H) -ylcarbonvl) - 2-pyridinvl 1 -2- (aminomethyl) 4-ovridinylcarboxamide Example 8 ~ > N- f5- (Pyrido f2.3-bl f1.51benzoxazepir.-6 (5H) -vlcarbonvl) - 2-pyridiny! 1-2- (dimethylamino) -4-ovridinvlcarboxamide As described for Example 67, the following compounds can be prepared. Example 88 N-f4- (Pvridof2.3-bl fl.5!benzoxazepin-6 (5H) -vlcarbonvl) - 3-chloro-6-methvlphenvl1 f1.1 '-biphenvl1 -2-carboxamide Example 89 N-f4- (Pvridof2. -bl f1.51benzoxazepin-6 (5H) -vlcarbonvl) - 3. -dimethvlphenvll fl. '-biphenvli-2-carboxamide Example 90 N-f4- (Pvridor2.3-bl f1.51benznxazepin-6 (5H) -vlcarbonv ) - 2-me hvlphenvl! fl.1 '-biphenvl!-2-carboxamide Example 91 N-T - (Pvridof2.3-bl r1.51benzoxazepin-6 (5H) -vlcarbonyl) - 2-chi?ropnenyll fl, '-biphenvl 1 -2-carpgχamide Example 92 N-r4-(Pvridor2.3-b 1 r1.51benzoxazepir-6 (5H) -vlcarbonyl) - 3-chloro-6-methvlphenvl1-2- (2-thienvl)benzamide Example 93 N-f4- (Pvridof2.3-bl f1. 1benzoxazepin- (5H) -vlcarbonvl) - 3.6-dimethvlPhenvπ -2- (3-t ienvHbenzamide Example 94 N- T - (Pyrido f2. -bl .1.51benzoxazepin-6 (5H) -ylcarbonyl) - 3-methvlPhenvl!-2- (2-thienvl)benzamide Example 95 N-f4-(Pyridof2.3-b! f1. 1benzoxazepin-6 (5H) -vlcarbonvl) - 3-chlorophenvl! -2- (2-thienvl)benzamide Example 96 N _ f4- (Pyri o f2.3-bl fl.51benzoxazepin- (5H) -vlcarbonvl) - 3-f.hlorophep.vn-2- (3-thienvl)benzamide Example 97 N- r4- (Pyrido r2. -bl f1■ 51benzoxazeoin-6 (5H) -vlcarbonvl) - 3-chlorophenyli -2- (2-furanyl)benzamide Example 98 N-f4- (Pyrido f2.3-bf1 ■ 51benzoxazeoin-6 (5H) -vlcarbonvl) -3- rhlnrophenvli-2- (2-pyridinvl)benzamide Example 99 N-T4- (Pvrido f2.3-bl f1.51benzoxazepin- (5H) -vl carbonyl) - 3-chlorophenvl1 -2- (3-Pvridinvl) benza i de Example 100 N- f - (Pvrido f2.3-bl ri , 51 benzoxazepJn-6 (5H) -vl carbonyl) - 3-chlorophenvll-2- (4-pvridinvl) benzamide Example 101 N-T4- (Pvrido f2.3-bl 11.51benzoxazepin- (5H) -vlcarhonyl ) - 3-chlorophenvl1 -2- (3-furanvl) benzamide Example 102 N-T4- (Pyrido r2.3-bl f 1.51benzoxazepin-6 (5H) -yl carbonyl ) - • 3-methvlphenvli fl.1 'biphenvl 1 -2-carboxamide Example 3 N- f - (Pvrido f2. -b 1 f 1.51benzoxazepin- (5H) -ylcarbonyl ) - 3-methvlPhenvll -2- (3-thienvl) benzamide Example 104 N-T4- (Pvrido f2.3-bl fl.51benzoxazepin-6- (5H) -yl carbonyl) - 3-methvlphenvl 1 -2- (2-Pvridinvl) benzamide Example 105 N-f4- (Pyri nf2. -bl f1.51 benzoxazepin-6- (5H) -ylcarbonyl) - 3-met.hvphenv11 -2- (3-pyridinvl) benzami de Example 106 N-f4- (Pyrido f2.3-b i f 1.51benzoxazepin-6 (5H. -vl carbonvl) - 3-methylphenvll-2- (4-Pvridinvl) benzamide Example 107 N- f4- (Pyridpr2. -bl fl.51benzoxazepin-6 (5H) -vlcarbonyl) - 3-met-hvlohenvl1 -2- (2-furanvl)benzamide Example 108 N- U- (Pyrido \ ? .3-bl f 1.51ben.znxazeoir.-6 (5H) -vlcarbonyl) - 3.6-dimethvlPhenyl 1 -2- (2-thienvl) benzamide As described for Example 67, the following compounds can be prepared. Example 109 N-.4- (Pvridof2.3-bl f1.51benzoxazeoin- (5H) -vlcarbonvl) 3-fluoro-6-methvlphenvl i n.1-biphenvl1-2-carboxamide Example 110 N-T4- (Pvridof2.3-bl fl.51benzoxazepine-6(5H) -vlcarbonvl) 3.6-dichlorophenvl1 f1.1 '-biphenvl1-2-carboxamide Example 111 N- r4- (Pvridof2.3-bl r1.51benzoxazepin- (5H) -vlcarbonvl ) 3-fluorop envl1 fl. '-biphenvl!-2-carboxamide Example 112 N-T4- (Pvrido f2.3-b1 f1.5 benzoxazepin- (5H ) -vlcarbonvl ) phenvl1 f .1 '-biphenvl1 -2-carboxamide Example 13 N-T - (Pvrido r2.3-bl f1. 1 benzoxazepin-6 (5H) - vlcarbonvl) -phenvl1-2- (2-thienvl)benzamide Example 14 N- f4- (Pvridof2.3-bl f1.51benzoxazepin-6 (5H) - vlcarbonvl) -phenvl 1 -7- ( -thienvl)benzamide Example 115 N- f4- (Pvridof2.3-bl f1.5!benzoxazepin-6 (5H) - vlcarbonvl) -ohenvl 1 -7- (2-thienvl)benzamide Example 116 N- f4- (PvridoT2. -bl f1.51benzoxazepin- (5H) -vlcarbonvl) 3-fluorcphenvl1-2- (2-thienyl)benzamide Example 117 -T4- (Pvrido f2.3-bl f1.51benzoxazepin-6 (5H) - vlcarbonvl) -ohenvll -2- (3-thienvl) benzamide Example 118 N-f4-(Pvridof2.3-b1.1.51benzoxazepin-6 (5H) - ylcarbonvl) -ohenvl 1 -2- (2-f ranvl)benzamide Example 119 N-f4- (Pvrido ^2.3-bi f1.51benzoxazepin-6 (5H) - vlcarbonvl) -ohenvll-2- (2-pvridinvl)benzamide Example 120 N- f4- (Pvrido f2.3-b 1 f1.5!benzcxazepin-6 (5H) - vlrarbonvl ) -ohenvl 1 -7- (3-pvridinvl)benzamide Example 121 N-T4- (Pvridof2.3-bl r1.51benzoxazepin-6 (5H) - vlcarbonvl) -Phenvl! -2- (4-pvridinvl)benzami e Example 122 N-r4-(Pvridof2.3-bl f1.51benzoxazep n- (5H) -vlcarbonyl) - 3-flurorophenvll-2- (3-furanvl)benzamide Example 123 N-f4-(Pvridof2.3-bl fi.51benzoxazepi.n-6 (5H)-ylcarbonyl-3- methvl-6-fluorophenyl1 fl.1 '-biphenvl! -2-carbnxamirie Example 124 N- f4- (Pvridof2.3-b 1 r 1.51benzoxazepin-6 (5H) -ylcarbonyl) - 2-methvlphenvH -2- (2-furanvl)benzamide E ample H N- f4- (Pvrid f2.3-b 1 '1 ■ 51benzoxazeoin-6 (5H) -ylcarbonyl) - 3-methvlohenvl 1 -2- (3-furanvl )benzam de Example 126 N- f4- (Pyrid f2. -bl f1.51benzoxazepin-6 (5H) -ylcarbonyl) - 3. -riimethvlPhenvl1 -2- (3-Pvridinvl)benzamide Example 12 -7 N- f4- (Pyrido f2.3-bl '1.5!benzoxazepin-6 (5H) -ylcarbonyl) - 3.6-riichloroPhenvl1-2- (4-Pvridir.vl)benzamide Example 128 N _r4-fPvridor2.3-bl fl.5.benzoxazepin-6(5H)- ylcarbonvl) -phenvli -2- (3-furanvl)benzamide Example 129 N- f4- (Pyrido r2. -bl r l.51benzoxaze P in-6 (5H) -ylcarbonyl) - 3-f1urorophenvl 1 -2- (2-thienvl)benzamide Example 13Q N- r - (Pyrido f2.3-bl f 1.41benzoxazepιn-5 (6H) -ylcarbonyl) - ?-pyririinvl 1 -5-fluoro-2-methvlbenzamide As described for Example 46, the reaction of 5, 6-dihydroρyrido [2, 3-£>] [1, 4]benzoxazepine (1 mmol) with 2- [ (2-methyl-5-fluorobenzoyl) amino] -5-pyridinylcarbonyl chloride (1.0 mmol) in dichloromethane in the presence of ϋ,^-diisopropylethylamine (3 mmol) gives the product as a glass. Example 131 N- f5- (Pvridor2.3-bl f1.41benzoxazepin- (6H)-vlcarbonvl ) - 2-pvridinvl 1 r1.1 '-biphenvl1-2-carboxamide As described for Example 66., the reaction of 5, 6-dihydroρyrido [2, 3-b] [1, 4]benzoxazepine (0.198 g) with 6- [ ([1,1 '-biphenyl]-2-carbonyl) amino]pyridine-3- carbonyl chloride (0.404 g) in dichoromethane in the presence of ϋ. N-diisopropylethylamine (0.155 g) gives the product as a solid. Example 132 N- f - (Pvridof2.3-bl f1. 1benzoxazepi -5 (6H)-vlcarbonvl )- 3-chlorophenvll F1.1 'biphenvl1 -2-carboxamide As described for Example 66, reaction of 0.198 g of 5, 6-dihyaropyrido[2, 3-b] [1, 4]benzoxazepine with 0.444 g of 4- [( [1, 1 ■ -biphenyl] -2-carbonyl) amino]-2- chlorobenzoyl chloride in dichloromethane in the presence of N,H _ diisopropylethylamine gives the product as a solid. Example 133 N-f4-(6.11-Dihvdropyridof2.3-bl r1.5!benzodiazepin-6 (5H) - ylcarbonvl) -ohenvl 1 f1.1 '-biphenvl 1 -2-carboxamide To a mixture of 10.55 g of 6,11- dihydropyrido [2, 3-b] [1,5]benzodiazepin-5 (6H) -one in 40 ml of tetrahydrofuran is added 15 ml of 10 molar borane- dimethylsulfide in tetrahydrofuran. The mixture is stirred at room temperature 2 hours and then refluxed (under argon) for 4 hours. An additional 40 ml of tetrahydrofuran is added and the mixture refluxed overnight. To the cooled mixture is added 12 ml of methanol and the solvent removed. To the residue is added 30 ml of 2H NaOH and the solution refluxed 2 hours under argon. The mixture is extracted with ethyl acetate and the extract washed with 2N citric acid. The aqueous layer is made basic with 2N NaOH and extracted with ethyl acetate. The extract is washed with H2O, brine and dried (Na2S0 ) . The solution is filtered through a thin layer of hydrous magnesium silicate and the filtrate concentrated to dryness to give 4.65 g of brown solid. The solid is purified by chromatography on silica gel to give the product as a solid. A 4.85 g sample of crude product is triturated with ether to give 2.68 g of 6, 11-dihydropyrido [2, 3-b] [1, 5]benzodiazepine as a solid. A mixture of 0.296 g of 6,11- dihydropyrido [2, 3-b] [1, 5]benzodiazepine, 0.604 g of 4- [( [1, 1 '-biphenyl] -2-carbonyl) amino]benzoyl chloride and 0.232 g of /ϋ-diisopropylethylamme in 6 ml of dichloromethane is stirred at room temperature for 1.5 hours. The mixture is poured into water and extracted with dichloromethane. The extract is washed with H2O, saturated NaHC03, H2O,brine and dried (Na2Sθ4) . The solution is filtered through a thin pad of hydrous megnesium silicate and the filtrate concentrated to dryness. The residue is purified on thick layer silica gel plates with hexane-ethyl acetate (1:2) as solvent to give the product as a solid which is crystallized from ethyl acetate to give off-white crystals, m.p. 220°C- 221°C. Example 134 N-r4-(6.11-Dihvdropyridor2.3-h1 r1.51benzodiazepin- (5H) - vlcarbonvl) -3-chloroPhenvl 1 fl.1 '-biphenvl1-2-carboxamide A mixture of 0.197 g of 6, 11-dihydropyrido [2,3-b] [l,5]benzodiazepine, 0.444 g of 4-[([l,l'- biphenyl] -2-carbonyl) amino] -2-chlorobenzoyl chloride and 0.155 g of ϋ,N-diisopropylethylamine in 8 ml of dichloromethane is stirred at room temperature for 1.5 hours. The mixture is poured into water and extracted with dichloromethane. The extract is washed with H2O, saturated NaHC03, H2O, brine and dried (Na2S04) . The solution is filtered through a th n pad of hydrous magnesium silicate and the filtrate concentrated to dryness. The residue is chromatographed on thick layer silica gel plates with hexane-ethyl acetate (1:2) to give 0.160 g of solid, m.p. 147°C-165°C. Anal Found: C, 72.1; H, 5.1; N, 9.1; Cl, 6.3. Example 135 N- f4- (6. Il-Dihvdropvrido f2.3-bl r1.5!benzodiazepin-6 (5H) - vlcarbonvl) -Phenvl! fl.1 '-biphenvli-2-carboxamide. hydrochloride Hydrogen chloride (gas) is bubbled into 50 ml of anhydrous chilled methanol for 15 minutes. A 25 ml sample of the methanolic hydrogen chloride is added to 0.30 g of ϋ-[4- (6, ll-dihydropyrido[2, 3- b] [1, 5]benzodiazeρin-6 (5ϋ) -ylcarbonyl) phenyl] [1,1'- biphenyl] -2-carboxamide. The mixture is stirred at 0°C for 0.5 hours and allowed to warm to room temperature. The solvent is removed and the solid dried under vacuum to give 0.31 g of solid, m.p. 195°C-210°C. As described for Example 134, the following compounds can be prepared by reaction of 6,11- dihydropyrido [2, 3-b] [1, 5]benzodiazepine with the appropriate substituted or unsubstituted [ (arylcarbonyl) amino]benzoyl chloride or the appropriate substituted or unsubstituted[ (arylcarbonyl)- amino]pyridinylcarbonyl chloride. Example 136 N- f4- ( .11-nihvdropvrido f2.3-b! f1.51benzodiazepin-6 (5H) - ylcarbonyl) -3-chlorophenvll -2- (2-thienvl)benzamide Example 137 N- f4- (6. ll-nihvdropvrido f2.3-bl f1.51benzodiazepin-6 (5H) - ylcarbonyl ) -3-chlcroohenvl1-2- (3-thienvl)benzamide Example 138 N-r4-f6.ll-Dihvdropvridor2.3-bl r 1.5 1 benzodiazepin- (5H) - y 1 carbonvll-3-chloro-6-methvlphenvl 1 -7- (2- thienvl)benzamide Example 139 N-r4-(6.11-Dihvdropvridof2.3-bl fl.51benzodi azeoin-6 (5H) - vlcarbonvl) -ohenvll -2- (2-thienyl)benzamide Example 140 N- f4- (6. Il-Dihvdropvrido f2.3-bl f .51benzodiazepin-6 (5H) - vlcarbonvl) -ohenvl!-2- (3-thienvl)benzamide Example 141 N- - 4 - (6. Il-Dihvdropvrido f2.3-bl .51benzodiazepJn-6 (5H) - vlcarbonvl) -3-methvlphenvl1-2- (2-thienvl)benzamide Example 142 N- f4- (6, ll-Dihvdropvrido f2.3-bl f .51benzodiazepin-6 (5H) - vicarbonvl)-3.6-dimethvlPhenvl i -2- (2-thienvl)benzamide Example 1 3 N-r4-(6.11-Dihvdropvridof2.3-b 1 f1.51benzodiazepJn-6 (5H) - vlcarbonvl) -3-methvlPhenvli fl.1 '-biphenvl! -2-carboxami e Example 144 N-r4-(6.11-Dihvdropyridor2.3-bl r1■ 5!benzodiazepin-6 (5H) - vlcarbonvl) -3.6-dimethvlphenyli 11. '-biphenvl1-2- carboxamide Example 145 N-r4-(6.11-Dihvdropyridor2.3-bl f1. 1benzodiazeoin-6 (5H) - vlcarbonvl) -3. -dichlorophenvl1 fl.1 'biphenvl! -2- carboxamide Example 146 N-r4-f6.ll-DihvQropyridof2.3-b! f1.51 benzodiazepin-6 (5H) - ylcarbonyl ) -3-methvl-6-chlorophenvl1 fl.1 '-biphenvl1 -2- carboxmide Example 147 N-r4-(6.11-Dihvdropyridof2.3-bi r: , 1benzodiazeoin-6 (5H) - ylcarbonvl) -3-chloro-6-fluoroohenyl1 r l.1 '-biphenvl) -2- carboxamide Example 148 N-r4-(6.1--Dihvdropyrido r 2.3-bi ' . 1 benzodiazeoin-6 (5H) - ylcarbonyl) -2-methylphenyli fl. '-biohenvl!-2-carboxamide Example 149 N-f4-(6.11-Dihvdropvridof2.3-bl f1. 1benzodiazepin-6 (5H) - vlcarbonvl) -2-chlorophenvl1 f1.1 '-biphenvl1-2-carboxamide Example 150 N- T4- (6.1 -nihvdropvrido f2.3-b! f1.5!benzodiazepin- (5H)- vl carbonvl) -phenvl1 -2- (2-pvridinvl)benzamide Example 151 N-r4-(6.11-DihvdroPvridof2.3-b1 fl .51benzodiazepin- (5H) - vlcarbonvl) -phenvl1 -2- (3-pvr dinvl)benzami e Example 15? N-r4-(6.11-Dihvdropyridor2.3-bl r . 1benzodiazepin- (5H) - ylcarbonyl) -phenvll-2- (4-pvr dinvl)benzamide Example 1 3 N- r 4-(6.11-Dihvdropvridcr2.3-b 1 f1. 1 benzodiazepin-6 (5H) - vlcarbonvl) -3-chlorophenvl1 -2- (2-pvridinvl)benzamide Example 154 N-f4-(6.11-DihvdrθPyridθf2.3-b! f1.51benzodiazepin-6 (5H) - vlcarbonyl ) -^-chlorophenvl! -2- (3-pvridinvl)benzamide Example 155 N-f4-(6.11-Dihvdropvridof2.3-bl f1.51benzodiazepin-6 (5H) - ylcarbonvl ) -3-chlorophenvl1-2- (4-pvridinvl)benzamide Example 156 N-r4-(6.11-Dihvdropvridof2.3-bl f . 1benzodiazepin-6 (5H) - ylcarbonvl ) -^-methvlohenvli-2- (2-pvridinvl)benzamide Example 157 N- f4- (6.11-Dihydroovrido f2.3-bl fl . 1beπzodiazepJn-6 (5H) - ylcarbonvl ) -3-methvlphenvl! -2- (3-pvridinv )benzamide Example 158 N-r4-(6.11-Dihvdropvridof2.3-bl f1.51benzodiazepin- (5H) - ylcarbonvl ) -3-methvlphenvli -2- (4-pyridinyl)benzamide Example 15? N-r4-(6.11-Dihydropvridof2.3-b 1 f1. 1benzodiazepin-6 (5H) - yl r hnnvl) -3-π.ethvl-c-fluorophenyl1 -2- (2- thienvl)benzamide Example 160 N-r4-(6.11-Dihvdropyridof2.3-b11 .51benzodiazepi - (5H) - yl carbonvl) -3.6-dimethvlphenvl1 -2- (2-Pvridinyl)benzamide Example 161 N-f4-(6.11-Dihvdropvridor2.3-b1 f .51benzodiazepin-6 (5H) - vlcarbonvl) -3.6-dimethvlphenvl } -2- (3-Pvridinyl)benzamide Example 162 N-f4-(6.11-Dihvdrcpvridor2.3-bi '1.51benzodiazepin-6 (5H) - vlcarbonvl) -3.6-dimethvlphenvl1 -2- (4-pvridinyl)benzamide E amp e lξ3 N-r4-(6.: -Dihvdropyridor2.3-b 1 f .51benzodiazepin-6 (5H) - ylcarbonyl) -ohenvli-2-methoxvpyridine-3-carboxamide Example 164 N-r -(6.11-Dihvdrooyridof2.3-bi r 1.51benzcdiazepin-6 (5H) - ylcarbonvl)-3-chlorophenvlι -2-methvlthiopvridine-3- carbo amide Example 165 N- r4- (6. ll-Dihvdropyrido f2.3-bl fl .51benzodiazeoin-6 (5H) - ylcarbonvl' -3-methvlphenvl1 -2-methvlPvridine-3- carbQxamide Example 166 N- f4- (6. l-Dihvdropyrido f2.3-bl ri, 51benzodiazepin-6 (5H) - v carbonv ) -3.6-dimethvlPhenvl1 -2-methvlpvridine-3- carboxa ide Example IP N-r4-(6.11-Dihvdropyridof2.3-bi f1.51benzodiazepin-6 (5H) - ylcarbonvl ) -Phenvlι-2-methvlpvridine-3-carboxamide Example 168 N-f -(6.11-Dihydropyridof2.3-bl r . 1benzodiazepin- (5H) - ylcarbonyl) -3-chlorophenvl 1 -2-nethvlPvridine-3- carboxamide Example 1 9 N-r4-(6. l-Dihvdropvrido . 2 .3-b 1 r l.51benzodiazepin-6 (5H) - ylcarbonyl) -^-chloro-6-methvlphenvli -2-fluoropvridine-3- ςarboxaπide Example 170 N-r4-(6.11-Dihvdropvridor2.3-bl f1.5!benzodiazepin-6 (5H) vlcarbonvl) -3-chlorophenvl!-2-fluoropyridine-3- carboxamide Example 171 N-f4-(6.11-Dihvdropvridor2.3-bl <1. 1benzodiazepin-6 (5H) ylcarbonvl) -3-methvlphenvl1 -2-chloropyridine-3- carboxamide Example 172 N-r4-(6.11-DihvdroPvridor2.3-bl fl.51benzodiazepin-6 (5H) vlcarbonvl) -3.6-dimethvlohenvli -2-chloropvridine-3- carboxamide Example 73 N-r4-(6.11-Dihvdropyridor2.3-bl 1.5!benzodiazepin- (5H) vlcarbonvl) -Phenvl! -3-methvlpvridine-2-carboxamide Example 174 N- f4- (6. ll-Dihvdropvrido f2. -b! r1.51benzodiazepin-6 (5H) vlcarbonvl) -3-chlorophenvli-3-methvlpyridine-2- carboxamide Example 175 N-r4-(6.11-Dihvdropyridor2.3-bl r1. 1benzodiazepin-6 (5H) ylcarbonvl) -3-chlorophenvll -2-chloropvridine-3- carboxamide Example 176 N-X^-(6.11-Dihvdropyridor2.3-bl f1.51benzodiazepin-6 (5H) ylcarbonyl ) -2-ovridinvl 1 π . '-biohenyl^ -2-carboxamide. m.p. 278°C-281°C Example 177 N- f - (6. Il-Dihydropvrido f2.3-bl r1.51benzodiazepin-6 (5H) ylcarbonyl) -2-pyridinyl 1 -2- (2-thienyl)benzamide Example 178 N-f5-(6.11-DihvdroPvridor2.3-b1 fi .51benzodiazepin-6 (5H) yVarhnnvl) -2-pyridinvl1-2- (3-thienvl)benzamide Example 179 N-L5- (6. l-Dihvdropyridor2.3-b1 r 1.51benzndiazepin-6 (5H) ylcarbonvl) -2-ovridinvl <-2-fluorobenzamide Example 180 N-f5-(6.11-Dihvdropvridof2.3-b1 fl.51benzodiazepin-6 (5H) - vlcarbonvl) -2-pvridinvll -2- (2-pvridinvl)benzamide Example 181 N- r5- (6.11-Dihvdropvrido f2.3-bl ri, 51benzodiazepin-6 (5H) - vlcarbonvl)-2-Pvridinvl 1 -2 (3-Pvridinvl)benzam e Example 182 N- f5- (6.11-Dihvdropvrido T2.3-b1 r ■ 51benzodiazeoin-6 (5H) - vlcarbonvl) -2-Pvridinvll -2- (4-Pvridinvl)benzamide Example 183 N-f5- (6.11-Dihvdropvridor2.3-bl f1.51benzodiazepin-6 (5H) - vlcarbonvl) -2-Pvridinvl1 -2- (2-furanvl)benzamide Example 184 N- r - (6.1 -Dihvdropvrido f2.3-bl f1.51benzodiazepin-6 (5H) - vlcarbonvl) -2-ovridinvl^-2- ( -furanvl)benzamide Example 185 N-f5- (6. ll-Dihvdropvridor2.3-bl f1.51benzodiazepin-6 (5H) - vlcarbonyl)-2-pvridinvll-3-chloroovridine-2-carboxamide Example 186 N- f5- (6.11-Dihvdropyrido f2.3-bl f1.51benzodiazepin-6 (5H) - vlcarbonyl) -2-ovridinvli -2-methvlovridine-3-carboxamide Example 187 N-f5-(6.11-Dihvdropyridof2.3-bl f1.51benzodiazepin-6 (5H) - ylcarbony 1 . -2-ovridinvl1 -5-fluoro-2-methvlbenzamide Example 188 N-f5-(6.11-DihydroPvridof2.3-bl f .51benzodiazepin-6 (5H) - y 1 rarhnnvl) -2-Pvridinvl1 -2-chlorobenzamide Example 189 N- f5- (6.11-Dihvdropvrido f2.3-bl rl. ϋ1benzodiazepin-6 (5H) - ylcarbonvl ) -2-ovridinvl1 -2-chloro-5-fluorobenzamide Example 1?Q N-r5- (6. ll-Dihyriropyridor2.3-bi M , 51benzodiazepin-6 (5H) - yl carbonvl) -2-oyridinvl1 -2-methvlbenzamide Example 191 N- f5- (6.11-Dihvdropvrido f2.3-bl '1.51 benzodiazepin-6 (5H) - yl carbonyl ) -2-ovridinvli -2.5-dimethvlbenzamide Example 192 N-r5-(6.11-Dihvdroovridof2.3-bl r1. 1benzoriiazepin- (5H) - vlcarbonvl) -2-Pvridinvll-2-chloro-4-flijorobenzamide Example 1 3 N- r.5- (6. , -Dihvdropvrido r7.3-bl fl.51benzodiazepin-6 (5H) - vlcarbonvl) -2-Pvridinvl 1 -2-chloro-6-f norobenzamide Example 4 N-f5-(6.11-Dihvdropyridof2.3-b1 fl . 1benzodiazepin-6 (5H) - vlcarbonvl) -2-ovridinvli-2-methvl-3-flnorohenzam de Example 195 N-r5-(6.11-Dihvdroovridof2.3-bl f1.51benzodiazepin-6 (5H) - ylcarbonvl) -2-Pvridinvl1-2-hvdroxybenzamide Example 196 N-f5-(6.11-DihvdroPvridof2.3-b1 r l .51benzodiazepin-6 (5H) - vlcarbonvl) -2-Pvridinyl 1 -2-acetvloxvbenzamide Example 197 N- 15- (6. 1-Dihvdrooyrido f2.3-bl f1.51benzodiazepin-6 (5H) - vlcarbonvl) -2-ovridinvlT -2-aminobenzamide Example 198 N-f5-(6.11-Dihvdropvridof2.3-b1 π . 1benzodi zepin-6 (5H) - ylcarbonyl) -2-Pvridinvl τ-2- (methvlamino) benzamide Example 199 N-r5-(6.11-Dihvdropyridor2.3-bl f1.51benzodiazepin-6 (5H) - ylcarbonyl) -2-ovridinyl1 -2- (dimethylamino)benzamide Example 2QQ N-f5-(6.11-Dihvdropvridof2.3-bl f1.51benzodiazepin-6 (5H) - ylcarbonvl ) -2-Pvridinyl1-2-aminomethvlbenzamide Example 2Q1 N-r5-(6.11-DihydrcPvridof2.3-b! f1.51benzodiazepin-6 (5H) - ylcarbonyl ) -2-Pvridinvli -2- (diethvlamino)benzamide Example 2Q2 N- r.5- (6. 11 -Dihvdropvrido f?.3-bl fl.5 1 benzodiazepin-6 (5H) - vlcarbonvl) -2-pvridinvll -2- (dimethvlaminomethvl)benzamide Example 203 N-r5-(6.11-Dihvdropvridof2.3-bl f1.51 benzodiazepin- (5H) - vlcarbonyl ) -2-ovridinvl1 -2- (methvlth o)benzamide Example 204 N- r.5- (6. ll-Dihvdropvrido f2.3-bl f1.51 benzodiazepin-6 (5H) - vlcarbonvl) -2-pvridinvl1 -2-chloroPvridine-3-carboxamide Example 205 N-r.5- (6.11-Dihvdropvridof2.3-b1 f1.51benzodiazepin-6 (5H) - vlcarbonvl) -2-pvridinvl1 -2-fluoropvridine-3-carbnxam de Example 206 N- r.5- (6. ll-Dihvdropvrido f2.3-bl f1.51 benzodiazepin-6 (5H) - vlcarbonvl) -2-pvridinvl1 -2-methoxvpvridine-3-carboxamide Example 207 N-^-(6.11-Dihvdropvridof2.3-bl f1.51 benzodiazepin-6 (5H) - ylcarbonvl) -2-pyridinvli-2-met vlthiopyridine-3- carboxamide Example 208 N- f5- (6. ll-Dihvdropvrido f2.3-bl f1.51 benzodiazeoin-6 (5H) - vlcarbonvl) -2-Pvridinvll -2-aminoPvridine-3-carboxamide Example 209 N- f - (6.11-Dihyriropyrido f2.3-bl f1.51 benzodiazepin-6 (5H) - ylcarbonvl . -2-pvridinvl1 -2-methvlamino-pvridine-3- carboxamide Example 210 N-f5-f6.ll-nihvriropvridof2.3-b1 f 1.51 benzodiazeoin-6 (5H) - ylcarbonyl ) -?-pvridinvl 1 -2- (dimethylamino)Pvridine-3- carboxamide Example 211 N- r5- (6. l-Dihvdropyridof2.3-b! f1.51 benzodiazepin- (5H) - ylcarbonyl ) -2-ovridinvl 1thiophene-2-carboxamide Example 212 N-^-(6.11-DJhyriropyririof2.3-bi f1.5 1 benzodiazepin-6 (5H) - yl carbonyl ) -2-Pvridinvl 1 thiophene-3-carboxamide Example 213 N-T - (6. l 1 -nihvdrcoyridof2.3-bl f . 1 benzodiazepin-6 (5H) - yloarhnnyl ) -2-pyridinvl1 furane-2-carboxamide Example 214 N- f5- (6.11-Dihvdropvrido \2 .3-bl f1.51benzodiazepin-6 (5H) - ylcarbonvl) -2-pyridinvl1-2-methvlthiophene-3-carboxamide Example 215 N-r5-(6.11-Dihvdropvridof2.3-b! f1.5!benzodiazepin-6 (5H) - vlcarbonvl) -2-Pvridinvli-3-methvlthiophene-2-carboyamide Example 216 N-r5- ( 6.11-Dihvdropvridof2.3-b! f1.51benzodiazepin-6 (5H) - ylcarbonvl) -2-Pvridinvli-2-chlorothiophene-3-carboxamide Example 217 N-r.5-f6.ll-Dihvdropvridof2.3-b1 f1.51benzorii.azepin-6 (5H) - ylcarbonvl-2-Pvridinvl1-2-methvlthiophene-3-carboxamide Example 219 N- ( 4-r (5.11-Dihvdro-lOH-dibenzfb.e 1 f1.41diazepJn-10- yl) carbonvll -3-chlorophenv l ri. '-biphenvl 1 -2- carboxamide A mixture of 0.196 g of 5, ll-dihydro-10H- dibenzo [b,e] [1, 4]diazepine, 0.155 g of U, - diisopropylethyla ine and 0.444 g of 4-[([l,l'- biphenyl] -2-carbonyl) amino]-2-chlorobenzoyl chloride in 12 ml of dichloromethane is stirred at room temperature overnight. The mixture is poured into water and extracted with dichloromethane. The extract is washed with 2N K2Cθ3,H2θ,brine and dried (Na2Sθ ) . The solution is filtered through a thin pad of hydrous magnesium silicate. The filtrate is concentrated to dryness and the residue triturated with ether and the solvent removed. The residue is triturated with dichloromethane to give 0.31 g of solid, m.p. 158°C- 184°C. Anal. Found for C33H24CIN3O2 1/2 H2O; C,73.7; H, 4.6; N,7.5; Cl,6.9. As described for Example 218, the following compounds can be prepared by the reaction of 5, 11- dihydro-10ϋ-dibenz [b,e] [1, 4]diazepine with the appropriate substituted or unsubstituted [ (aryl- carbonyl) amino]benzoyl chloride or the appropriate substituted or unsubstituted [ (aryl¬ carbonyl) amino]pyridinylcarbonyl chloride. Example 21 N-f4-r (5.11-Dihvdro-lOH-dibenzrb.el f .41diazepJn-10- yl) carbonvl 1 -ohenvl1 f1.1 '-biphenyl1 -2-carboxamide Example 220 N-f4-r (5.11-Dihvdro-lOH-dibenzfb.el f .41 diazepjn-l 0- yl) carbonvli -3-methvlphenv11 f . '-biphenyl 1-7- carboxamide Example 221 N-U-r (5. ll-Dihvdro-10H-diben r b.el f1.41 diazepin-10- yl) carbonvl1-3. -dimethvlphenvl i r l . '-biphenyl1 -2- carbQxamide. Example 22? N-U-r (5.11-Dihvdro-lOH-dibenzrb.e 1 '1.41 diazepin-10- yl) carbonvl1 -3-chlorophenvl i -2- (2-thienvl)benzamide Example 223 N-f - f (5.11-Dihydrc-lQH-dibenzfb.ei ■ " ! , 41 diazepin-10- yl) carbonyl l -3-chloroPhenyli -2- (3-thienvl)benzamide Example 224 N- -r (5.11-Dihydro-lOH-dibenzfb.el f .41 diazepin-10- yl) carbonyl! -3-chlorophenvll-2- (3-furanyl)benzamide Example 225 yl) carbonyl 1 -3-chlorophenvl1-2- (2-furanyl)benzamide Example 226 N-f -r (5.11-Dihvdro-lθH-dibenz^b.ei r1. 1 diazepin-10- yl) carbonyH -3-methvlPhenvll-2- (2-thienyl)benzamide Example 22 ^ N-U-r (5.11-nihvdro-10H-dibenz r b.ei f1. 1diazepin-10- y ) carbonyl 1 -3-methvlPhenvl 1 -2- ( -thienyl)benzamide Example 228 N-f4-r (5.11-Dihvdro-10H-diben fb.ei f1. 1diazepin-10- yl) carbony i -3-methvlPhenvH f1. 'biphenv i -2-carboxamide Example 229 N- r - r ( 5. 1 -Dihvdro-l H-dibenz rb . e ! f 1 ■ 4 1 riiazepi n- - vl ) carbonvl 1 - 3. 6-dimethvlPhenvl 1 f 1 . 1 ' -biphenyl -7- carboxamide Example 23Q N-f4-f (5.11-Dihvdro-lOH-dibenzfb.el f1.41 diazepin-10- yl) carbonvll -3-methvl-6-chlorophenvl 1 fl.1 '-biphenyl! -7- ςarbQxamide Example 231 N- r4- r (5.11-Dihvdro-lOH-dibenz fb. l r1.41diazepin-10- vl ) carbonvl 1 -3-chloro-6-fluorophenvll f1.1 '-biphenvl1 -?- ςarbQxamlde Example 232 N-1 -r (5.11-Dihvdro-lOH-dibenzrb.ei f1.41 diazepJn-10- yl) carbonvll -2-methvlphenyl! fl. '-biphenvli-2- carboxamide Example 233 N-r4-r (5.11-Dihvdro-l H-dibenzfb.e! f1.41 diazepin-10- vl) carbonv l-3-chloro-6-methvlPhenvll f1.1 '-biphenyl1 -2- carboxamide Example 234 N-H-r (5.11-Dihyriro-lOH-riibenzfb.el f .4!diazep -10- yl) carbonvl1-2-chlorophenvll fl. '-biphenvl1-2- carboxamide Example 235 N-T4r (5.11-Dihydro-l H-diben fb.el f1.41diazepJn-10- y1) carbonvl1-phenyl i-2- (2-pvridinvl)benzamide Example 236 N-r4-r (5.11-Dihvdro-l H-dibenzrb.el r1.41diazepJn-10- yl) carbonvl 1 -ohenvl1-2- (3-pvridinvl)benzamide Example 237 N-U-r (5.1 -Dihvdro- PH-dibenzfb.ei fl. 1 diazepin-10- yi carbonvll -ohenyll -2- (4-Pvridinvl)benzamide Example 238 N-f4-r (S. -Dihvdro- H-dibenzfb.ei fl.41 diazepJn-10- yl) carbonyl 1 -3-chloroohenyl1-2- (2-pvridinvl)benzamide Example 239 N-U-f (5. 1-Dihvdro-lOH-dibenzfb.el f .4!diazepin-10- yl ) carbonvl i -3-chlorophenvll -2- (3-pvridinvl)benzamide Example 240 N-r4-. (5.11-Dihvdro-lQH-dibenzfb.el ri .41diazeoin-l - vl lcarbonv 11 -3-chlorophenvl 1 -2- (4-pvridinvl)benzamide Example 241 N-f4-r (5.11-Dihvdro-lOH-dibenzfb.el f1.41diazepjn-l0- yl ) carbonvl < -3-methvlphenvl 1 -2- (2-Pvridinvl)benzamide Example 242 N-f4-f (5. -Dihvdro-lOH-dibenzfb.e. 1 r1.41 diazepjn-l 0- yl) carbonvl1 -3-methvlPhenvl ' -2- (3-ovridinvl)benzamide Example 24.3 N-r-i-r (5. ,ι-Dihvdrc-10H-diber.zfb.e1 f1.41 diazepjn-l 0- yl) carbonvl 1 -3-methvlPhenvll -2- (4-pvridinvl)benzamide Example 244 N-r4-r (5.11-Dihvdrc-lOH-dibenzfb.ei ri , 41 diazepJn-10- yl ) carbonvl 1 -3. -dimethvlphenyl1 -2- (2- pvridinyl) benzamide Example 245 N-r4-r (5.11-Dihvdro-lθH-diben fb.ei f .41 diazepin-10- yl ) carbonvl i -3. -dimethvlphenvl1 -2- (3- pvridinvl) benzamide Example 246 N- r - r (5 . ^ -Dihvdro- l H-diben f b . 1 f 1 . 4 i diazepin- 0- y 1 ) carbonvl 1 - 3. 6-dimethvlphenvl 1 -2- (4- pvridinvl ) benzamide Example 24^ N-f4-r (5. l-Dihvdro-10H-dibenzrb.ei r1.41diazepJn-10- y 1 ) carbonv 1 phenv . 1 -2-ohenvlmethyl)benzamide Example 248 N-r-i-r (5. -Dihvdro-lOH-dibenzfb.ei r 1.41 diazepin-10- y ) carbonvl 1ohenvll -2- (3-chlorophenvlmethvl)benzamide Example 249 N-r4-f (5. 1 -Dihvdro-10H-dibenzfb.e 1 r 1.41 diazepin- 0- yDcarbony 1 1-3-chloroohenvl 1 -2- (phenylmethyl)benzamide Example 25Q. N-f4-r (5. ll-Dihvdro-lOH-dibenzrb.e! f1. 1diazep n-10- yl) carbonyl1-3-chlorophenyll-2-methoxvpvridine-3- carboxamide Example 251 N-f4-f (5.11-Dihvdro-lOH-dibenzrb.el f1.41 diazepJn-10- vl) carbonvl i -3-chlorophenvH-2- (methvlthio)Pyridine-3- carboxamide Example 252 N-f4-r (5. 1-Dihvdro-lQH-dibenzrb.e! f ■ 41 diazepJn-10- vl) carbonvli-3-methvlphenvli-2-methvlpvridine-3- carboxamide Example 253 N- f 4- r ( 5. 1-Dihvσro-l H-dibenz f b . e 1 f . 4 1 riiazepJ n- O- vl ) carbonvl T - 3-methvlohenv l 1 -3-methvlPvridine-2- carboxamide Example 254 N-f4-r (5.11-Dihvdro-lOH-dibenzfb.el f1, 41 diazepJn-10- vl) carbonyl 1 -3-methylphenvll -2-chloropvridine-3- carboxamide Example 255 N-r4-(5.11-Dihvdro-10H-dibenzrb.e 1 fl.4!diazepJn-10- vl) carbonyl! -3.6-dimethvlphenvl 1 -2-fluoropvridine-3- carfrp mide Example 256 N- -r (5.11-Dihvdro-lPH-dibenzfb.el f1.41 diazepJn- 0- yl) carbonyl . -3-methvl-6-chlorθPhenvl 1 -2-chloropvridine- 3-carboxamide Example 257 N- r5- r (5.11-Dihvdro-lOH-dibenz fb. l f1.41diazepJn-10- yl) carbonyli -2-Pvridinvl1 f1.1 '-biphenvl1 -2-carboxamide. m.p.280°C-285°C Example 258 N-f.^-r (5.11-Dihvdro-lOH-dibenzfb.el f1.41diazepin-10- yl) carbonvli-2-pvridinvl < -2- (2-thienvl1benzamide Example 259 N-f5-f (5. ll-Dihvdro-10H-dibenzrb.e1 f 1.41 diazepjn-l - yl) carbonyll -2-pyridinyll -2- (3- hieny1 ) benzamide Example 260 N- Γ E - Γ (5.11-Dihvdro-lOH-dibenzfb.el f 1.41 di azepi n- l vl) carbonvll -2-ovridinvl 1 -2- (2-furanvl) ) benzamide Example 261 N-f5- ' (5.11-Dihvdro-lOH-diben fb.el fl .41 diazepi n-10- vl ) carbonvl 1 -2-ovridinvl 1 -2- (2-pvridinvl ) benzami ri° Exam p le 262 N-f -r (5.11-Dihvdro-lOH-dibenzfb.e 1 f 1.41 diazepi -10- yl) carbonvl1-2-Pvridinvl 1 -2- (3-ovridinvl) benzamide Example 763 N-f5- r (5. ll-Dih.vdro-10H-diben fb.ei ' 1 , 41 diazepi n-10- yl) carbonvl 1-2-Pvridinvl 1 -2- (4-ovridinvl) benzamide Example 6 N-fS- f (5. l-Dihvdro-lOH-dibenz fb.el fl.41diazepin- 10-vl) carbonvl 1 -2-Pvridinvl 1 -2- (2-furanvl ) benzamide Example 265 N- f -r (5. 1-Dihvdro-lOH-dibenzfb.e.1 fl.41 diazepin- 10-yl) carbonvl 1 -2-Pvridinvl 1 -2- (3-furanvl) benzamide Example 766 N-r^-r (5. X. - ihvdro-lOH-diben fh.e 1 fl .41 di zepi n- P-yl) carbonyl 1 -2-pyridiny 1 -2-methoxypyridine-6- carboxamide Example 267 N- r :; - r rs. -M -n- j hydro-1 PH-dibenz. fb. e 1 11.41 di azepi n- 1 n-y 1 ) carbony "1 1 -2-Pvridinv 1 1 pvri dine-3-carhnyamide Example 268 κt_r: ; _r /s ι ι -T J yri""- 1 Q^- ib ^z Γ l f 1.41 di a^m' - 1 -yl) carbonyl 1 -2-ovridinvl 1 -2-Pvridinecarboxamide Example 769 N- r - r L . 1 - . hvdro-1 PH-dibenz fb. el f 1.41 di az.epin- -yl . carbonyl i -?-pyridinyl 1 -2-methvl-5-fluorohenza ide Example 270 N-f5-r (5.11-Dihvdro-lOH-dibenzrb.el f1■ 1diazepin- 10-vl) carbonvl1-2-pvridinvll-2-chlorobenzamide Example 271 N- fF- r f5.11-Dihvdro-lOH-dibenz fb.el f1.41diazepin- 10-vl, __arbonvl1-2-Pvridinvl1-2-chloro-5-fli.nrobenzam.rie Example 272 N- r - r (5.11-Dihvdro-lOH-dibenz fb. el f1.41diazepin- 10-vl. carbonvl1 -2-Pvridinvl 1-2-methvlbenzam de Example ^ N-r5-r (5.11-Dihvdro-lOH-diben rb.el f .41 iazepin- 10-vl. carbonvl ■ -2-ovridinvl1 -2.5-dimethvlbenzamide Example 274 N-r -r (5.11-Dihvdro-10H-dibenzrb.ei f1.41riiazepin- 10-vl) carbonvl -2-pyridinvll-2-chloro-4-fluorobenzamide Example 275 N- f5- f f5.11-Dihvdro-lOH-dibenz fb.el f1.41diazepin- 10-vl) carbonvl -2-ovridinvl1-2-chloro-6-fluorobenzamide Example 276 N-fS- r (5.11-Dihvdro-lOH-dibenzrb.el f1.4 1 diazeoin- 10-vl) carbonvl1 -2-ovridinvl1-2-met.hvl-3-fluorobenzamide Example 277 N-fF-r .5.11-Dihvdro-lOH-dibenzfb.el f1.41diazepin- 10-vl) carbonvl 1 -2-ovridinvll -2-hvdroxvbenzamide Ssample 27g N- r .F-r (5.11-Dihvdro-lOH-diben rb.el f1.41diazepin- 10-yl) carbonvl 1 -2-ovridinvl 1 -2-acetvloxvbenzamide Example 279 N-rό-r (5.11-nihvdro-lOH-dibenzrb.el f1.41diazeoin- ^-vl) carbonvl1 -2-ovridinvl1-2-aminobenzamide Example 280 N-r.F-r (5.1 -Dihvdro-lOH-dibenzfb.el f1.41diazeoin- 10-yl) carbonvl -2-Pvridinyl1 -2- (methvlamino)benzamide Example 281 N-f -f fS.ll-Dihvdro-lOH-dibenz fb.el r 1.41diazepin- 10-yl) carbonyl 1 -2-pvridinvl 1 -2- .aminomethvl)benzamide Example 282 N- f5- r (5.11-Dihvdro-lOH-dibenz fb. l f .41diazepin- 10-vl) carbonvl1 -2-pvridinvl1-2- (dimethylamino)benzamide Example 283 N-f5-r (5.11-Dihvdro-10K-dibenzfb.e1 f1.41diazepjn-l -vl . carbonvl 1 -2-ovridinvl1-2-chloropvridine-3-carbnxamide Example 284 N- f5- f (5.11-Dihvdro-lOH-dibenz fb. el f1.41diazepjn- -vl ) carbonvl1-2-pvridinvl1-2-fluoropvridine-3-carboxamide Example 285 N-r5-r (5.11-Dihvdro-lQH-dibenzfb.el f1.41 diazepJn-10-yl) carbonvll-2-Pvridinvli-2-methoxypvridine-3-carboyamide Example 286 N-fF-r (5.11-Dihvdr -10H-diben?Xb.ei r 1.41diazepin- 10-vl) carbonvli-2-Pvridinvl!-2- (methvlthio)pvridine-3- carfroxamide Example 287 N-r5-r (5.11-Dihvdro-lOH-dibenzrb.e! f1.41diazepJn-10-vl) carbonyl 1 -2-pyridinyl 1 -2-aminopyridip.e-3-carboxan.ide Example 288 N-15-r .5.11-Dihvdrp-lOH-dibenzrb.e! f1.41diazepJn-10-vl) carbonvl 1 -2-ovridinvl 1 -2- (methvlamino)pvridine-3- carboxamide Example 289 N-fF-r (5.11-Dihvdrc-lOH-dibenzrb.e- ' .41 diazeoin-l -yl) carbonyl T -2-Pvridinv 1-2- (dimethylamino) vridine-3- carboxamide Example 290 N-r5-r (5.11-Dihvdro-l H-dibenzrb.ei fi, 1diazepJn-10-yl) carbonyl 1 -2-pyridiny2 ^ -2-methyl r.ioohene-3-carboxamide Example 300 N-r5-r (5.11-Dihvdro-lOH-diben rb.ei r1 , 41diazepin-10-vl) carbonyl 1 -2-ρyridinyl 1 -3-methyl hiophene-2-carboxamide Example 3Q1 N-14- r (6.11-Dihvdro-5H-dibenz fb. l zepin-5-yl ) rarhnnyl 1 -phenvl fl.1 '-biphenvl1 -2-carboxamide A mixture of 6, ll-dihydro-5ϋ-dibenz [b,e] azepine (0.195g), 4- [( [1, 1 '-biphenyl] -2-carbonyl) amino] benzoyl chloride (0.41g) and 0.155 g of t H- diisopropylethylamine in 12 ml of dichloromethane is stirred at room temperature for 3 hours. The mixture is poured into water and extracted with dichloromethane. The extract is washed with H2O, saturated NaHCθ3, H2O, brine and dried (Na2Sθ4) . The solution is filtered through a thin pad of hydrous magnesium silicate and the filter pad washed with dichloromethane. The filtrate is concentrated to dryness to give 0.66 g of a yellow solid. Chromatography on thick layer silica gel plates with hexane-ethyl acetate (1.5:1) gives crystals (0.165g) (from dichloromethane-ethyl acetate), m.p. 224°C-225°C Example 302 N- . A- r (6. ll-Dihvdro-5H-dibenz rb. l azepin-5-yl) carbonvl -3-chlorophenvll 11.1 '-biphenvl 1 -2-carboxamirie A mixture of 0.195 g of 6, ll-dihydro-5ϋ- dibenz [b,e]azepine, 0.444 g of 4- [( [1, 1 '-biphenyl]-2- carbonyl) amino] -2-chlorobenzoyl chloride and 0.155 g of H / ϋ-diisopropylethylamine is stirred at room temperature for 3 hours. The mixture is poured into water and extracted with dichloromethane. The extract is washed with H2O, saturated NaHCθ3,H2θ, brine and dried (Na2Sθ4) . The solvent is removed and the residue chromatographed on thick layer silica gel plates with solvent hexane-ethyl acetate (1.5:1) to give 0.32 g of crystals, m.p. 120°C-125°C. As described for Example 302, the following compounds can be prepared by reaction of 6, 11-dihydro- 5ϋ-dibenz [b,e]azepine with the appropriate substituted or unsubstituted 4- [ (arycarbonyl) amino]benzoyl chloride or the appropriate substituted or unsubstituted 6- [ (arycarbonyl)amino]pyridine-3-carbonyl chloride Example 303 N- . A- r (6. -Dihvdro-FH-riibenz fb. el azepin-5-yl ) carbonvl 1 ohenvll-?- (2-thienyl)benzamide Example 304 N- - r (6. ll-Dihvdro-5H-dibenz lb. elazepin-5-yl) carbonvl Phenyll-2- (3-thienvl)benzamide Example 305 N-f4-r (6.11-?ihvdro-5H-dibenzrb.e1azepin-F-yli carbonyl!Phenyl 1 -3.6-dichlcrophenyl 1 -2- (2- thienyl)benzamide Example 306 -T4-' (6. ll-Dihvdro-FH-dibenz r b. l azepin-5-yl) carbonvlτ-3-chlcrophenvlτ-2- (2-thienvl)benzamide Example 307 N- r - r ( .1 - ihvdro-5H-dibenz rb. el azepin-5-yl) carbonvl 1 -3-chlorophenvli -2- (3-thienvl)benzamide Example 308 N-f4-f (6.11-Dihvdro-5H-dibenzrb.e1azepin-5-yl) carbonvl 1 -3-chloro-€-methvlphenvl " 1-2- 12- thienvl)benzamide Example 3Q9 N- r4- r (6.11-Dihvdro-5H-dibenz rb. el azepin-5-vl1 carbonyl 1 -3-methvlPhenvl 1 -2- .2- hienyl)benzamide Example 310 N- r - r (6. ll- ihvdro-5H-dibenz fb. ei azepin-5-vl) carbonyl 1 -3. -dimethvlpher.vl 1 -2- (2-thienvl)benzamide Ex p e 21 I N-.4-. (g< li- ihvdro-SH-diber.zrb.e^azeoin-F-yll carbonyl 1 -3-methvlphenvll r l.1 ■ -biphenvl! -2-carboxamide Example 312 N- r4- r (6. ll-Dihvdrc-5H-diber.z r . elazepin-F-yl) carbonyl 1 -3.6-dimethylpher.yl 1 fl.1 '-biphenvl1 -2- carboxamide Example 31 N- - A- r (6. ll-Dihvdro-5H-dibenz fb. elazepin-5-y ) carbonvll -3-methvl-6-chlorophenvll n.l '-biphenvl1 -2- carboxamide Example 314 N-f4-f (6.l 1 ,-Pihγdr g -5H-dibenzfb,e1a2'5Pin-5-yI) carbonvl 1 -3-chloro-6-methvlphenvl1 r l.1 '-biphenvl1 -2- carfroxaπύde Example 315 N- r-4- r (6. ll-Dihvdro-5H-dibenz fb. elazepin-5-yl ) carbonvll -2-methvlohenvli fl. '-biphenvl -2-carboxamide Example 316 N-U-r (6. 1-Dihvdro-5H-dibenzrb.elazepin-5-vl) carbonv 1 -2-chlorophenvll fl.l '-biphenvl i-2-carboxamide Example 317 N- r4- r (6. ll-Dihvdro-5H-dibenz fb. elazepin-5-vl) carbonvl1ohenvll -2- (2-pvridinvl)benzamide Example 318 N-f4-r (6.11-Dihvdro-5H-dibenzrb.elazepin-5-yl) carbonvl 1 ohenvl!-2- (3-pvridinvl)benzamide Example 319 N- f4- r (6. ll-Dihvdro-5H-dibenz fb. elazepin-5-vl) carbonvllPhenvl1-2- (4-pvridinvl)benzamide Example 320 N- - 4- r (6. ll-Dihvdro-5H-dibenz fb. elazepin.-ό-yl) carbonyl i-3-chlorophenyl 1 -2- (2-pvridinyl)benzamide Example 321 N- -f (6.11-Dihvdro-5H-diben rb.e1azepin-5-vl) carbonyl 1-3-chlorophenvl1-2- (3-pvridin.vl)benzamide Example 322 N-f4-r (6.11-Dihvdro-5H-dibenzrb.e!azepin-5-vl) carbonyli-3-methvlohenvl1-2- (2-pvririinvl)benzamide Example 323 N- - 4- ■ (6. ll-Dihvdro-5H-dibenz rb. el azepin-5-vl) carbonyl 1 -3-methylPhenvll -2- (3-pyridinyl)benzamide Example 324 N- T4- f (6. l-Dihvdro-5H-dibenz fb. el azepin-5-yl ) rarbnnvl 1-3.6-dimethvlPhenvl1 -2- (2-Pvridinvl ) benzami e Example 325 N-r -r (6.11-Dihvdro-5H-dibenz fb. e 1 azepin-5-yl) carbonvl 1 -3.6-dimethylohenvl1 -2- (3-Pvridinvl) benzamide Example 326 N- - A - r (6- ll-Dihvdro-FH-dibenz fb. el azepin-5-yl ) carbonvl 1 - . -dimethvlphenvl1 -2- (4-pvridinvl) benzamiHe Example 32^ N-f -r (6. ll-Dihvdro-FH-dibenz fb.eiazepip.-F-yn carbonvl 1 -?-chloro p henvl — T3 ' -methvlthio-1.1 ' -biphenvl 1 - 2-carboxamide Exa ple ;29 N-r4-r f6.11-Dihvdro-5H-dibenzrb.elazepin-F-yl) carbonvl > -3-chloroohenvl 1 - r ' -methoxv-1.1 ' -biphenyl 1 -?- carbcxamide Example 329 N-r4- r (6.11-Dihvdro-5H-dibenzrb.elazepin-5-yl) carbonyllohenvl1 ' -dimethvlaminc-1.1 ' -biphenyl 1 -2- carboxamide Example 330 N- \ A - r (6. l-Dihvdro-5H-dibenz fb. el azepin-5-γl) carbonyl 1 -3-me hvlphenvl 1 - r ' -chloro-1.1 ' -biphenvl1 -?- carboxa ide Example 331 -r4-. ( . 1-Dihvdro-5H-dibenz fb. el azepin-5-vl ) carbonv 1 -3-chlorophenvl 1 -2- (3-furanvl) benzamide Example 332 - r - ' (6- 1-Dihvαro-FH-dibenz fb. el azeoin-F-vl ) ra^-hnnvllPhenvl 1 -2- (2-f ranvl) benzamide Sha pie 223 - . A - ' (6. ll- ihvdro-FH-dibenz lb. l azeoin-F-yl) carbnnyl lohenvl i - ■ 3 ' -chloro-1.1 ' -biphenvl 1 -2-carboxamide - 144 - SUBSTΓΓUTE SHEET (RULE 26) Example 334 N- .A- r (6. ll-Dihvdro-5H-dibenz fb. el azepin-5-yl) carbonvl1-3-chlorophenvl1 r3'-chloro-1.1 '-biphenyl1-2- carboxamide Example 335 N- T4- r (6. ll-Dihvdro-5H-dibenz fb. el azepin-5-vll carbonvl 1 -3-methvlohenvl1 f '-chloro-1.1 '-biphenvl1-2- carboxanide Example 336 N- r 5- 1 (6. ll-Dihvdro-5H-dibenz Fb. el azepin-5-yl) carbonvli-2-pvriainvl 1 r3 '-chloro-1. '-biphenvl1 -2- carboxamide Example 337 N- -r (6.11-Dihvdro-5H-dibenzrb.elazepin-5-yl) carbonvl 1 -3-chlorophenγl1 r4 '-fluoro-1.1 '-biphenvl1-2- ca_rboκam;de Ex m le 338 N-fF-r (6.11-Dihvdro-5H-dibenzrb.elazepin-5-vl) carbonvl 1 -2-ovridinvll-2-chloropvridine-3-carboxamide Example 339 N-fF-r (6.11-Dihydrn-5H-diben. rb.elazepin-5-yl) carbonvl 1 -2-Pvridinvl! -2- fluoropvridine-3-carboxamide Example 340 - ΓF- ■ (6. ll-Dihvdro-5H-dibenz r b. el azepin-5-vl) carbonyl ι-2-Pyridip.yl 1 -2-aminopvridine-3-carboxamide Example 341 - f -r (6.11-Dihvdro-5H-dibenzrb.e1azepin-5-yl) carbonvlτ-2-Pvridinvll -2- (methvlamino)ovridine-3- ςsgfroxa tie Exampl 34.2 N-X5-r (6.11-Dihvdro-5H-diben rb.elazepin-5-vl) carbonyl 1 -2-pyridinyl 1 -2- (dimethylamino)Pvridi.ne-3- carboxamide Example 343 N-XF-r (6.11-Dihydrn-5H-dibenz r b.eiazepin-5-vl) carbonyll-2-pyridinyl -3-methylthiophene-2-carboxamide Example 344 N-fF-r (6..l-Dihvdro-FH-dibenzfb.elazepin-F-yl . carbonvl 1 -2-pvridinvl1-2-methvlth_.ophene-3-carboxami.de Example 345 N-fF-r (6.11-Dihvdro-5H-dibenzrb.elazepin-5-yl) carbonvl 1 -2-ovridinvH -2-chlorobenzamide Example 346 N- r.F- r (6. l-Dihvdro-5H-dibenz fb. el azepin-.F-yl ) carbonvl1 -2-ovridinvl1 -2-chloro-F-fluorobenzamide Example 347 N- - r (6.11-Dihvdro-FH-dibenz rb. el azeoin-5-yl ) carbonvl 1 -2-pyridinvl 1 -2-chloro-6-fluorobenzamide Example 34B N- 'F- r (6.11-Dihvσro-FH-dibenz r b. el zepin-F-yl ) carbonvll -2-pvridinvl -2-methvl- -fluorobenzamide Example 349 N-rF-r (6.11-Dihvdro-FH-dibenzfb.elazepin-F-yl. carbonv 1 -2-ovridinvl1 -2- (methvlamino)benzamide Example 350 N-r.F-r (6.11-Dihvdro-5H-diben rb.el zepin-5-yl) carbonv i -2-pyridinvl!-2-hvdroxvbenzami e Example 351 N-fF-r (6.11-Dihvdro-5H-diben rb.elazepin-F-vl) carbonv! i -2-pvridinvl i -2- (a inomethvl)benzamide Example 352 N-r.F-r f . ll-Dihvdro-FH-pyridof2.3-b 1 f 1.41benzodiazepin- 5-yl ) carbonvl 1 -2-Pvridinvl ^ -5- luoro-2-methvlbenzamide As described for Example 1, 6, ll-dihydro-5ϋ- pyrido [2, 3-bJ [1, 4]benzodiazepine (2 mmol) is reacted with 6- [ (5-fluoro-2-methylbenzoyl) amino]pyridine-3- carbonyl chloride (2.1 mmol) in the presence of triethylamine (4 mmol) in dichloromethane to give the product as a solid, m.p. 102°C-104°C. Example 35.3 N-f4-f (6.11-Dihvdro-5H-Pvridof2.3-b1 f1.41benznd azeni - 5-vl) carbonvl1-3-chlorophenvl! f1.1 '-biphenvl 1 -?- carboxamide As described for Example 134, 6, ll-dihydro-5ϋ- ρyrido[2, 3-bJ [1, 4]benzodiazepine (0.197 g) is reacted with 4- [ ([1,1 '-biphenyl]-2-carbonyl) amino] -2- chlorobenzoyl chloride (0.444 g) in the presence of N_,£- diisopropylethylamine (0.155 g) in 12 ml of dichloromethane to give the product as a solid. As described for Example 352, the following compounds can be prepared by reaction of 6, 11-dihydro- 5ϋ-ρyrido [2, 3-bJ [1, 4]benzodiazepine with the appropriate substituted or unsubstituted 4- [ (arylcarbonyl) amino] benzoyl chloride or the appropriate substituted or unsubstituted 6- [ (arylcarbonyl) amino]pyridine-3-carbonyl chloride Example 354 N-f4-f (6.11-Dihvdro-5H-Pvridof2.3-b1 fl.41benzodiazepi - 5-vl) carbonvl 1 ohenvll n.. '-biphenyl1 -2-carboxamide Example 355 N-f4-r (6. ll-Dih.vdrc_--5H-pvridor2.3-b1 f1.4Ibenzodiazepin- F-vl ) carbonvllPhenvll-2- (2-thienvl)benzamide Example 356 N-f4-r (6. ll-Dihvdro-5H-Pvridof2. -bl fl.41benzodiazepin- 5-yl) carbonvl 1 -3-methvlPhenvl1 r1.1 '-biphenyl1 -2- carboxamide Example 357 N-r4-f (6.11-Dihvdro-5H-pvridor2.3-bl fl.4Ibenzodiazepin- 5-yl) carbonvl ι -3-methvl-6-chloroohenvl 1 n.1 '-biphenvl1- 2-carboxamide Example 358 N- f4- r (6. ll-Dihvdro-5H-pvridof2. -bl fl.41benzodiazeoin- 5-yl) carbnnvl 1 -3.6-dimethylphenvll ri.1 '-biohenvll -2- carboxamide Example 359 N-f4-r (6.11-Dihvdro-5H-Pvridor2.3-b fl.4Ibenzodi azepi - 5-vl) carbonvl i -3-methvlPhenvl1 -2- (2-thienvl) benzam e Example 360 N-f4-f (6.11-Dihvdro-5H-pvridof2.3-bl f1.41benzodiazeoin- F-vl) carbonvl 1 -3-chlorophenvll -2- (2-thienvl) benzami e Example 361 N- \ A- r (6. ll-Dihvdro-5H-Pvridor2. -bl 11.41benzodiaze i - F-vl) carbonvllPhenvl1-2- (2-pvridinvl) benzamide Example 362 N- . A - r (6. ll-Dihvdro-5H-Pvridof2. -bl 11.41benzodiazepin- F-vll carbonvl 1 Phenvl 1 -2- (3-ovri invl) benzamide Example 363 N- f4- r (6. ll-Dihvdrc-FH-Pvrido r 2.3-b 1 r l. 1benzodiazepi - 5-vl) carbonvl 1 -3-chlorophenvl1 -2- (2-pyridinvl) benzamide Example 364 N-r4-r (e.ll-Dihvdrc-SH-PvridorP.S-b 1 ri.41benzodiazepin- F-yl) carbonvl 1 -3-chlorophenvl1 -2- (3-pvridinvl) benzamide Example 365 N- \ 4 - r (6. ll-Dihvdro-FH-pvridof2.3-bl f1. 1benzodiazepin- F-vl) carbonvll -3-methvlohenyll -2- (2-Pvridinvl) benzamide Example 366 N- f4-r (6. l-Dihydro-5H-Pvridor?.3-bl 11.41benzodiazepin- 5-y l carbonvl 1 -3. -dimethvlphenvli -2- (3- pyridinyl) benzamide Example 367 N- 14- r (6. ll-Dihvdro-FH-pyridor2. -bl fl.41benzodiazepin- F-vl ) carbonvllohenvl 1 -2- (4-Pvridinvl) benzamide Example 368 N- f4- r (6. -Dihvdro-FH-ovridor2.3-bl r1.4 ibenzodiazepin- 5-yl) carbonvllohenvl 1 -2-chloropvri ine-3-carboxamide Example 369 N- r4- r (6. 1-D . hvdro- H-pyrido f2. -bl ri .41 benzodiazeoin- 5-yl)carbnnvl1Phenvl 1 -2-fluoropvridine-3-carboxamide Example 370 N- r4- r (6. ll-Dihvdro-5H-Pyrido f2.3-bl f1.41benzodiazepin- carboxamide Example 371 N- f4- (6. l-Dihvdro-5H-ovridor2.3-bl fl .41benzodi azepin- 5-yl) carbonvl1phenvl 1 -2-methoχypvridine-3-carhnxaτnide Examp e 3^2 N- r4- r (6. ll-Dihvdro-5H-ovridof2.3-bl fl .4Ibenzod azepi - 5-yl) carbonvl <-3-methvlPhenvl 1 -2- (methvlthio)pvri dine-3- carbQXgmj.de, Example 373 N- f - r ( 6. l l -Dihvdro- 5H-Pvrido f 2 . 3-b 1 f . 4 I benzodiazepi n- 5-y ) carbonvl 1 - 3-methvlPhenv l 1 -2-chloropyridine-3- arbQ anide Example 374 N- r4-r (6. ll-Dihvdro-5H-oyridof2.3-bl fl, 41benzodiazepin- 5-yl) carbonvl!Phenvl!-2-aminopvridine-3-carboxamide Example 375 N-f-5-r (6.11-Dihvdro-5H-ovridor2.3-b! f1.41benzodiazepin- 5-yl) carbonyl -2-ovridinvl 1 fl.1 '-biphenvl i-2-carboxamide Example 376 N-r5-r (6.11-Dihvdro-5H-pyridor2.3-b1 f1. Ibenzodiazeoin- 5-vl) carbonvl -2-ovridinvli -2- (2-thienvl)benzamide Example 377 N-fF-r (6.11-Dihvdro-5H-Pvridor2.3-b 1 f1.4Ibenzodiazepin- 5-yll carbonvl 1 -2-Pvridinvl1-2- (3-thienvl)benzamide Exa p e 378 N-f5-f (6.11-Dihvdro-FH-Pvridor2.3-b 1 r1.4Ibenzodiazepin- 5-yl)carbcnvϋ-2-pyridinv 1 -2- (2-Pvridinvl)benzamide Example 379 N- f - r f .1 -Dihvdro-FH-ovrido f2.3-bl f1. ibenzodiazeoin- 5-vn carbonvl 1-2-Pvridinvl 1 -2- (3-Pvridinvl)benzamide Example 380 N- fF- Γ (6. , -πihvdro-FH-pvrido f2.3-bl r 1.4lbenzodiazepin- F-yl) carbonvl 1 -2-Pvridinvl 1 -2- (4-Pvridinvl)benzamide Example 381 N-f5-r (6.11-Dihvdro-5H-Pvridor2.3-b1 f .41benzodiazep - 5-vl) carbonvll -2-ovridinvll -2- (2-fnranvl)benzam e Example 38 N-LF-r (6.11-Dihvdro-5H-pvridor2.3-bl r1.41benzodiazepin- 5-vl) carbonvl -2-Pvridinvll -2- (3-furanvl)benzamide Example 383 N- T5- (6.11-Dihvdro-5H-Pyridor2.3-b! fl■ 41benzodiazepin- F-vl) carbonvll -2-pyridinvl -2-chlorobenzamide Example 384 N- f5- r (6. ll-Dihvdrc-5H-pvridor2, 3-bl r1.41benzodiazeoin- F-vl) carbonvl 1 -2-ovridinvll -2-chloro-F-fluorobenzam e Example 385 N- fF- r (6. ll-Dihvar -FH-pyrid f2.3-b 1 fl.4Ibenzodiazepin- 5-vl) carbonvl1-2-Pvridinvl 1 -2. F-dimethvlbenzamide Example 386 N- r5- r (6.11-Dihvάro-FH-oyridc 12.3-b 1 f1.41benzodiazepin- 5-yl) carbonyl!-2-pyridinyll-2-chloro-6-fluorobenzamide Example 387 N-r.F-r (6.11-Dihvdro-FH-pyridor2.3-bl r1.41benzodiazeoin- 5-yl) carbonvl1 -2-Pvridinvϋ -2-methvl-3-fluorobenzamide Example 388 N- f.F- r (6.11-Dihvdro-FH-pvridof2.3-bl \1.41benzodiazeoin- 5-vl ) carbonvl 1 -2-ovridinvl -2-hvdroxvbenzamide Ex mp 399 N- TF- f (6. l-Dihvdro-5H-oyridof2.3-bl r1. 1benzodiazeoin- 5-yl) carbonyli-2-oyridinvl 1 -2-aminobenzamide Example 390 N- fF-r (6. ll-Dihvdro-5H-oyridor2. -bl r .41benzodiazeoin- 5-yl) carbonyl 1 -2-pyridinyl 1 -2- (methylamino)benzamide Example 391 N- X5-f (6. l-Dihvdro-FH-Pyridof2.3-bl ri , 4ibenzodiazeoin- F-yl) carbonyl 1 -2-oyridinyl 1 -2- (dimethylamino)benzamide Example 392 N- r.F- r (6. ll-Dihvdro-5H-Pvridof2.3-bl f1.41benzodiazepin- 5-vl) carbonvl1-2-Pvridinvll-2-chloropvridine-3- carboxamide Example 393 N-fF-r (6. ll-Dihvdro-5H-ovridor2. -bl fi.4Ibenzodiazepin- 5-vl) carbonvll -2-pvridinvl1-2- (dimethylamino. vridine-3- carbo ide Example 394 N-fF-r (6.11-Dihvdro-5H-ovridor2.3-b11 .41benzodiazepin- 5-vl) carbonvl 1 -2-Pvridinvl 1 -2-methylthiophne-3- carboxamide Example 395 N- f - r (6. l-Dihvdro-5H-pyrido f2.3-bl f 1.41benzodiazepin- 5-vl) carbonvl 1 -2-Pvridinvl1-3-methvlthiophene-2- carboxamide Example 396 N-f4-r (4.5-DihvdrθPyrazolor4.3-dl f lbenzazepin-6 flH - yl) carbonvl1ohenvl . ' 1 .1 '-biphenvl 1 -2-carboxamide A mixture of 0.278 g of 4,5- dihydropyrazolo [4, 3-d [1]benzazepine, 1.11 g of 4- [( [1, 1 '-biphenyl]-2-carbonyl) amino]benzoyl chloride and 0.426 g of N_,H-diisopropylethylamine in 12 ml of dichloromethane-tetrahydrofuran (1:1) is stirred at room temperature overnight. The mixture is poured into water and extracted with dichloromethane. The extract is washed with 2M Na2Cθ3, H2O, brine and dried (Na2Sθ4) . The solvent is removed under vacuum to give 1.45 g of solid. To the proceding solid in 25 ml methanol- tetrahydrofuran (1:1) is added 2.78 ml of 2N_ NaOH and the solution stirred at room temperature for 3.5 hours. The solvent is removed under vacuum, water added to the residue and the mixture extracted with dichloromethane. The extract is washed with H2O, 0.5 N. citric acid; H2O, brine and dried (Na2S0_j) . The solution is passed through a thin pad of hydrous magnesuim silicate and the filtrate concentrated to dryness. The residue (0.95 g) is triturated with ether-dichloromethane to give 0.17 g of crystals, m.p. 255°C-260°C; Anal, found for C3iH24 4θ2'l 2H2θ: C, 75.9; H, 5.1; N, 10.8. Example 397 N-f4-r (4.5-Dihvdropyrazolor4. -dl f11benzazepin- f1HI- vl ) carbonvl 1 -3-ch orooheny 1 fl.1 '-biphenyl1-2- carboxa e A mixture of 0.185 g of 4,5- dihydropyrazolo [4, 3-d] [1]benzazepine, 0.814 g of 4- [([1,1'-biphenyl] -2-carbonyl) amino] -2-chlorobenzoyl chloride and 0.284 g of M. --.-diisopropylethylamine in 9 ml of dichloromethane-tetrahydrofuran (1:1) is stirred at room temperature overnight. The mixture is poured into water and extracted with dichloromethane. The extract is washed with 2N NaOH, H2θ, brine and dried (Na2Sθ4) . The solvent is removed under vacuum to give 0.99 g of a solid. To the preceding solid in 15 ml of methanoi-tetrahydrofuran (1:1) is added 1.75 ml of 2N_ NaOH and the solution stirred at room temperature for 2 hours. The volatiles are removed under vacuum and the mixture extracted with chloroform. The extract is washed with 1H citric acid, H2O, brine and dried (Na2SO-j) . The solution is filtered through a thin pad of hydrous magnesium silicate and the filtrate concentrated to dryness. The residue (0.76 g) is chromatographed on thick layer silica gel plates with hexane-ethyl acetate (1:2) as solvent to give 0.37 g of white solid, m.p. 172-202°C, Anal, found for 1/2 hydrate: C, 70.1; K, 5.0; _ , 9.8; Cl, 6.4. Example 398 N-fF-r f . F- ihvdropyrazolo r 4.3-d 1 r 1 1 benzazepin-6 (1H) - yl) carbonvl 1 -2-Pvridinvll fl. '-biphenvl 1 -2-carboxamide As described for Example 396, (0.1 mmol) of 4, 5-dihydropyrazolo [4, 3-d] [l]benzazepine is reacted with (0.21 mmol) of 6- [([1, ' -biphenylj -2-carbonyl) amino] pyridine-3-carbonyl chloride to give the product as a light tan solid. Recrystallized from ethyl acetate/hexane, m.p. 228°C-234°C as white crystals. Example 399 N-f5-r (4.5-Dihvdropvrazolor4.3-dl fllbenzazepin-6 (1H) - yl) carbonvl1-2-pvridinvl 1 -5-fluoro-2-methvlbenzamide As described for Example 396, 0.10 mmol of 4, 5-dehydropyrazolo[4, 3-d] [l]benzazepine is reacted with 0.21 mmol) of 6- [ (5-fluoro-2-methylbenzoyl) amino]-2- pyridine-3-carbonyl chloride to give the product as a tan solid, (0.15 g) m.p. 126°C-176°C: Mass Spec (FAB) - found 442 (M + +H) . Example 4QQ N-f5-(4H-Thienor3.4-b 1 1 .51benzodiazepin-9 (10H) -yl-2- pvridinvl1 -5-fluoro-2-methvlbenzamide As described by J.B. Press et al in . Med. Chem.. 22 J - 725 (1979), 9, 10-dihydro-4H-thieno [3, 4- £_] [1, 5]benzodiazepin-10 (9H) -one is prepared. This intermediate (4.8 g) is dissolved in tetrahydrofuran under nitrogen and 4.2 g of lithium aluminum hydride (LAH) is added portionwise with stirring. The mixture is refluxed for 18 hours and quenched by the dropwise addition of water. The mixture is extracted with chloroform and the extract is filtered through diatomaceous earth. The organic layer is washed with water (200 ml), dried ( a2Sθ ) and the solvent removed. The residual oil is chromatographed on thick layer silica gel plates with chloroform as eluent to give 1.2 g of 9, 10-dihydro-4ϋ-thieno[3, 4-b] [1, 5]benzodiazepine as a solid. The proceeding compound (0.5 g) is reacted with 1.06 g of 6- [ (5-fluoro-2-methylbenzoyl) amino] pyridine-3-carbonyl chloride, hydrochloride in dichloromethane which contains 7 ml of H. E~ diisopropylethylamine. The mixture is stirred at room temperature for 16 hours and then is washed with water, 1H HCI, saturated sodium bicarbonate solution, water and dried (Na2Sθ4) . The solvent is removed and the residue purified by chromatography on silica gel with ethyl acetate-hexane (1:3) to give 1.1 g of a solid, m.p. 89°C-92°C. Example 401 N- - MH-Thieno r 3.4-bl f1.51benzodi azepin-9 (1 OH! -yl . - phenyl 1 r1.1 '-biphenyl 1 -2-carboxamide As described for Example 400, 9, 10-dihydro-4ϋ- thieno [3, 4-b_] [1, 5]benzodiazepine is reacted with 4- [ ( [1, 1 ' -biphenyl]-2-carbonyl) amino]benzoyl chloride to give the product as a solid. Example 402 N- -f4H-T ienor .4-bl f:, 51 benzodiazepin-9 (1 OH. -V 1 . -?- chlorophenvl 1 r 1.1 '-biphenvl i -?-carbnxami e As described for Example 400, 9, 10-dihydro-4H~ thieno [3, 4-b] [1, 5]benzodiazepine is reacted with 4- [ ([1,1'-biphenyl]-2-carbonyl) amino] -2-chlorobenzoyl chloride to give the product as a solid. Example 403 N-r.F- f4H-TV..enof...4-hi f1 ■ lbenzodiazepin-9 (1 OH) -yl ) -2- pyridinyll r 1 - 1 '-biphenyl i -2-carboxamide As described for Example 400, 9, 10-dihydro-4H- thieno[3, 4-b] [1, 5]benzodiazepine is reacted with 6- [ ([1,1' -biphenyl] -2-carbonyl) amino]-pyridine-3-carbonyl chloride to give the product as a solid. Example 404 . ιι -n .hvπr -in- r4- (2-thi nvl)benznyl 1 -10H- ri-ibenz f b.e 1 f1.4i diazepine A mixture of 3 g of 4- (2-thienyl)benzoic acid and 30 ml of sulfonyl chloride is refluxed for 45 minutes and the solvent removed. The residue is dissolved in carbon tetrachloride and the solvent removed under vacuum (2-times) to give 4- (2-thienyl) benzoyl chloride. To a cooled (0°C) solution of 2.0 g of 5, ll-dihydro-10ϋ-dibenz [b,e] [1, ]diazepine and 7 ml of H » ----diisopropylethylamine in 30 ml of dichloromethane is added dropwise a solution of 3.15 g of 4- (2- thienyl)benzoyl chloride in 30 ml of dichloromethane. The mixture is stirred at room temperature for 16 hours and diluted with 50 ml of chloroform. The solution is washed with 30 ml each of water, 2N HCI, saturated NaHC03, water and dried (Na2Sθ4) . The solvent is removed under vacuum and the residue (3.1 g) chromatographed on silica gel (column) with hexane-ethyl acetate (2:1) as eluent to give 1.8 g of solid, m.p. 114°C-116°C. Example 405 5.11-Dihvdro-10-r4-(3-thienyl)benzoyl 1 -10H- dibenz r b.ei f1.41 iazepine To a mixture cf 2.0 g cf 5, 11-dihydro-10ϋ~ dibenz [b,e] [1, 4]diazepine and 7 ml of H,M.- diisopropylethylamine in 30 ml of dichloromethane is added dropwise a solution of 3.15 g of 4- (3- thienyl)benzoyl chloride in 30 ml of dichloromethane. The mixture is stirred 16 hours at room temperature and diluted with dichloromethane (50 ml) . The solution is washed with 30 ml each cf H2θ, 2H HCI, saturated NaHCθ3, water and dried (Na2Sθ ) . The solvent is removed under vacuum and the residue purified by chromatography on silica gel with hexane-ethyl acetate as eluent to give a solid. Binding Assay to Rat Hepatic V^ Receptors Rat liver plasma membranes expressing the vasopressin Vi receptor subtypes are isolated by sucrose density gradient according tc the method described by lesko et al., (1973) . These membranes are quickly suspended in 50.0 m.M Tris.HCl buffer, pH 7.4, containing 0.2% bovine serum albumin (3SA) and 0.1 mM phenylmethylsulfonyifluoride (PMSF) and kept frozen at - 70°C until used in subsequent binding experiments. For binding experiments, the following is added to the wells of a ninety-six well format micrctiter plate: 100 ml of 100.0 mM Tris.HCl buffer containing 10.0 mM MgCl2, 0.2% heat inactivated BSA and a mixture of protease inhibitors: leupeptin, 1.0 mg%; aprotinin, 1.0 mg %; 1, 10-phenanthroline, 2.0 mg %; trypsin inhibitor, 10.0 mg % and 0.1 mM PMSF, 20.0 ml of [phenylalanyl-3, , 5,- 3 H] vasopressin (S.A. 45.1 Ci/mmole) 0.8 mM, and the reaction initiated by the addition of 80 ml of tissue membranes containing 20 mg of tissue protein. The plates are kept undisturbed on the bench top at room temperature for 120 min. to reach equilibrium. Non¬ specific samples are assayed in the presence of 0.1 mM of the unlabeled antagonist phenyialanylvasopressin, added in 20.0 ml volume. Fcr test compounds, these are solubilized in 50% dimethylsulfoxide (DMSO) and added in 20.0 ml volume to a final incubation volume of 200 ml. Upon completion of binding, the content of each well is filtered off, using a Brandel® cell Harvester (Gaithersburg, MD) . The radioactivity trapped on the filter disk by the iigand- receptor complex is assessed by liquid scintillation counting in a Packard LS Counter, with an efficiency of 65% for tritium. The data are analyzed fcr IC50 values by the LUNDON-2 program for competition (LUNDON SOFTWARE, OH) and displayed in Table I. Binding Assay to Rat Kidney Medullary 7 Receptors Medullary tissues from rat kidneys are dissected out, cut into small pieces and soaked in a 0.154 mM sodium chloride solution containing 1.0 mM EDTA with many changes of the liquid phase, until the solution is clear cf blood. The tissue is homogenized in a 0.25 M sucrose solution containing 1.0 mM EDTA with many changes of the liquid phase, until the solution is clear of blood. The tissue is homogenized in a 0.25 M sucrose solution containing 1.0 mM EDTA and 0.1 mM PMSF using a Potter-Eiveh e ho ogenizer with a teflon pestle. The homoαenate is filtered throuαh several layers (4 layers) cf cheese cloth. The filtrate is rehomogenized using a dounce homogenizer, with a tight fitting pestle. The final homogenate is centrifuged at 1500 X g for 15 min. The nuclear pellet is discarded and the supernatant fluid recentrifuged at 40,000 x g for 30 min. The resulting pellet formed contains a dark inner part with the exterior, slightly pink. The pink outer part is suspended in a small amount of 50.0 mM Tris.HCl buffer, pH 7.4. The protein content is determined by the Lowry's method (Lowry et al., J. Biol. Chem.. 1953) . The membrane suspension is stored at - 70°C, in 50.0 mMTris.HCi, containing 0.2% inactivated BSA and 0.1 mM PMSF in aiiquots of 1.0 ml containing 10.0 mg protein per ml of suspension until sue in subsequent binding experiments. For binding experiments, the following is added in ml volume to wells of a 96 well format of a icrotiter plate: 100.0 ml of 100.0 mM Tris.HCl buffer containing 0.2 % heat inactivated BSA, 10.0 mM MgCL2 and a mixture of protease inhibitors: leupeptin, 1.0 mg %; aprotinin, 1.0 mg % 1, 10-ρhenanthroline, 2.0 mg %; trypsin inhibitor, and C .1 mM PMSF, 20.0 ml of [ 3 H] Arginineδ, vasopressin (S.A. 75.0 Ci/mmole) at 0.8 nM and the reaction initiated by the addition of 80.0 ml of tissue membranes (200.0 mg tissue protein) . The plates are left undisturbed on the bench top for 120 minutes to reach equilibrium. Non-specific binding is assessed in the presence of 1.0 mM of unlabeled ligand, added in 20 ml volume. For test compounds, these are solubilized in 50% dimethylsulfoxide (DMSO) and added in 20.0 ml volume to a final incubation volume cf 200 ml. Upon completion of binding, the content of each well is filtered off, using a Brandel® cell Harvester (Gaithersburg, MD) . The radioactivity trapped en the filter disk by the ligand- receptor complex is assessed by liquid scintillation counting in a Parkard LS Counter, with an efficiency of 65% for tritium. The data are analyzed for IC50 values by the LUNDON-2 program for competition (LUNDON SOFTWARE, OH) and displayed in Table I. Radioliσand Binding Experiments with Human Platelet Meiacranes (a) Platelet Membrane Preparation: Frozen platelet rich plasma (PRP) , received from the Hudson Valley Blood Services, are thawed to room temperature. (Platelet Source: Hudson Valley Blood Services, Westchester Medical Center, Valhalla, NY) . The tubes containing the PR? are centrifuged at 16, 000 x g for 10 minutes at 4°C and the supernatant fluid discarded. The platelets resuspended in an equal volume of 50.0 mM Tris. HCL, pH 7.5 containing 120 mM NaCl and 20.0 mM EDTA. The suspension is recentrifuged at 16,000 x g for 10 minutes. This washing step is repeated one more time. The wash discarded and the lysed pellets homogenized in low ionic strength buffer of Tris. HCI, 5.0 m, pH 7.5 containing 5.0 mM EDTA. The homogenate is centrifuged at 39,000 x g for 10 minutes. The resulting pellet is resuspended in Tris.HCl buffer, 70.0 mM, pH 7.5 and recentrifuged at 39,000 x g for 10 minutes. The final pellet is resuspended in 50.0 mM Tris.HCl buffer pH 7.4 containing 120 mM NaCl and 5.0 mM KC1 to give 1.0-2.0 mg protein per ml of suspension. (b) Binding to Vaso p ressin Vτ_ receo or subtype in Human Plst-'l 1 ?*'. Membranes: In wells of a 96 well format microtiter plate, add 100 ml of 50.0 mM Tris. HCI buffer containing 0.2% BSA and a mixture of protease inhibitors (aprotinin, leupeptin etc.) Then add 20 ml of [-H]Ligand (Manning or Arg^Vasopressir.) , to give final concentrations ranging from 0.01 to 10. C nM. Initiate the binding by adding 80.0 mi cf platelet suspension (approx. 100 mg protein) . Mix all reagents by pipetting the mixture up and down a few times. Non specific binding is measured in the presence of 1.0 mM of unlabeled ligand (Manning or Arg^Vasopressin) . Let the mixture stand undisturbed at room temperature for ninety (90) minutes. Upon this time, rapidly filter off the incubate under vacuum suction over GF/B filters, using a Brandel Harvester. The radioactivity caught on the filter disks is determined by the addition of liquid scintillant and counting in a liquid scintillator. Binding to Membranes of Mouse Fibroblast Cell Line (LV- 21 Transferred with the cDNA Expressing the Human V Vasopressin Receptor (a) Membrane Preparation Flasks of 175 ml capacity, continuing attached cells grown to confluence, are cleared of culture medium by aspiration. The flasks containing the attached cells are rinsed with 2 x 5 mi cf phosphate buffered saline (PBS) and the liquid aspirated off each time. Finally, 5 ml cf an enzyme free dissociation Hank's based solution (Specialty Media, Inc., Lafayette, NJ is added and the flasks are left undisturbed for 2 minutes. The content cf all flasks is poured into a centrifuge tube and the cells pelleted at 300 x g for 15 minutes. The Hank's based solution is aspirated off and the cells homogenized with a polytron at setting #6 for 10 sec in 10.0 mM Tris.HCl buffer, pH 7.4 containing 0.25 M sucrose and 1.0 mM EDTA. The homogenate is centrifuged at 1500 x g for 10 minutes to remove ghost membranes. The supernatant fluid is centrifuged at 100,000 x g for 60 minutes to pellet the receptor protein. Upon completion, the pellet is resuspended in a small volume of 50.0 mM Tris.HCl buffer, pH 7.4. The protein content is determined by the Lowry method and the receptor membranes are suspended in 50.0 mM Tris.HCl buffer containing 0. I mM phenylmethylsulfonylfluoride (PMSF) and 0.2% bovine serum albumin (BSA) to give 2.5 mg receptor protein per ml of suspension. (b) Receptor Bindin g Fcr binding experiments, the following is added in ml volume to wells of a 9c well format of a microtiter plate: lOC.O ml of 100. C mM Tris.HCl buffer containing 0.2% heat inactivated BSA, 10.0 mM MgCl2 and a mixture of protease inhibitors: ieupeptin, 1.0 mg%; aprotinin, 1.0 mg%; 1, 10-phenanthroline, 2.0 mg %; trypsin inhibitor, 10.0 mg % and 0.1 mM PMSF., 20.0 ml of [^H] Arginine 8 , vasopressin (S.A. 75.0 Ci/mmole) at 0.8 nM and the reaction initiated by the addition of 80.0 ml of tissue membranes (200.0 mg tissue protein). The plates are left undisturbed on the bench top for 120 minutes to reach equilibrium. Non specific binding is assessed in the presence of 1.0 mM of unlabeled ligand, added in 20 ml volume. For test compounds, these are solubilized in 50% dimethylsulfoxide (DMSO) and added in 20.0 ml volume to a final incubation volume of 200 ml. Upon completion cf biding, the content of each well is filtered off, using a Brandel® cell Harvester (Gaithersburg, MD) . The radioactivity trapped on the filter disk by the iigand-receptcr complex is assessed by liquid scintillation counting in a Packard LS Counter, with an efficiency of 65% for tritium. The data are analyzed for IC50 values by the LUNDON-2 program for competition (LUNDON SOFTWARE, OH) and the data is displayed in Table I. Vasopressin V Antagonist Activity in Conscious Hvdrated Rats; Conscious hydrated rats are treated with compounds under study from 0.1 to 100 mg/kg orally or vehicle. Two to four rats are used for each compound. One hour later, arginine vasopressin (AVP, antidiuretic hormone, ADH) dissolved in peanut oil is administered at 0.4 mg/kg intraperitoneally. Two rats in each test would not receive arginine vasopressin but only the vehicle (peanut oil) to serve as water-loading control. Twenty minutes later each rat is given 30 mL/kg of deionized water orally by gavage and is placed individually in a metabolic cage equipped with a funnel and a graduated glass cylinder tc collect urine fdr four hours. Urine volume is measure and osmolality analyzed by use cf a Fiske One-Ten osmometer (Fiske Assoc.., Norwood, MA, USA) . Urinary sodium, potassium, and chloride are analyzed by use cf ion-specific electrodes in a Beckman E3 (Electrolye 3) Analyzer. In the following results, decreased urine volume and decreased osmolality relative to AVP-control indicates activity. Vasopressin V j _ Antagonist Activity in Conscious Ra s: Conscious rats are restrained in a supine position with elastic tape. The area at the base of the tail is locally anesthetized by subcutaneous infiltration with 2% procaine (0.2 ml) . Using aseptic technique to the ventral caudal tail artery is isolated and a cannula made of FE 10 and 20 (heat-fused) tubing is passed into the lower abdominal aorta. The cannula is secured, heparinized (1000 iu/cc) , sealed and the wound closed with one or two stitches of Dexon 4-0. The caudal vein is also cannulated in the same manner for intravenous drug administration. The duration of the surgery is approximately 5 minutes. Additional local anesthesia (2% procaine or iidocaine) is provided as needed. The animals are placed in plastic restraining cages in an upright position. The cannula is attached to a Statha P23Db pressure transducer and pulsatile blood pressure is recorded. Increase of systolic blood pressure responses to arginine vasopressin 0.01 and 0.2 international unit (I.U.) (350 I.U.= 1 mg) injections are recorded prior to any drug (compound) administration, after which each rat is dosed orally with compounds under study 0.1-100 mg/kg (10 cc/kg) or intravenously 0.1-30 mg/kg (1 cc/kg) . The vasopressin injections are repeated 30,60,90,120,180,240 and 300 minutes later. Percentage of antagonism by the compound is calculated using the ore-drug vasopressin vasopressor response as 100%. Oxytocin Receptor Binding (a) Membrane Preparation Female Sprague-Dawley rats weighing approximately 200-250 g are injected intramuscularly (i.m.) with 0.3 mg/kg of body weight of diethylstilbestrol (DES) . The rats are sacrificed 18 hours later under pentobarbital anesthesia. The uteri are dissected out, cleaned of fat and connective tissues and rinsed in 50 ml of normal saline. The tissue pooled from six rats is homogenized in 50 ml of 0.01 mM Tris. HCI, containing C .5 mM dithiothreitol and 1.0 mM EDTA, adjusted to pH 7.4, using a polytron at setting 6 with three passes of 10 sec each. The homogenate is passed through two (2) layers cf cheesecloth and the filtrate centrifuged at 1000 :. g for 10 minutes. The clear supernatant is removed and recentrifuged at 165,000 x g for 30 minutes. The resulting pellet containing the oxytocin receptors is resuspended in 50.0 mM Tris.HCl containing 5.0 mM MgCl2 at pH 7.4, to give a protein concentration cf 2.5 mg/ml of tissue suspension. This preparation is used in subsequent binding assays with [ 3 H] oxytocin. (b) Radicliσand Binding Binding cf 3, 5- [ 3 H]Oxytocin ([ 3 H]OT) to its receptors is done in micrctiter plates using [ 3 H]OT, at various concentrations, in an assay buffer of 50.0 mM Tris.HCI, pH 7.4 and containing 5.0 mM MgCl2. and a mixture cf protease inhibitors: BSA, 0.1 mg; aprotinin, 1.0 mg; 1, 10-ρhenanthroiine, 2.0 mg; trypsin, 10.0 mg; and PMSF, 0.3 mg per 100 mi cf buffer solution. Non¬ specific binding is determined in the presence of 1.0 uM unlabeled OT. The binding reaction is terminated after 60 minutes, at 22°C, by rapid filtration through glass fiber filters using a Erandel® cell harvester (Biomedical Research and Development Laboratories, Inc., Gaithersburg, MD) . Competition experiments are conducted at equilibrium using 1.0 nM [ 3 H]OT and varying the concentration of the displacing agents. The concentrations cf agent displacing 50% of [ 3 H]OT at its sites (IC50) are calculated by a computer assisted LUNDON-2 program (LUNDON SOFTWARE INC., Ohio, USA) . Binding Assay to Rat Hepatic VJL Receptors and Rat Kidney Medullary V Receptors or *3indino to V^ Receptor Subtype in Human Platelet and **RLnding to membranes of Mouse Fibroblast Cell Line (T.V-2. Transfected with the cDNA Expressing the Human V2 Receptor Table I Ex. No. Structure IC 50 (μM ) C 5Q (μ ) Cont'd. Ex. No. Structure IC 50 (μM) IC 50 (μM) atlμM 90% at μM Cont'd. V. Ex. No. Structure IC 5Q (μM) IC 50 (μ ) Cont'd. Ex. No. Structure IC 50 (μM) IC 50 (μM) Table II Vasopressin V^ Antagonist Activity In Conscious Hyς-rated Rats Water-load control Water-load Control +DMSO(10%) (20%) AVP-control Vasopressin Antidiuretic (V^) Response in Conscious Rats with Free Access to Water Drinking Before But Not During Male or female normotensive Sprague-Dawley rats (Charles River Laboratories, Inc., Kingston, NY) of 400-450 g of body weight were supplied with Laboratory Rodent Feed #5001 (PMI Feeds, Inc., Richmond, IN) and water ad libitum. On the day of test, rats were placed individually into metabolic cages equipped with stainless steel screens (to separate the feces from the urine) and funnels for collection of urine. Compounds, vehicle, or reference agent was given at various oral doses. During the test, rats were provided with no water or food. After dosing, urine was collected in graduated cylinders for four hours. Urine volume was measured. Urinary osmolality was determined using a Fiske One-Ten Osmometer (Fiske Associates, Norwood, MA 02062) . An aliquot of each urine collection was analyzed for Na + ,K + and Cl " using ion specific electrodes a in Beckman E3 (Electrolyte 3) analyzer. The vehicle used for testing compounds was 20% dimethylsulfoxide (DMSO) in 2.5% preboiled starch. Table IV list results with compounds tested by this procedure. Table iv Vasopressin V Antagonist Activity in Conscious Rats •Control DMSO (20%)-2.5% corn starch Compounds were dissolved in DMSO and then diluted in 2.5% corn starch (final concentration of DMSO was 20%) . All rats were orally dosed with this mixture at lOmV kg, by gavage . Table III Ox tocin Bindin Assa The compounds of the present invention can be used in the form of salts derived from pharmaceutically or physiologically acceptable acids or bases. These salts include, but are not limited to, the following: salts with inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid and, as the case may be, such organic acids as acetic acid, oxalic acid, succinic acid, and maieic acid. Other salts include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium cr magnesium or with organic bases. The compounds can also be used in the form of esters, carba.mates and other conventional "pro-drug" forms, which, when administered in such form, convert to the active moiety n vi vo . When the compounds are employed for the above utilities, they may be combined with one or more pharmaceutically acceptable carriers, fcr example, sol- vents, diluents and the like, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for exam¬ ple, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% cf sugar, and elixirs containing, for example, from about 20 to 50% ethanol, and the like, or parenterally in the form of sterile injectabie solutions cr suspensions contain¬ ing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations may contain, for example, from about 25 to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight. The effective dosage cf active ingredient employed may vary depending on the particular compound employed, the mode cf administration and the severity of the condition being treated. However, in general, satisfactory results are obtained when the compounds of the invention are administered at a daily dosage cf from about 0.5 to about 500 mg/kg of animal body weight, preferably given in divided doses two to four times a day, or in a sustained release form. For most large mammals the total daily dosage is from about 1 to 100 mg, preferably from about 2 to 80 mg. Dosage forms suitable for internal use comprise from about 0.5 to 500 mg cf the active compound in intimate admixture with a solid cr liquid pharmaceutically acceptable carrier. This dosage regimen may be adjusted to provide the optimal therapeutic response. Fcr example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. These active compounds may be administered orally as well as by intravenous, intramuscular, or sub¬ cutaneous routes. Solid carriers include starch, lac¬ tose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glyccls, non-ionic surfac- tants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active in¬ gredient and the particular form of administration de¬ sired. Adjuvants customarily employed in the prepara- tion of pharmaceutical compositions may be advan¬ tageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA. The preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard- filled or liquid-filled capsules. Oral administration of the compounds is preferred. These active compounds may also be adminis- tered parenterally or intraperitoneally. Solutions or suspensions cf these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydrox- ypropylcellulose. Dispersions can also be prepared in glycerol, liquid, polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. The pharmaceutical forms suitable for in- jectable use include sterile aqueous solutions or dis¬ persions and sterile powders for the extemporaneous preparation cf sterile injectabie solutions or disper¬ sions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exits. It must be stable under conditions cf manufacture and storage and must be preserved against the contaminating action cf microorganisms such as bacterial and fungi. The carrier can be a solvent cr dispersion medium con¬ taining, for example, water, ethanol (e.g., glycerol, propylene glycol and liquid polyethylene glycol) , suitable mixtures thereof, and vegetable oil. The new tricyclic non-peptide vasopressin antagonists of this invention are useful in treating conditions where decreased vasopressin levels are desired, such as in congestive heart failure, in disease conditions with excess renal water reabsorption and in conditions with increased vascular resistance and coronary vasoconstriction. In particular, the vasopressin antagonists of this invention are therapeutically useful in the treatment and/or prevention cf hypertension, cardiac insufficiency, coronary vasospasm, cardiac ischemia, renal vasospasm, liver cirrhosis, congestive heart failure, nephritic syndrome, brain edema, cerebral ischemia, cerebral hemorrhage-stroke, thrombosis- bleeding and abnormal states cf water retention. In particular, the oxytocin antagonists of this invention are useful in the prevention of preterm labor and premature birth which is a significant cause of infant health problems and infant mortality.

Claims: We claim: Formula I wherein Y is selected from (CH2) n , C, S, NH, NCOCH3. N- lower alkyl (C1-C3) , CH-lower alkyl (C1-C3) , CHNK-lower alkyl (C1-C3) , CHNH2, CHN[lower alkyl (C1-C3) ]2,CHO-Iower alkyl (C1-C3) , CHS-lower alkyl (C1.-C3) , wherein n is an integer from 0-2; A-B is wherein m is an integer from 1-2, provided that when Y is -(CH2)n~ and n= 2, πt may also be zero and when n is zero, m may also be three, provided aiso that when Y is -(CH2)n- and n is 2, m may not also be two; Rl is hydrogen, halogen (chlorine, bromine, fluorine, iodine), OK, -S-lower alkyl (C1-C3) , -SH, -SO lower alkyl (C1-C3) , -SO2 lower alkyl (C1-C3) , -CO-lower alkyl (C1-C3) , -CF3, lower alkyl (C1-C3) , O-lower alkyl (C1-C3) , -NO2, -NH2, -NHCO lower alkyl (C1-C3) , -N- [lower alkyl (C1-C3) ]2, -SO2NH2, -SO2NH lower alkyl (C1-C3), or -S02NIlower alkyl (C1-C3) ] 2 -' R2 is hydrogen, Cl, Br, F, I, -OH, lower alkyl (C1-C3) , O-lower alkyl (C2 . -C3) , or Ri and R2 taken together are methylenedioxy cr ethylenedioxy; R3 is the moiety O II - CAr wherein Ar is a moiety selected from, the group and X is 0, S , -NCH3 or -NH R4 is selected from hydrogen, lower alkyl (C1-C3) , -C0- lower alkyl (C1-C3) ; R5 and R7 are selected from hydrogen, (C1-C3) lower alkyl, (C1-C3) lower alkoxy and halogen R6 is selected from (a) moieties of the formula: O -NH-C-O-lower alkyl(C 3 -C 8 )straight or branched O II -NH-C-lower alkyl(C 3 -C-)straight or branched, O II -NH-C-O-lower alkenyl(C 3 -C 8 )s_raight or branched, O II -NH-C-lower alkenyl(C--C 8 )s.raigh. or branched, wherein cycloalkyl is def ined as C3 to ^6 cycloalkyl , cyclohexenyl or cyclopentenyl ; R a is hydrogen , CH3 , C2H5 , moieties of the formulae : - (CH2) 2-O-lower alkyl (C1-C3) or -CH2CH2OH; q is one, twc cr three; Rb is hydrogen, -CH3 or -C2H5,-and (b) a moiety of the formula: -X-RlC- wherein P.χo is lower alkyl (C3-C8) , lower alkenyl (C3-C8) - - ( CH2 ) p-cycloalkyl ( C3-C6) - and p is zero to three; X is C, S, NH, NCH3, \ C= O or a bond / and R5 and P.7 are as previously defined, (c) a moiety of the formula: R_ N-COJ wherein J is R a , lower alkyl {C3-C8) branched or unbranched, lower alkenyl (C3-C8) branched cr unbranched, -O-lower alkyl (C3-C8) branched or unbranched, -O-lower alkenyl (C3-C8) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties or -CH2-K' wherein K' is halogen, -OH, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety: —N E \ / G=F wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C1-C3) lower alkyl, hydroxy, -CO-lower alkyl (C1-C3) , CHO, (C1-C3) lower alkoxy, -Cθ2- lower alkyl (C1-C3) , and R a and Rb are as hereinbefore defined; (d) a moiety selected from those of the formulae: -N- COCHAr' R O II -O-C-lower alkyl (C j -C 3 ) , -S-lovver alkyl(C j -Cg) / , •R, - S- ^ - N χ , - NH(CH.) q - CON , R b NHCH^- N , _ o- (CH . ) . - N χ b * wherein R c is selected from halogen, (C1-C3) lower alkyl -O-lower alkyl (C1-C3) and OH; Rb is as hereinbefore defined; wherein Ar ' is selected from the group: -ISO- R3 and R? are independently hydrogen, lower alkyl (C1-C3), O-iower alkyl (C1-C3) , S-lower alkyl (C1-C3 ) , -CF3, -CN, -OH, -SCF3, -OCF3, halogen, NO2, amino, or -NH-lower alkyl (C1-C3) ; -N- [lower alkyl (C1 . -C3) ]2, -N ( Rb ) ( CH2 ) q-N ( Rb ) 2 V," is selected from 0, S, NH, N-lower alkyl (C1-C3), -NCO-lower alkyl (C3.-C3) , or NS02-lower alkyl (C1-C3) R25 is selected from the moieties and the moiety Z O represents: (1) phenyl or substituted phenyl optionally substituted by one or two substituents selected from (C1-C3) lower alkyl, halogen, amino, (C1-C3) lower alkoxy, and (C1-C3) lower alkylamino; (2) a 5-membered aromatic (unsaturated) heterocyclic ring having one heteroatom selected from C, 11 and S; (3) a 6-membered aromatic (unsaturated) heterocyclic ring naving one nitrogen atom; (4) a 5 or 6-membered aromatic (unsaturated) heterocyclic ring having two nitrogen atoms; (5) a 5- membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom together with either one oxygen or one sulfur atom; wherein the 5 or 6-membered heterocyclic rings are optionally substituted by (C1-C3) lower alkyl, formyl, a moiety of the formula: ~ (CH 2 ) α N R, halogen or (C^- 23 ) lower alkoxy; and the pharmaceutically acceptable salts, esters and pro-drug forms thereof. 2. A compound according to Claim 1 wherein themoiety Z represents a phenyl ring optionally substituted by one or two substituents selected from (C1-C3) lower alkyl, halogen, amino, (C1-C3) lower alkoxy and (C1-C3) lower alkyl amino and n, , W , X, Y, A-B, R a , b. Rl- P-2. P>3> R4 , R5, R6, R7 , R8- p -9 ■ R 10, P-25 are as previously defined in Claim 1. -182- SUBSTTTUTE SHEET (RULE 26) A compound according to Claim 1 wherein the moiety Z Cj X represents a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen heteroatom and n, m, W\ X, Y, A-B, R a , Rb, Rl, R2, R3, 4, R5, R6 , R8, R9, RlO, R 25 are as previously defined in Claim 1. 4. A compound according to Claim 1 wherein themoiety Z Q XX represents a 6-membered aromatic (unsaturated) heterocyclic ring having two nitrogen heteroatoms and Y, A-B, R a , Rb, Rl/ 2, R3, 4, R5, 6, R7, 8/ R , RlO, R25 are as previously defined in Claim 1. 5. A compound according to Claim 1 wherein themoiety ZO represents a 5-membered aromatic (unsaturated) heterocyclic ring having one sulfur heteroatom and Y, A-B, R a , Rb, l/ R 2, R 3, R- , R 5, 6, R 7, R8/ 9, RlO, R25 are as previously defined in Claim 1. 6. A compound according to Claim 1 wherein themoiety ZO X represents a 5-membered aromatic (unsaturated) heterocyclic ring having one oxygen heteroatom and Y, A-B, R a , Rfa/ Rl/ R 2/ 3, R4, R 5, R6, 7, R8/ R9, RlO, R25 are as previously defined in Claim 1. 7. A compound according to Claim 1 wherein themoiety represents a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen heteroatom and Y, A-3, R a , Rb, Ri, 2/ R3/ R4, 5/ R 6/ R7, 8, R9/ RlO, R25 are as previously defined in Claim 1. 8. A compound according to Claim 1 wherein the moiety represents a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen heteroatom and Y, A-B, R a , Rb, Rl, R2, R3/ 4/ R5, R6, 7, R8, R9/ R 10, R25 are as previously defined in Claim 1. 9. A compound according to Claim 1 wherein themoiety ZO represents a fused 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen and one sulfur heteroatom and Y, A-E, R a , R , l, 2, R 3/ R 4/ 5/ R6/ R7, Rs, R9, RlO, R 25 are as previously defined in Claim 1. 10. A compound according to Claim 1 wherein the moiety represents a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen and one oxygen heteroatom and V, A-B, R a , Rb, Rl , R2. P>3, R 4- R5. P-β ■ R7, R8, RQ, RlO, P-25 ars as previously defined in Claim 1. 11. A compound according to Claim 1 wherein themoiety ZO represents a phenyl ring, optionally substituted by one cr two substituents selected from (C1 . -C3) lower alkyl, halogen, amino, (C1-C3) lower alkoxy and (C1-C3) lower alkyl ammo, Y in selected from -CII2-, -CH-loweralkyKC j -Cg), -CHNH 2 ; -CHNH-loweralkyl (C j -Cg), -CHN(CH, 3) 2 9 - JC- H H M N t ( rC 2 wH 5 ) .2 -C ' HO-lower alkyl (C r C 3 ), -CHS-lower alkyKC j -Cg) and A-E, R a , Rb, Rl - 2- R 3 , 4/ R 5- R 6- R7 , R8- R 9■ RlO, P-25 are as previously defined in Claim 1. 12. A compound according to Claim 1 wherein themoietv represents a 6-membered aromatic X(unsaturated) heterocyclic ring having one nitrogen heteroatom, i s selected from -CH2-. -CH-lower alkyl(C j -Cg), -CHNH 2 ; -CHNH-lower alkyl (C j-C 3 ), 32 -CHN(C 2 H 5 ) 2 -CHO-loweralkvKC ^ -C,), ■ 1 ^ 3' -CHS-lower alk lfC j -Cg) and A-B,R a , Rb- R l . R 2 - R 3. R4. R 5< R 6. R7. R 8- R 9< R 10, R25 are as previously defined in Claim 1. 13. A compound according to Claim 1 wherein the moiety represents a 6-membered aromatic (unsaturated) heterocyclic ring having two nitrogen heteroatoms, Y is selected from -CH2-. -CH-loweralkyl(C 1 -C 3 ), -CHNH 2 ; -CHNH-lower alkyl (C j -C-,) I i . 32 -CHN(C 2 H 5 ) 2 . -CHO-lower alkyl (C ] -C 3 ), -CHS-lower alkyKC j -Cg) and A-B,R a , R , R l - R 2 - R 3- R 4. R 5- R 6- R 7. R 8- R ? ■ R 10, R25 are as previously defined in Claim 1. 1 . A compound according to Claim 1 wherein -186- SUBSTΓΓUTE SHEET (RULE 26) the moiety Z represents a 5-membered aromatic (unsaturated) heterocyclic ring having one sulfur heteroatom wherein Y is selected from -CH2-, -CH-loweralkyl(C--C 3 ), -CHNH 2 ; -CHNH-loweralkyl (C--C-.), 32 -CHN(C 2 H 5 ) 2 -CHO-loweralkyl (C r C 3 ), -CHS-loweralkyl(C 1 -C 3 ) and A-B,R a , Rb- R l, R 2 , R 3 ■ R . R 5- R 6- R 7, R 8- R 9- R 10, R25 are as previously defined in Claim 1. 15. A compound according to Claim 1 wherein themoietv ZO represents a 5-membered aromatic (unsaturated) heterocylic ring having one oxygen heteroatom wherein Y is selected from -CH2-, -CH-lower alkyl(C 1 -C 3 ), -CHNH 2 ; -CHNH-lower alkyl (C j -Cg) 3 2 -CHN(C 2 H 5 ) 2 -CHO-lower alkyl (C r C 3 ), -CHS-lower alkyl(C.. -C 3 ) and A-B.Ra- R b- R L R 2 - R . R 4. F5, R6, R 7, R 8- R 9. R 10, R25 are as previously defined in Claim 1. 16. A compound according to Claim 1 wherein themoiety ZO represents a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen heteroatom, Y is selected from -CH2-, -CH-lower alkyl(C 1 -C 3 ), -CHNH 2 ; -CHNH-loweralkyl (C^), 32 -CHN(C 2 H 5 ) 2 -CHO-lo eralkyl (C r C 3 ), -CHS-loweralkyl(C 1 -C 3 ) and A-B, R a , Rb. R l - R 2 - R 3. R . X . R 6- R 7 , R 8- R 9- R 10, P.25 are as previously defined in Claim 1. 17. A compound according to Claim 1 wherein -188- SUBSTΓΓUTE SHEET (RULE 26) the moiety Z O represents a 5-membered aromatic (unsaturated) heterocylic ring having two nitrogen heteroatoms, Y is selected from -CH2-, -CH-loweralkyKC^Cg), -CHNH 2 ; -CHNH-lower alkyl (C j -Cg), -CHN(CH-.) ΓL ,.,, Γ TJ . I -CHN(C 2 H 5 ) 2 -CHO-lower alkyl (C--C-,), -CHS-lower alkyKC j -Cg) and A-B,R a , Rb, Rl, 2 , R 3 , R 4 • R 5, R 6- R 7 , 8< R 9 , R 10, R25 are as previously defined in Claim 1. 18. A compound according to Claim wherein the moiety Z O represents a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen and one sulfur heteroatom, Y is selected from -CH2-, -CH-lower alkyKC j -Cg), -CHNH 2 ; -CHNH-lower alkyl (C j -C 3), HN. H . I 32 -CHN(C 2 H 5 ) 2 . -CHO-lower alkyl (C j -C 3), -CHS-loweralkyKC j -Cg) and A-B,R a , P-b- R l - R 2. R 3 - R , PL- R 6- R 7 , R 8 , R 9. R 10, P.25 are as previously defined in Claim 1. 19. A compound according to Claim 1 wherein the moiety Z O represents a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen and one oxygen heteroatom, Y is selected from -CH2-, -CH-lower alkyKC j -C j ), -CHNH 2 ; -CHNH-lower alkyl (C j -C 3), 32 -CHN(C 2 H 5 ) 2 -CHO-lower alkyl (C r C 3 ), -CHS-loweralkyUC j -Cg) and A-B,R a , Rb- Pi- R 2. R 3. R 4 , R - . R 6 , R 7 , R 8. R 9. R 10, c 25 are as previously defined in Claim 1. 20. A compound according to Claim 1 wherein -190- SUBSTΓΓUTE SHEET (RULE 26) themoiety ZO represents a phenyl ring, optionally substituted by one or two substituents selected from (C1-C3) lower alkyl, halogen, amino, (C1-C3) lower alkoxy and (C1-C3) lower alkyl amino, Y is -(CH2)n, n is zero and A-B,R a , R , Rl, R2, R3, R4, R5, R6/ R7, R8, R 9, R 1C, R 25 re as previously defined in Claim 1. 21. A compound according to Claim 1 wherein themoiety ZO represents a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen heteroatom, Y is (CH2)n/ n is zero and A-B,R a , Rb, Rl, R2, R3» R 5/ R6, R7, R8/ R RlO, R 25 are as previously defined in Claim 1. 22. A compound according to Claim 1 wherein themoietv represents a 6-membered aromatic (unsaturated) heterocyclic ring having two nitrogen heteroatoms, Y is "(CH2)n, n is zero and A-B,R a , Rb, Rl, R2, R 3, R4, 5, R6, R7, R8, R9, RlO, R 25 are as previously defined in Claim 1. 23. A coimoound accordinσ to Claim 1 wherein themoiety ZO represents a 5-membered aromatic (unsaturated) heterocyclic ring having one sulfur heteroatom, Y is - (CH2)n/ n is zero and A-B,R a , Rb, R l, R2 3, R4 , R5/ R6, R7, R8/ R 9/ RlO, R 25 are as previously defined in Claim 1. 24. A compound according to Claim 1 wherein themoiety ZO represents a 5-membered aromatic (unsaturated) heterocyclic ring having one oxygen heteroatom, Y is - (CH2)n, n is zero and A-B,R a , Rb, R l, R2, R 3, 4, R5, R6, R7, R8, R9» R 10, R 25 are as previously defined in Claim 1. 25. A compound according to Claim 1 wherein themoiety Z X(_) represents a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen heteroatom, Y is (CH2)n, n is zero and A-B,R a , Rb, R l, R 2, R3, R4, R5/ R6, R7, 8, R , RlO, R 25 are as previously defined in Claim 1. 26. A compound according to claim 1 wherein themoiety represents a 5-membered aromatic (unsaturated) heterocyclic ring having two nitrogen heteroatoms, Y is -(CH2)n, n is zero and A-B,R a , Rb, Rl, R2, R3, R , 5, R6, R7, R8, R 9/ R 10, R 25 are as previously defined in Claim 1. 27. A compound according to Claim 1 wherein themoietv ZO represents a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen and one sulfur heteroatom, Y is -(CH2)n, n is zero and A-B,R a , Rb/ R l/ R2/ R3/ R4/ R5, 6/ R7, R8, R9, RlO, R25 are as previously defined in Claim 1. 28. A compound according to Claim 1 wherein themoiety Z X represents a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen and one oxygen heteroatom, Y is -(CH2)n, n is zero and A-B,R a , Rb, R l, R2, R3, R4, R5, 6/ R 7, R8, R9/ RlO, R25 are as previously defined in Claim 1. 29. A compound according to Claim 1 wherein the moiety Z Q represents a phenyl or substituted phenyl ring, Y is selected from 0, S, NH, NCOCH3 and N-lower alkyl (C1-C3) and and A-B,R a , Rb, Rl, R2, R3 R 4, R5 R6, R7, R8, R , R 10, R 25 are as previously defined in Claim 1. 30. A compound accordinσ to Claim 1 wherein themoiety Z(_} represents a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen heteroatom, Y is selected from 0, S, NH, NCOCH3 and N-lower alkyl (C1-C3) and A-B,R a , R , Rl , R2, R3/ 4, 5, 6, R7, R8, R9, R 10, R25 are as previously defined in Claim 1. 31. A compound according to Claim 1 wherein themoiety ZO represents a 6-membered aromatic (unsaturated) heterocyclic ring having two nitrogen heteroatoms, Y is selected from 0, S, NH, NCOCH3, and N-lower alkyl (C1-C3) and A-B,R a , Rb, R l, R2, R3, R4, R5, R6, R7, Rδ, 9, RlO, R25 are as previously defined in Claim 1. 32. A compound according to Claim 1 wherein the moiety represents a 5-membered aromatic (unsaturated) heterocyclic ring having one sulfur heteroatom, Y is selected from 0, S, NH, NCOCH3, and N-lower alkyl (C1-C3) and A-B,R a , Rb, R l, R2, R3# 4, R5# Rδ, R 7, R8, R 9, RlO, R 25 re as previously defined in Claim 1. 33. A compound according to Claim 1 wherein themoiety ZO represents a 5-membered aromatic (unsaturated) heterocyclic ring having one oxygen heteroatom, Y is selected from 0, S, NH, NCOCH3 and N-lower alkyl (C1-C3) and A-B,R a , Rb, R l, R 2, R 3, R4, R5# R 6/ R7, R8, R9, R 10, R25 are as previously defined in Claim 1. 34. A compound according to Claim 1 wherein themoiety ZO represents a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen heteroatom, Y is selected from 0, S, NH, NCOCH3 and N-lower alkyl (C1-C3) and A-3,R a , Rb, Rl, R2# R3, R4» 5, R6, R7, Re, R9, RlO, R25 are as previously defined in Claim 1. 35. A compound according to Claim 1 wherein themoietv Z(X) ' X> represents a 5-membered aromatic (unsaturated) heterocyclic ring having two nitrogen heteroatoms, Y is selected from 0, £, NH, NCOCH3 and N-lower alkyl (C1-C3) and A-B,R a , R , Rl, R2, R3/ R 4/ R 5/ R 6/ 7, R8/ R 9/ RlO, R25 are as previously defined in Claim 1. 36. A compound according to Claim 1 wherein themoiety Z represents a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen and one sulfur heteroatom, Y is selected from 0, S, NH, NCOCH3 and N- lower alkyl (C1-C3) and A-B,R a , Rb, R l, 2, R 3» R4/ R5, R6/ R7, R8 R 9 R 10, R 25 are as previously defined in Claim 1. 37. A compound accordinσ to Claim 1 wherein themoiety ZO represents a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen and one oxygen heteroatom, Y is selected from 0, S, NH, NCOCH3 and N- lower alkyl (C1-C3) and A-B,R a , Rb, Rl , R2, R3/ R4< R5, R , R7, 8/ R9, RlO, R 25 are as previously defined in Claim 1. 38. A compound according to Claim wherein Y is selected from -(CH2)n~, -CH-lower alky C -Cg), -CHNH 2 ; -CHNH-lower alkyl (C -CHN(C 2 H 5 ) 2 -CHO-lower alkyl (C r C 3 ), -CHS-lower alkyKC j -Cg) wherein n is an integer zero or one; P.3 is the moiety O II -CAr wherein Ar is a moiety selected from the σrouD 0 and Rδ is selected from the group wherein Ar ' is selected from the croup W is 0 or S; A-B,R a , Rb, P-l , R2 , R 4 - R5< R7 , Rδ , R 9 , R 10, P-25, X, cycloalkyl and the moiety Z (_) are as previously defined in Claim 1. 39. A compound according to Claim 1 wherein Y" is selected from -CH2-, -CH-lower alkyl(C j -C 3 ), -CHNH 7 ; -CHNH-lower alkyl (C .. -C 3 ), 3 2 -CHN(C 2 H 5 ) 2 -CHO-lower alkyl (C r C 3 ), -CHS-lower alkyl^-Cg) R3 is the moiety O II - CAr wherein Ar is a moiety selected from the group and R6 is selected from the group -NCOAr' , -NCO(CH 2 ) p -cycloalkyl, R R -NCOCH^Ar -NCONAr ' , " χ - R ιo I R. R_ , wherein Ar ' is selected from the group -200- SUBSTΓΓUTE SHEET (RULE 26) W is O or S; A-B,R a , Rb, Rl , R2 , R4 , R 5, R 7 , R 8 , R 9 R 10, R 25- • '' *■ and cycloalkyl and the moiety Z O are as previously defined in Claim 1. 40. a compound according to Claim 1 wherein Y is selected from -CH2-, -CH-lower alkyHC j -Cg), -CHNH 2 ; -CHNH-lower alkyl (C j -Cg), 32 -CHN(C 2 H 5 ) 2 -CHO-lower alkyl (C--C 3 ), -CHS-lower alkyKC j -Cg) R3 is the moiety O II CAr wherein Ar is a moiety selected from the group -201- SUBSTTTUTE SHEET (RULE 26) NH R, and R6 i s selected from the group -NCOAr' -NCO(CH 2 ) n -cycloalkyl R R -NCOC Ar -NCONAr ' , - χ - R ιo R. R a -202- SUBSTΓΓUTE SHEET (RULE 26) wherein Ar ' is selected from the group and W is 0 or S; and themoiety ZO represents a phenyl ring optionally substituted by one or two substituents selected from (C3 . -C3) lower alkyl, halogen, amino, (C1-C3) lower alkoxy and (C1-C3) lower alkyl amino and A-B,R a , Rb, R l, R 2- R 4, R 5, R 7- R 8, R 9, R 10> P-25- X and cycloalkyl are as previously defined in Claim 1. 41. A compound according to claim 1 wherein Y is -(CH2)n-< wherein n is an integer zero; R3 is the moiety O -CAr wherein Ar is a moiety selected from the group -203- SUBSTΓΓUTE SHEET (RULE 26) 0 and R6 is selected from the group -NCOAr ' , -NCO(CH ? ) -cycloalkyl, R R -NCOCH 2 Ar" -NCONAr ' , "χ - R ιo R a R„ a R b wherein Ar ' is selected from the group and W is 0 or S; and -204- SUBSTΓΓUTE SHEET (RULE 26) the moiety Z O represents a phenyl ring optionally substituted by one or two substituents selected from (C1-C3) lower alkyl, halogen, amino, (C1-C3) lower alkyl amino and A-B,R a , Rb, Rl, F2, R 4< R 5- R 7, R 8- R 9< R 10, R 25, X and cycloalkyl are as previously defined in Claim 1. 42. A compound according to Claim 1 wherein Y is selected from O, S, NH, NCOCH3 and N-lower alkyl (C1-C3) ; R is the moiety O II -CAr wherein Ar is a moiety selected from the group 0 and Rό is selected from the group -NCOAr' , -NCO(CH,)_ -cycloalkyl, R R -NCOCH 2 Ar' -NCONAr , - χ -R 10 wherein Ar ' is selected from the group and W is 0 or S; and -206- SUBSTΓΓUTE SHEET (RULE 26) the moiety Z represents a phenyl ring optionally substituted by one or two substituents selected from (C1 . -C3) lower alkyl, halogen, amino, (C1-C3) lower alkoxy and (C1 . -C3) lower alkyl amino and A-B,R a , Rb, Rl, R 2- R 4- R 5, R 7, R 8, R 9■ R 10 < R 25, x an ^ cycloalkyl are as previously defined in Claim 1. 43. A compound according to Claim 1 wherein Y is -(CH2)n-<" n i Ξ an integer zero; R3 is the moiety O II -CAr up and R f is selected from the group 25 -NCOAr ' , -NCO(CH ) -cycloalkyl, R R . 30 - r ' , - χ - R ιo v. ' herein Ar' is selected from the group and W is 0 or S; and the moiety ZO represents a 6-ιneπιbered aromatic (unsaturated) heterocyclic ring having one nitrogen heteroatom A-E,R a , R b- Rl« R 2 , R 4 , R 5- P.7. R 8- R 9- R 10 , R 25< X and cycloalkyl are as previously defined in Claim 1. 44. A compound according to claim 1 wherein Y is -CH2-; P>3 is the moiety O II -CAr wherein Ar is a moiety selected from the group -209- SUBSTΓΓUTE SHEET (RULE 26) and R6 is selected from the group -NCOAr ' , -NCO(CH ? ) -cycloalkyl, R R - Ar ' , - χ ' R ιo wherein Ar' ; is selected from the group and W is 0 or S; and themoiety Z O represents a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen heteroatom A-B , R a , Rb , Rl. R 2, P-4- R 5. R 7 - R 8- R 9. R 10< R 25- X and cycloalkyl are as previously defined in Claim 1. 45. A compound according to Claim 1 wherein Y is -(CH2)n _ ; n is an integer zero; R3 is the moiety O II -CAr wherein Ar is a moiety selected from the σroup NHZ R. and R5 is selected from the group -NiCOAr , -Ni CO(OiXz.)n -cv' cloalky- l, R R -NCOCH 2 Ar' -NCONAr', -X-R 10 R a R b wherein Ar ' is selected from the group and W is 0 or S; and themoiety Z( represents a 5-membered aromatic iunsaturated) heterocyclic ring having one sulfur heteroatom A-E,R a , Rb , Rl , P-2- R 4- R 5, P-7. R 8< R 9. R 10- R 25< < " ' ' • and cycloalkyl are as previously defined in Claim 1. 46. A compound according to Claim 1 wherein is -CH2-; R3 is the moiety O -CAr wherein Ar is a moiety selected from the group ■ 212- SUBSTΓΓUTE SHEET (RULE 26) 0 and R is selected from the group -NCOAr , -NCO(CH 2 ) n -cycloalkyl, R -NCOCH 2 Ar ' -NCONAr , - χ - R ιo I I I R. R_ R wherein Ar ' is selected from the group and W is 0 or S ; and the moiety Z O represents a 5-membered aromatic (unsaturated) heterocyclic ring having one sulfur heteroatom A-Ξ,R a , Rb, Rl, R 2, R 4> R 5- P-7, R 8- R 9> Pl0< R 25< > * and cycloalkyl are as previously defined in Claim 1. 47. A compound according to Claim 1 wherein Y is selected from C, S, NH, NCOCH3 N-lower alkyl ( C1-C3 ) ; R3 is the moietv O II -CAr wherein Ar is a moiety selected from the group and R6 is selected from the group -NCOAr' -NCO(CH 2 ) n -cycloalkyl, R R -NCOCH 2 Ar' f -NCONAr , - χ -R 10 R R. R, wherein Ar' is selected from the group and W is 0 or S; and themoiety Z represents a 5-membered aromatic (unsaturated) heterocyclic ring having one sulfur heteroatom A-B,R a , Rb- R l- R 2 , R 4, R 5 , R 7, R 8 , R 9< R 10> R 25, X and cycloalkyl are as previously defined in Claim 1. 48. A compound selected from those of the formulae: wherein m is an integer one or two; -215- SUBSTΠΓUTE SHEET (RULE 26) R is hydrogen, halogen (chlorine, bromine, fluorine, iodine), OH, S-lower alkyl (C1-C3) , -SH, -SO-lower alkyl (C1-C3) , -SC2-iower alkyl (C1-C3 ) , -CO-lower alkyl (C1-C3) , -CF , lower alkyl (C -C3 ) , O-lower alkyl (C1-C3) , -NO , - H2- -NHCO lower alkyl (C1-C3 ) , -H-[lower alkyl (C1-C ) ] 2, -SO2NH2; -SO2NH lower alkyl (C1-C3), or -SO2IUlower alkyl (C1-C3)] ; P-2 is hydrogen, Cl, Bre, F, I, -OH, lower alkyl (C1-C3] O-lower alkyl (C1-C3 ) , or Ri an d R 2 taken together are ethylenedioxy or ethylenedioxy; R3 is the moiety: O II -CAr wherein Ar is selected from moieties of the formula: X - R R5 and R 7 are selected from hydrogen, (C1-C3) lower alkyl, (C1-C3) lower alkoxy and halogen. R6 is selected from (a) moieties of the formula: -216- SUBSTΠΓUTE SHEET (RULE 26) -NSO.-lower alkvl(C-C 8 ), -NS0 2 -lower alkenyl(C 3 -C 8 ) I R R O -NH-C-O-lovver alkyl(C 3 -C 8 )straight or branched O II -NH-C-lower alkyl(C 3 -C.)straight or branched, O II -NH-C-O-lower alkenyl(C--C 8 )straight or branched, O II -NH-C-lower alkenyl(C 3 -C 8 )straight or branched, wherein cycloalkyl is defined as C3 to C cycloalkyl cyclohexenyl cr cyclopentenyl; R a is hydrogen, CH3 , C2H5, moieties of the formulae: :i7- (CH^-N -(CI^lq-N^ , \ R. - (CH2) 2-O-lower alkyl (C1-C3) or -CH2CH2OH; q is one, two or three; Rb is hydrogen, -CH3 or -C2H5;and (b) a moiety of the formula: -X-P-1C, wherein Rio is lower alkyl (C3-C8) , lower alkenyl (C3-C8) , - (CH2) p-cycloalkyl (C3-C6) , and p is zero to three; X is 0, S, NH, CH3, \ C= O or a bond / P.5 and R7 are as previously defined, (c) a moiety of the formula: R b - N-COJ wherein J is R a , lower alkyl (C3-C8) branched or unbranched, lower alkenyl (C3-C8) branched or unbranched, -O-lower alkyl (C3-C8) branched or unbranched, -O-lower alkenyl (C3-C8) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties or -CH2-K' wherein _. ' is halogen, -OH, tetrahydrofuran, tetrahydrothiophene cr the heterocyclic ring moiety: -219 - SUBSTΓΓUTE SHEET (RULE 26) wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C1-C3) lower alkyl, hydrox , -CO-lower alkyl (C1-C3) , CHO, (C1-C3) lower alkoxy, -CO2- lower alkyl (C1-C3) , and R a and Rb are as hereinbefore defined; (d) a moiety selected from those cf the formulae: R I a - N- COCHAr ' . R O II -O-C-lower alkyl (C 1 -C 3 ) , -S-lower alkyUC j -Cg) R x b_ NHCH,) q - N , - θ- (CH.) 2 - N χ R.b ^ wherein R c is selected from halogen, (C1-C3) lower alkyl -O-lower alkyl (C1-C3) and OH, Rb is as hereinbefore defined; Ar ' is a moiety selected from the group -220- SUBSTΓΓUTE SHEET (RULE 26) P.8 and P. are independently hydrogen, lower alkyl (C1-C3), O-lower alkyl (C1-C3) , S-lower alkyl (C1-C3) , -CF3, -CN, -OH, -SCF3, -OCF3, halogen, NO2, amino, or NH-lower alkyl (C1-C3) ; N- [lower alkyl (C1-C3) ] 2, -N ( Rb ) ( CH2 ) q-N ( Rb ) 2; R25 is selected from the moieties W is 0, S, NH, N-lower alkyl (C1-C3) , NCO-lower alkyl (C1-C3) or NSO2-lower alkyl (C1-C3) or NSO2 lower -221- SUBSTΓΓUTE SHEET (RULE 26) alkyl (C1-C3) and the pharmaceutically acceptable salts thereof . 49. A compound selected from those of the formula: wherein V is selected from 0, S. NH, and N-lower alkyl (C1-C3) ; Rl is hydrogen, halogen (chlorine, bromine, fluorine, iodine), OH, S-lower alkyl (C1-C3 ) , -SH, -SO-lower alkyl (C1-C3) , -Sθ2-lower alkyl (C1.-C3) , -CO-lower alkyl (CI-C3), -CF3, lower alkyl (C1-C3) , O-lower alkyl (C1-C3: -NO2, -NH2, -NHCO lower alkyl (C1-C3) , -N- [lower alkyl (C1-C3) ]2, -NH lower alkyl (C1-C3) -SO2NH2; -SO2NH lower alkyl (C1-C3) , or -Sθ2N[lower alkyl (C1-C3) ]2; R2 is hydrogen, Cl, Br, F, I, -OH, lower alkyl (C1-C3) , O-lower alkyl (C1-C3 ) , or R and P taken together are methylenedioxy or ethylenedioxy; R3 is the moiety: O II -CAr wherein Ar is selected from moieties of the formula: -222- SUBSTΓΓUTE SHEET (RULE 26) 0 P5 and R7 are selected from hydrogen, (C1-C3) lower alkyl, (C1-C3) lower alkoxy and halogen; R5 is selected from (a) moieties cf the formula: -223- SUBSΠTUTE SHEET (RULE 26) -NSO. -lower alkyl(C.-C 8 ), -NSO,-lower alkenyl(C -C.) I R R O II -NH-C-O-lower alkyl(C 3 -C-)straight or branched O I! -NH-C-lower alkyl(C 3 -C-)straight or branched, O II -NH-C-O-lower alkenyl(C 3 -C 8 )s_raight or branched, O II -NH-C-loweralkenyl(C--C 8 )straightorbranched, wherein cycloalkyl is defined as C3 to Co cycloalkyl cyclohexenyl or cyclopentenyl; R a is hydrogen, CH3 , C2H5, moieties of the formulae: - (CH2)2"0-lower alkyl (C1-C3) or -CH2CH2OH; q is one, two or three Rb is hydrogen, -CH3 or -C2H5;and (b) a moiety of the formula: -X-P-IG, wherein Rio is lower alkyl (C3-C8) , lower alkenyl ( C3-C8 ) . - ( CH2. p-cycloalkyl (C3-C6) - and p is zero to three; X is O, S, NH, NCH3 \ C— O or a bond / and F5 and P,ι are as previously defined. ic) a moietv of the formula: R_ N-COJ wherein J is R a , lower alkyl (C3-C8) branched or unbranched, lower alkenyl (C3-C8) branched cr unbranched, -O-lower alkyl (C3-C8) branched or unbranched, -O-lower alkenyl (C3-C8 ) branched or unbrancned, tetrahydrofuran, tetrahydrothiophene, the moieties or -CH2- ' wherein ' is halogen, -OH, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety: —N E \ / G=F wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C1-C3) lower alkyl, hydroxy, -CO-lower alkyl (C1-C3) , CHO, (C1-C3) lower alkoxy, -CO2- lower alkyl (C1-C3 ) , and R a and Rb are as hereinbefore defined; ( d ) a moiety selected from those of the formulae : R 1 Λ - N- COCHAr . R O II -O-C-Iower alkyl (C r C 3 ) , -S-lower alkyKC j -C 3) - NHfCHJ ^ , - O- CCH^- ^ X R b ^ wherein R c is selected from halogen, (C1-C3) lower alkyl -O-lower alkyl (C1-C3) and OH, Rb is as hereinbefore defined; Ar ' is a moiety selected from the group RR and RQ are independently hydrogen, lower alkyl (C1-C3), O-lower alkyl (C1-C3 ) , 3- lower alkyl (C1-C3) , -CF3, -CN, -OH, -SCF3, -OCF3, halogen, NO2, amino, or NH-lower alkyl (C1-C3) ; N- [lower alkyl (C1-C3) ] 2, -N ( Rb ) ( CH2 ) q-N (R b ) 2; R25 is selected from the moieties - 228 - SUBSTTTUTE SHEET (RULE 26) W is 0, S, NH, N-lower alkyl (C1-C3) , NCO-lower alkyl (C1-C3) or NS02~lower alkyl (C1-C3) or NSO2 lower alkyl (C1-C3) and the pharmaceutically acceptable salts thereof. 50. The compound according to claim 1, M-[5- [ (6, ll-Dihydro-5ϋ-dibenz [b,e] azepin-5-yl) carbonyl]-2- pyridinyl] [1,1'biphenyl]-2-carboxamide. 51. The compound according to claim 1, ~[5- [ (6, ll-Dihydro-5ϋ-dibenz [b,e]azepin-5-yl) carbonyl]-2- pyridinyl]-2-dimethylamino pyridine-3-carboxamide. 52. The compound according to claim 1, N~[5- [ (9, 10-Dihydro-4ϋ-thieno [2 , 3-c] [1]benzazepin-9- yl) carbonyl] -2-pyridinyl] [1,1'-biphenyl]-2-carboxamide. 53. The compound according to claim 1, ϋ-[5- [ (9, 10-Dihydro-4ϋ-thieno[2,3-c [1]benzazepin-9- yl) carbonyl] -2-pyridinyl] -2-dimethylamino pyridine-3- carboxamide. 54. The compound according to claim 1, -[5- [ (4, 10-Dihydro-5E-thieno [3,2-£] [1]benzazepin-5- yl) carbonyl] -2-pyridinyl] [1, 1 '-biphenyl] -2-carboxamide. 55. The compound according to claim 1, H- [5 [ (4 , 10-Dihydro-5ϋ-thieno [3, 2-£] [1]benzazepin-5- yl) carbonyl] -2-pyridinyl] -2-dimethylamino pyridine-3- carboxamide. 56. The compound according to claim 1, M~[5- [9, 10-Dihydro-4ϋ-thieno[2, 3-ϋ] [1]benzazeρin-9- yl) carbonyl] -2-pyridinyl] -5-fluoro-2-methylbenzamide. 57. The compound according to claim 1, ϋ-[5- [4, 10-Dihydro-5H-thieno[3, 2, -£.] [l]benzazepin-5- yl) carbonyl]-2-pyridinyl]-5-fluoro-2-methylbenzamide. 58. The compound according to claim 1, N-[5- [ (4,5-Dihydropyrazolo [4, 3-d] [1]benzazepin-β (1H) - yl) carbonyl] -2-pyridinyi]-2-dimethylamino pyridine-3- carboxamide. 59. The compound according to claim 1, ϋ-[5- [ (4, 5-Dihydropyrazolo [4, 3- .] [1]benzazepin-6 (1H- yl) carbonyl]-2-pyridinyl]-5-fluoro-2-methylbenzamide. 60. The compound according to claim 1, .- [5 (pyrido [2, 3-fc] [1, 4]benzoxazepin-5- (6ϋ) -ylcarbonyl) -2- pyrdinyl] -5-fiuoro-2-methyl benzamide. 61. A pharmaceutical composition useful for treating diseases characterized by excess renal reabsorption of water as well as congestive heart failure, liver cirrhosis, nephrotic syndrome, central nervous system injuries, lung disease and hyponatremia in a mammal comprising a suitable pharmaceutical carrier and an effective amount of a compound of claim 1. 62. A method of treating diseases characterized by excess renal reabsorption of water as well as congestive heart failure, liver cirrhosis, nephrotic syndrome, central nervous system injuries, lung disease and hyponatremia in a mammal comprising administering a compound of Claim 1 to said mammal in an amount effective to alleviate the disease. 63. A process for preparing a compound of the formula: Formula 1 wherein Y is (CH2)n, 0, S. NH, NCCCH3, N-lower alkyl (C1-C3), CH-lower alkyl (C1-C3) , CKNK-iower alkyl (Cr C3) , CKNH2, CHN[lower alkyl (C -C3) ] 2, CHO-lower alkyl (C:-C3) , CHS-lower (C1-C3) , wherein n is an integer from 0-2; A-B is wherein m is an integer from 1-2, provided that when Y is -(CH2)n~ and n=2, m may also be zero and when n is zero, m may also be three, provided also that when Y is -(CH2)n~ and n is 2, m may not also be two; Rl is selected from the group of hydrogen, halogen (chlorine, bromine, fluorine, iodine) , OH, -S-lower alkyl (C1-C3) , -SK, -SO lower alkyl (C1-C3) , -SO2 lower alkyl (C1-C3) , -CO-lower alkyl (C1-C3) , -CF3, lower alkyl (C1-C3) , O-lower alkyl (C1-C3) , O-lower alkyl (Cl- C3), -NO2, -NH2, -NHCO lower alkyl (C1-C3) , -N- [lower alkyl (C1-C3) ]2, -SO2NH2, -SO2NH lower alkyl (C1-C3) , - SO2N[lower alkyl (C1-C3) ) 2 ! R2 is selected from the group of hydrogen, Cl, Br, F, I, -OH, lower alkyl (C1-C3) , O-lower alkyl (C1-C3) , or Ri and R2 taken together are methylenedioxy or ethylenedioxy; R3 is the moiety O II -CAr wherein Ar is a moiety selected from the group R_j is hydrogen, lower alkyl (C1-C3) ; -CO-lower alkyl ( C1-C3 ) ; R5 and R7 are selected from the group, hydrogen, (C1-C3) lower alkyl, (C1-C3) lower alkoxy and halogen R6 is selected from (a) moieties of the formulae: -NSO : -lower alkyl(C 3 -C 8 ), -NS0 2 -lower alkenyl(C 3 -C 8 ) R R O II -NH-C-O-lower alkyl(C 3 -C-)s_raight or branched O II -NH-C-lower alkyl(C 3 -C-)straight or branched, O II -NH-C-O-lower alkenyl(C 3 -C-)straight or branched, O II -NH-C-loweralkenyl(C 3 -C 8 )straightorbranched, wherein cycloalkyl is defined as C3 to ζ cycloalkyl cyclohexenyl or cyclopentenyl; R a is hydrogen, CH3 , C2H5, moieties of the formulae: - (CH2)2-0-lower alkyl (C1-C3) or -CH2CH2OH; q is one, two cr three; Rb is hydrogen, -CH3 or -C2H5; and (b) a moiety cf the formula: -X-P.1 is lower alkyl (C3-Cg) , lower alkenyl (C3-Cg) , - ( CH2 ) o -cycloalkyl ( C3-C6 ) , R_ ■ CH 2 ) O and p is zero to three; X is 0, S, NH, NCH3, \ C= O or a bond / and R5 and R7 are as previously defined, (c) a moiety of the formula: R- - N-COJ wherein J is R a , lower alkyl (C3-C8) branched or unbranched, lower alkenyl (C3-C8) branched or unbranched, -O-lower alkyl (C3-C8)branched or unbranched, -O-lower alkenyl (C3-C8)branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties or -CH.2-K wherein K is halogen, -OH, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety: -N E G=F -235- SUBSTΓΓUTE SHEET (RULE 26) wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with iialogen, (C1-C3 ) lower alkyl, hydroxy, -CO-lower alkyl (C1-C3 ) , CHO, (C1-C3) lower alkoxy, -CO2- lower alkyl (C1-C3) , and R a and R} are as hereinbefore defined; (d) a moiety selected from those of the formulae: R I a -N-COCHAr' R O -O-C-lower alkyl (C j -Cg) , -S-lower alkyUC j -C 3) S- (CH,^ - N ^ # _ NH(CH . ) q - CON ^ ^ NHCH j ) q - N , - 0- (CH . ) 2 - N χ R. ^ wherein R c is selected from halogen, (C1-C3) lower alkyl -O-lower alkyl (C1-C3) and OH; Rb is as hereinbefore defined; wherein Ar ' is selected from the group -236- SUBSTΓΓUTE SHEET (RULE 26) R« and R Q are independently hydrogen, lower alkyl (C1-C3), O-lower alkyl (C1-C3) , S-lower alkyl (C1-C3) , -CF3, -CN, -OH, -SCF3, -OCF3, halogen, O2, amino, or -NH-lower alkyl (C1-C3) ; -N- [lower alkyl (C1-C3 ) ]2, -N ( Rb ) ( CH2 ) q -N ( Rb ) 2; R25 is selected from the moieties W is selected from 0, S, NH, N-lower alkyl (C1-C3), -NCO-lower alkyl (C1-C3) , or NS02-lower alkyl (C1-C3 ) ; the moiety Z O represents: (1) phenyl cr substituted phenyl optionally substituted by one or two substituents selected from (C1-C3) lower alkyl, halogen, amino, (C1-C3) lower alkoxy, and (C1-C3) lower alkylamino; (2) a 5-membered aromatic (unsaturated) heterocyclic ring having one heteroatom selected from O, II and S; (3) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom; '4) a 5 or 6-membered aromatic (unsaturated) heterocyclic ring having two nitrogen atoms; (5) a 5- membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom together with either one oxygen or one sulfur atom; wherein the 5 or 6-membered heterocyclic rings are optionally substituted by (C1-C3) lower alkyl, formyi, a moiety of the formula: (CH 2 ) q N halogen cr (C1-C3) lower alkoxy; which comprises reacting a compound of the formulae: • 238- SUBSTΓΓUTE SHEET (RULE 26) with a compound of the formula: o II Ar-C-Q wherein the moiety represented by the formula is an aroyl chloride or an aryl carboxylic acid which has been activated by conversion to a mixed anhydride or activated with a peptide coupling reagent to give compounds of the Formula I. 6 . A compound selected from those of the formula: wherein Ri is hydrogen, halogen (chlorine, bromine, fluorine, iodine), OH, S-lower alkyl (C1-C3) , -SH, -SO- lower alkyl (C1-C3) , -Sθ2~lower alkyl (C1-C3) , -CO-lower alkyl (C1-C3) , -CF3, lower alkyl (C1-C3) , O-lower alkyl (C1-C3) , -NO2, -NH2. -NHCO lower alkyl (C1-C3) , -N- [lower alkyl (C1-C3) ]2, -SO2NH2; -SO2NH lower alkyl (C1-C3) , or -Sθ2N[lower alkyl (C1-C3) 12; R2 is hydrogen, Cl, Br, F, I, -OH, lower alkyl (C1-C3) , O-lower alkyl (C1-C3 ) , or Ri and R2 taken together are methylenedioxy or ethylenedioxy; R3 is the moiety: O II -CAr wherein Ar is selected from moieties of the formulae: x"R κ and X is 0, S, -NCH3, or -NH: R is independently selected from hydrogen, lower alkyl (C1-C3) , -(CH2)q-OH, - (CH2)q-0-alkyl(Cι-C3 ) ; q is one, two or three; P-4 is selected from hydrogen, lower alkyl (C1-C3), -CO- lower alkyl (C1-C3) , P.5 and R7 are selected from hydrogen, (C1-C3) lower alkyl, (C1-C3) lower alkoxy and halogen; •240- SUBSTΓΓUTE SHEET (RULE 26) Rζ is selected from (a) moieties of the formulae: -NS0 2 -lower alkyl(C 3 -C 8 ), -NS0 2 -lower alkenyl(C 3 -C 8 ) I R R O -NH-C-O-lower alkyl(C 3 -C-)straight or branched O II -NH-C-lower alkyl(C 3 -C 8 )straight or branched, O II -NH-C-O-lower alkenyl(C--C 8 )straight or branched, O II -NH-C-lower alkenyl(C 3 -C-)straight or branched, wherein cycloalkyl is defined as C3 to Cδ cycloalkyl, cyclohexenyl or cyclopentenyl; R a is hydrogen, CH3 , C2H5, moieties of the formulae: -241- SUBSTΓΓUTE SHEET (RULE 26) - (CH2) 2 -O- lo ιer alkyl (C1-C3) or -CH2CH2OH; q is one, two or three; R is hydrogen, -CH3 or -C2H5; and (b; a moiety of the formula: -X-RlC; wherein P-io is lower alkyl (C3-C8) , lower alkenyl (C3-C8) , - (CH2)p-cycioalkyl (C3-C6) , and p is zero to three: X is 0, S, NH, NCH3, •242- SUBSTΓΓUTE SHEET (RULE 26) \ C= O or a bond and R5 and R7 are as previously defined, (c) a moiety of the formula: R, - N- COJ wherein J is R a , lower alkyl (C3-C8) branched or unbranched, lower alkenyl (C3-C8) branched or unbranched, -O-lower alkyl (C3-C8) branched or unbranched, -O-lower alkenyl (C3-C8) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties or -CH2-K' wherein K' is halogen, -OH, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety: G=F wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally- substituted with halogen, (C1-C3) lower alkyl, hydroxy, -CO-lower alkyl (C1-C3) , CHO, (C1-C3) lower alkoxy, -CO2- lower alkyl (C1-C3) , and R a and R are as hereinbefore defined; (d) a moiety selected from those of the formulae: R I Λ -N-COCHAr ' . R O -O-C-loweralkyl (C-1-C3) -lower alkyl(C,-C o ) wherein R c is selected from halogen, (C1-C3) lower alkyl -O-lower alkyl (C1-C3) and OH; Rb is as hereinbefore defined; wherein Ar ' is selected from the group: -244- SUBSTΓΓUTE SHEET (RULE 26) R8 and RQ are independently hydrogen, lower alkyl (Cι-C3), O-lower alkyl (C1-C3) , S-lower alkyl (C1-C3 ) , -CF3, -CN, -OH, -SCF3, -OCF3, halogen, O2, amino, or -NH-lower alkyl (C1-C3) ; N- [lower alkyl (C1-C3) ]2 , -N ( Rb ) (CH2 ) q -N{Rb)2; R25 is selected from the moieties. W* is selected from O, S. NH, N-lower alkyl (C1-C3) , -NCO-lower alkyl (C1-C3) , or NSθ2~lower alkyl(C1-C3) ; and the pharmaceutically acceptable salts thereof. -245- SUBSTΓΓUTE SHEET (RULE 26) 65. A compound selected from those of the formula: wherein Ri is hydrogen, halogen (chlorine, bromine, fluorine, iodine), OH, S-lower alkyl (C1-C3 ) , -SH, -SO- lower alkyl (C1-C3) , -Sθ2"lower alkyl (C1-C3 ) , -CO-lower alkyl(Cl-C3) , -CF3 , lower alkyl (C1-C3) , O-lower alkyl (C1-C3) , -Nθ2, -NH2. -NHCO lower alkyl (C1-C3) , -N- [lower alkyl (C1-C3) ]2, -SO2NH2; -SO2NH lower alkyl (C1-C3) , or -Sθ2N[lower alkyl (C1-C3) ]2 R2 is hydrogen, Cl, Br, F, I, -OH, lower alkyl (C1-C3) , O-lower alkyl (C1-C3) , or Ri and P2 taken together are methylenedioxy or ethylenedioxy; R3 is the moiety: O II -CAr wherein Ar is selected from moieties of the formula: -246- SUBSTΓΓUTE SHEET (RULE 26) P. is independently selected from hydrogen, lower alkyl (C1-C3), -(CH2)q-OH, - (CH2)q-0-alkyl (C1-C3) ; q is one or two; R4 is selected from hydrogen, lower alkyl (C1-C3) , -CO- lower alki'l (C1-C3) ; Rς and R7 are selected from hydrogen, (C1-C3) lower alkyl, (C1-C3) lower alkoxy and halogen R6 is selected from (a) moieties of the formula: -247- SUBSTΓΓUTE SHEET (RULE 26) -NS0 2 -lower alkyl(C 3 -C 8 ), -NS0 2 -lower alkenyl(C 3 -C 8 ) I R R O -NH-C-O-lower alk (C--C 8 )straight or branched O II -NH-C-lower alkyl(C 3 -C-)straight or branched, O II -NH-C-O-lower alkenyl(C 3 -C 8 )straight or branched, O II -NH-C-loweralkenyl(C 3 -C 8 )straightorbranched, wherein cycloalkyl is defined as C3 to Cs cycloalkyl, cyclohexenyl or cyclopentenyl; R a is hydrogen, CH3 , C2H5, moieties of the formulae: - (CH2) 2-0-lower alkyl (C1-C3) or -CH2CH2OH; q is one, two or three; Rb s hydrogen, -CH3 or -C2H5; and (b) a moiety of the formula: -X-RlC; wherein Pio is lower alkyl (C3-C8) , lower alkenyl (C3-C8 ) - -(CH2 ) p-cycloalkyl ( C3-C6) , and p is zero to three: X is 0, S, NH, NCH3, ■ 249- SUBSΠTUTE SHEET (RULE 26) \ C= O or a bond and R5 and P7 are as previously defined (c) a moiety of the formula: R b - N-COJ wherein J is Ra, lower alkyl (C3-C8) branched or unbranched, lower alkenyl {C3-C8) branched cr unbranched, -O-lower alkyl (C3-C8) branched or unbranched, -O-lower alkenyl (C3-C8) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties or -CH2-K' wherein K' is halogen, -OH, tetrahyrofuran, tetrahydrothiophene or the heterocyclic ring moiety: -N E G=F wherein D. E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C1-C3) lower alkyl, hydroxy, -CO-lower alkyl (C1-C3 ) , CHO, (C1-C3) lower alkoxy, -CO2- lower alkyl (C1-C3 ) , and R a and Rb are as hereinbefore defined; ( d ) a moiety selected from those of the formulae : R N- COCHAr R O II -O-C-lower alkyl (C j -Cg) , -S-lower alkyl(C --C 3 ) - NH(CH.) N - 0- (CH,)-- N χ wherein Re is selected from halogen, (C1-C3) lower alkyl -O-lower alkyl (C1-C3) and OH; Rb is as hereinbefore defined; wherein Ar ' is selected from the group: Rg and RQ are independently hydrogen, lower alkyl (Cι~ C3), O-lower alkyl (C1-C3) , S-lower alkyl (C1-C3) , -CF3 -CN, -OH, -SCF3, -OCF3, halogen, NO2, amino, or -NH- lower alkyl (C1-C3) ; -N- [lower alkyl (C1-C3) ] 2, -N(Rb) ( CH2 ) q-N ( Rb ) 2; R 5 is selected from the moieties - 252 - SUBSTΓΓUTE SHEET (RULE 26) W is selected from 0, S, NH, N-lower alkyl (C1-C3) , -NCO-lower alkyl (C1-C3) , or NSO2-lower alkyl (C1-C ) ; and pharmaceutically acceptable salts thereof. 66. A compound selected from those of the formula wherein Pi is hydrogen, halogen (chlorine, bromine, fluorine, iodine), OH, S-lower alkyl (C1-C3 ) , -SH, -S0- lower alkyl (C1-C3) , -S02~lower alkyl (C1-C3 ), -CO-lower alkyl (C1-C3) , -CF3, lower alkyl (C1-C3) , O-lower alkyl (C1-C3) , -NO2, -NH2, -NHCO lower alkyl (C1-C3) , -N- [lower alkyl (C1-C3) ) 2 , -SO2NH2; -SO2NH lower alkyl (Cι-C3), or -Sθ2N[lower alkyl (C1-C3) ] 2; R2 is hydrogen, Cl, Br, F, I, -OH, lower alkyl (C1-C3) , O-lower alkyl (C1-C3) , or Pi and R2 taken together are ethylenedioxy or ethylenedioxy; R3 is the moiety: O II -CAr wherein Ar is selected from moieties of the formula: -253- SUBSTΓΓUTE SHEET (RULE 26) ιυ R is independently selected from hydrogen, halogen lower alkyl (C1-C3) , -(CH2)q-OH, - (CH2)q-0-alkyl (C1-C3) ; q is one or two; R4 is selected from hydrogen, lower alkyl (C1-C3 ) , -CO-lower alkyl (C1-C3 ) ; R5 is hydrogen, -CH3.-C2H5, Cl , Er, F, -O-CH3 , or -O- C2H5; R5 and P. are selected from hydrogen, (C1-C3) lower alkyl, (C1-C3) lower alkoxy and halo'gen: R6 is selected from (a) moieties of the formula: -NCOAr . - NCON-Ar -NCO(CH. -cycloalkyl, R R R -NS0 2 -lower alkvl(C 3 -C 8 ), -NS0 2 -lower alkenyl(C--C-) I I R R O II -NH-C-O-lower alkyl(C 3 -C 8 )straight or branched O II -NH-C-lower alkyl(C--C-)straight or branched, O II -NH-C-O-lower alkenyl(C 3 -C 8 )straight or branched, O II -NH-C-lower alkenyl(C 3 -C-)straight or branched, -255- SUBSTΓΓUTE SHEET (RULE 26) wherein cycloalkyl is defined as C3 to Cg cycloalkyl cyclohexenyl or cyclopentenyl; R a s hydrogen, CH3 , C2H5, moieties of the formulae: - (CH2) 2-O-lower alkyl (C1-C3) or -CH2CH2OH; q is one, two or three; Rb is hydrogen, -CH3 or -C2H5; and (b) a moiety of the formula: -X-RlO; wherein Rio is lower alkyl (C3-C8) , lower alkenyl (C3-C8) , -(CH2)p-cycloalkyl(C3-C6) , and p is zero to three: X is 0, S. NH, NCH3, -256- SUBSTΓΓUTE SHEET (RULE 26) \ C= O orabond / and R5 and R7 are as previously defined (c) a moiety of the formula: - wherein J is R a , lower alkyl (C3-C8) branched or unbranched, lower alkenyl (C3-C8)branched or unbranched, -0-lower alkyl (C3-C3) branched or unbranched, -O-lower alkenyl (C3-C6) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties or -CH2-K' wherein K" is halogen, -OH, tetrahydrofuran, tetrahydrothiophene cr the heterocyclic ring moiety: -N E G=F wherein D, E, F and G are selected from carbon or nitroαen and wherein the carbon atoms may be optionally -257- SUBSTΓΓUTE SHEET (RULE 26) substituted with halogen, (C1-C3 flower alkyl, hydroxy, -CO-lower alkyl (C1-C3 ) , CHO, (C1-C3) lower alkoxy, -CO2- iower alkyl (C1-C3) , and R a and Rb are as hereinbefore defined; (d) a moiety selected from those of the formulae: R 1 a - N- COCHAr , R O -O-C-lower alkyl (C ^Cg) , -S-lower alkyKC j -Cg) wherein R c is selected from halogen, (C1-C3) lower alkyl, -O-lower alkyl (C1-C3) and OH; Rb s as hereinbefore defined; wherein Ar; is selected from the group: Rg and RQ are independently hydrogen, lower alkyl (C1-C3), O-lower alkyl (C1-C3) , S-lower alkyl (C1-C3 ) , -CF3, -CN, -OH, -SCF3, -OCF3, halogen, NO2, amino, or -NH-lower alkyl (C1-C3);-N- [lower alkyl (C1-C3) ] 2, -N(Rb) ( CH2)q-N ( Rb ) 2; R25 is selected from the moieties W is selected from 0, S. NH, N-lower alkyl (C1-C3) , -NCO-lower alkyl (C1-C3 ) , or NSO2-lower alkyl (C1-C3) ; and pharmaceutically acceptable salts thereof. 67. A compound selected from those of the formula: wherein Ri is hydrogen, halogen chlorine, bromine, fluorine, iodine), OH, S-lower alkyl (C1-C3) , -SH, -S0- lower alkyl (C1-C3) , -Sθ2~lower alkyl (C1-C3) , -CO-lower alkyl (C1-C3) , -CF3, lower alkyl (C1-C3) , O-lower alkyl (C1-C3) , -NO2, -NH2, -NHCO lower alkyl (C1-C3) , -N- [lower alkyl (C1-C3) .2, -SO2NH2; -SO2NH lower alkyl (Ci- C3), or -S02N[lov ; er alkyl (C1-C3) ] 2; R2 is hydrogen, Cl, Br, F, I, -OH, lower alkyl (C1-C3) , O-lower alkyl (C1-C3 ) , or Ri and P2 taken together are methylenedioxy or ethylenedioxy; R3 is the moiety: o II -CAr wherein Ar is selected from moieties of the formula: -260- SUBSTΓΓUTE SHEET (RULE 26) NHZOR 25 R is independently selected from hydrogen, halogen, lower alkyl (C1-C3) , 7 \ CH.jq- fN (CH-)q-N O -(CH2)q-OH, - (CH2)q-0-alkyl(Cι-C3) ; q is one, two cr three; R4 is selected from hydrogen, lower alkyl (C1-C3) , -CO- lower alkyl (C1-C3) ; R5 and R7 are selected from hydrogen, (C1-C3) lower alkyl, (C1-C3) lower alkoxy and halogen. R6 is selected from (a) moieties of the formula: -NSO ; -lower alkyl(C--C-), -NSO.-lower alkenyl(C 3 -C 8 ) I R R O II -NH-C-O-lower alkyl(C--C 8 )straight or branched O II -NH-C-lower alkyl(C 3 -C 8 )straight or branched, O II -NH-C-O-lower alkenyl(C 3 -C 8 )straight or branched, O II -NH-C-lower alkenyl(C,-C-)straight or branched, wherein cycloalkyl is defined as C3 to C6 cycloalkyl cyclohexenyl cr cyclopentenyl ; R a i s hydrogen , CH3 , C2H5 , moiet ies of the formulae : -262 - SUBSTΓΓUTE SHEET (RULE 26) - (CH2) 2-O-lower alkyl {C1-C3) or -CH2CH2OH; q is one or two; Rb is hydrogen, -CH3 or -C2H5; and (b) a moiety of the formula: -X-RlO; wherein R o is lower alkyl (C3-C8) , lower alkenyl (C3-C8) , -(CH2)p-cycloalkyl(C3-C6) , and p is zero to three: X is C, S, NH, NCH3 ; -263 - SUBSTΓΓUTE SHEET (RULE 26) \ C= O or a bond and R5 and R7 are as previously defined (c) a moiety of the formula: ■ N-COJ wherein J is Ra, lower alkyl (C3-C8) branched or unbranched, lower alkenyl (C3-Cg) branched cr unbranched, -O-iower alkyl (C3-C8) branched cr unbranched, -O-lower alkenyl (C3-C8) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moitieε or -CH2-K' wherein K' is halogen, -OH, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety: G=F -264- SUBSTΓΓUTE SHEET (RULE 26) wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with haiogen, (C1-C3) lower alkyl, hydroxy, -CO-lower alkyl (C1-C3) , CHO, (Cι-C3)lower alkoxy, -CO2- iower aikyl (C1-C3) , and R a and Rb are as hereinbefore defined; ( d ) a moiety selected from those of the formulae : R I * - N- COCHAr , R O -O-C-lower alkyl (C j -Cg) , -S-lower alkyl(C j -Cg) R„ - NH(CH N 0-(CH . ) 2 -N χ R. wherein R c is selected from halogen, (C1-C3) lower alkyl, -O-lower alkyl (C1-C3) and OH; Rb is as hereinbefore defined; Ar" is selected from the group: -265- SUBSTΓΓUTE SHEET (RULE 26) R8 and Rq are independently hydrogen, lower alkyl (C1-C3), O-lower alkyl (C1-C3) , S-lower alkyl (C1-C3) , -CF3, -CN, -OH, -SCF3, -OCF3 , halogen, NO2, amino, or -NH-lower alkyl (C1-C3) ; -N- [lower alkyl (C1-C3) ] 2, -N(Rb) ( CH2 ) q- ( Rb ) 2 R25 is selected from the moieties -266- SUBSTTTUTE SHEET (RULE 26) W is selected from 0, S. NH, N-lower alkyl (C1-C3) , -NCO-lower alkyl (C1-C3) , or NSO2-lower alkyl (C1-C3 ) ; and pharmaceutically acceptable salts thereof. 68. A compound selected from those of the formula: wherein A-B is wherein R is hydrogen, halogen (chlorine, bromine, fluorine, iodine), OH, S-lower alkyl (C1-C3) , -SH, -SO- lower alkyl (C1-C3) , -Sθ2"lower alkyl (C1-C3) , -CO-lower alkyl (C1-C3) , -CF3 , lower alkyl (C1-C3) , O-lower alkyl (C1-C3) , -NO2, -NH2, -NHCO lower alkyl (C1-C3) , -N- [lower alkyl (C1-C3) ] 2, -S02NH2; -SO2NH lower alkyl (C1-C3) , or -SO2N[lower alkyl (C1-C3) ]2; R2 is nydrogen, Cl, Br, F, I, -OH, lower alkyl (C1-C3) , O-lower alkyl (C1-C3 ) , or Ri and R2 taken together are methyienedioxy cr ethyienedioxy; R3 is the moiety: O II -CAr wherein Ar is selected from moieties of the formula: -267- SUBSTΓΓUTE SHEET (RULE 26) R is independently selected from hydrogen, halogen, lower alkyl (C1-C3) , -(Cld^-N -(CH2)q-OH, - (CH2)q-0-alkyl(Cι-C3) ; q is one, two or three; R4 is selected from hydrogen, lower alkyl (C1-C3) , -CO- lower alkyl (C1-C3) , R5 and R7 are selected from hydrogen (C1-C3 ) lower alkyl (C1-C3) lower alkoxy and halogen; R6 is selected from ( a ) moieties of the formula : -NS0 2 -lower alkyl(C 3 -C 8 ), -NS0 2 -lower alkenyl(C,-C 8 ) I I R R O II -NH-C-O-lower alkyl(C 3 -C 8 )straight or branched O II -NH-C-lower alkyl(C 3 -C 8 )straight or branched, O II -NH-C-O-lower alkenyl(C 3 -C-)straight or branched, O II -NH-C-lower alkenyl(C--C 8 )straight or branched, wherein cycloalkyl is defined as C3 to 6 cycloalkyl cyclohexenyl or cyclopentenyl; R a is hydrogen, CH3, C2H5, moieties of the formulae: (CH^-N - (CH2) 2-O-lower alkyl (C1-C3) or -CH2CH2OH; q is one, two or three; Rb is hydrogen, -CH3 or -C2H5; and (b) a moiety of the formula: -X-RlO; wherein Rio is lower alkyI (C3-C8J , lower alkenyl (C3-C8) , - (CH2)p-cycloalkyl (C3-C6) - and p is zero to three : X is O, S , NH , NCH3 , -270- SUBSTΓΠ TE SHEET (RULE 26) \ C= O or a bond / and R5 and P7 are as previously defined (c) a moiety of the formula: R- N-COJ wherein J is R a , lower alkyl (C3-C8) oranched or unbrancned, Lowei alkenyl (C3-CP ) branched or unbranched, -O-lower alkyl (C1-C8) branched or unbranched, -O-lower alkenyl (C3-C8) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties or -CH2- .' wherein K' is halogen, -OH, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety: ■ N E \ / G=F -271- SUBSΠTUTESHEET(RULE26) wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C1-C3) lower alkyl, hydroxy, -CO-lower alkyl (C1-C3) , CHO, (C1-C3) lower alkoxy, -CO2- lower alkyl (C1-C3 ) , and R a and Rb are as hereinbefore defined; (d) a moiety selected from those of the formulae: R - N r- COCHAr' , R O II -O-C-loweralkyl (C j -Cg) , -S-loweralkyl(C ][ -C 3 ) wherein R c is selected from halogen, (C1-C3) lower alkyl -O-lower alkyl (C1-C3) and OH; Rb is as hereinbefore defined; Ar ' is selected from the group: Rg and R9 are independently hydrogen, lower alkyl (C1-C3), O-lower alkyl (C1-C3) , S-lower alkyl (C1-C3 ) , -CF3, -CN, -OH, -SCF3, -OCF3, halogen, NO2, amino, or -NH-lower alkyl (C1-C3) ; -N- [lower alkyl (C1-C3) ]2, -N ( Rb ) ( CH2 ) q-N ( Rb ) 2 R25 is selected from the moieties W is selected from 0, S, NH, N-lower alkyl (C1-C3) , -NCO-lower alkyl (C1-C3) , or NSθ2~lower alkyl (C1-C3) ; and pharmaceutically acceptable salts thereof. -273- SUBSTΓΓUTE SHEET (RULE 26) 69. A compound selected from those of the formulae: wherein Y is - ( CH2)n - an< ^ n is an integer zero or one; A-B is -(CH 2 ) m - - or -N-(CH 2 ) m - wherein is an integer one when n is one and m is an integer one or two when n is zero; R is hydrogen, halogen (chlorine, bromine, fluorine, iodine), OH, S-lower alkyl (C1-C3 ) , -SH, -SO-lower alkyl (C1-C3) , -Sθ2~lower alkyl (C1-C3 ) , -CO-lower alkyl (C1-C3) , -CF3, lower alkyl (C1-C3) , O-lower alkyl (C1-C3) , -NO2, -NH2, -NHCO lower alkyl (C1-C3 ) , -N- [lower alkyl (C1-C3) ] 2, -SO2NH2; -SO2NH lower alkyl (C1-C3), or -SO2N[lower alkyl (C1-C3 ) ] 2; P.2 is hydrogen, Cl, Br, F, I, -OH, lower alkyl (C1-C3 ) , O-iower alkyl (C1-C3 ) , or Ri and R2 taken together are methylenedioxy or ethylenedioxy; R3 is the moiety: O II -CAr wherein Ar is selected from moieties of the formula: -274- SUBSTΓΓUTE SHEET (RULE 26) NH OR 25 X o ~ χ - R4 is selected from hydrogen, lower alkyl (C1-C3) , -CO- lower alkyl (C1-C3) ; R5 and R7 are selected from hydrogen(C1-C3) lower alkyl (C1-C3) lower alkoxy and halogen; R6 is selected from (a) moieties of the formula: -NSO.-lower alkyl(C,-C 8 ), -NSO.-lower alkenyl(C 3 -C 8 ) R R O II -NH-C-O-lower alkyl(C 3 -C 8 )straight or branched O II -NH-C-lower alkyl(C--C-)straight or branched, O II -NH-C-O-lower alkenyl(C 3 -C 8 )s.raight or branched, O II -NH-C-loweralkenyl(C 3 -C 8 )straightorbranched, wherein cycloalkyl is defined as C3 to Co cycloalkyl cyclohexenyl or cyclopentenyl; R a is hydrogen, CH3, C2H5, moieties of the formulae: -27.6 - SUBSTTTUTE SHEET (RULE 26) - (CH2 ) 2-O-lower alkyl (C1-C3) or -CH2CH2OH; q is one, two or three; R is hydrogen, -CH3 or -C2H5; and (b) a moiety of the formula: -X-RlO; wherein Rio is lower alkyl (C3-C8) , lower alkenyl (C3-C8) , - (CH2)p-cycloalkyl(C3-C6) , and p is zero to three : X is C , S , NH , NCH3 , -277 - SUBSTΓΓUTE SHEET (RULE 26) \ C = O or a bond / and R5 and R7 are as previously de f ined ( c ) a moiety of the formula : R_ N- COJ wherein J is R a , lower alkyl (C3-C8) branched or unbranched, lower alkenyl (C3-C8) branched or unbranched, -O-lower alkyl (C3-C8) branched or unbranched, -O-lower alkenyl (C3-Cg) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties or -CH2-K' wherein K ' is halogen, -OH, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety: -N E G=F wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C1-C3) lower alkyl, hydroxy, -CO-lower alkyl (C1-C3) , CHO, (Cι-C3)lower alkoxy, -CO2- iower aikyl (C1-C3 ) , and R a and Rb are as hereinbefore defined; (d) a moiety selected from those of the formulae: R I a -N- COCHAr . R O II -O-C-lower alkyl (C j -Cg) , -S-lower alkyUC ^Cg) wherein R c is selected from halogen, (C1-C3) lower alkyl, -O-lower alkyl (C1-C3) and OH; Rb is as hereinbefore defined; wherein Ar ' is selected from the group: -279- SUBSTΓΓUTE SHEET (RULE 26) Rg and R9 are independently hydrogen, lower alkyl (Ci- C3), O-lower alkyl (C1-C3) , S-lower alkyl (C1-C3) , -CF3 -CN, -OH, -SCF3, -OCF3 , halogen, NO2 , amino, or -NH- lower alkyl (C1-C3) ; - N- [lower alkyl (C1-C3 ) ] 2, -N ( Rb ) ( CH2 ) q-N ( Rb ) 2 ; R25 is selected from the moieties -280 - SUBSTΓΓUTE SHEET (RULE 26) W is selected from 0, S, NH, N-lower alkyl (C1-C3) , -NCO-lower alkyl (C1-3), or NSθ2-lower alkyl (C1-C3) ; and pharmaceutically acceptable salts thereof. 70. A compound selected from those of the formula: wherein Y is selected from O, S, NH, and N-lower alkyl (C1-C3) ; Rl is hydrogen, halogen (chlorine, bromine, fluorine, iodine), OH, S-lower alkyl (C1-C3) , -SH, -SO-lower alkyl (C1-C3) , -Sθ2~lower alkyl (C1-C3) , -CO-lower alkyl (C1-C3) , -CF3, lower alkyl (C1-C3) , O-lower alkyl(Cι-C3) , -NO2, -NH2. -NHCO lower alkyl (C1-C3) , -N- [lower alkyl (C1-C3) ] 2, -SO2 H2; -SO2NH lower alkyl (Cl- C3), cr -S02N[lower alkyl (C1-C3) ]2; R2 is hydrogen, Cl , Br, F, I, -OH, lower alkyl (C1-C3) , O-lower alkyl (C1-C3) , or Ri and R2 taken together are methylenedioxy or ethyleneedioxy; R3 is the moiety: O II -CAr wherein Ar is selected from moieties of the formula: -281- SUBSTΓΓUTE SHEET (RULE 26) R4 is selected from hydrogen, lower alkyKCι-3), - CO- lower alkyl (C1-C3 ) ; R5 and R7 are selected from hydrogen(C1-C3) lower alkyl (C1-C3) lower alkoxy and halogen R6 is selected from (a) moieties of the formula: -282- SUBSTΓΓUTE SHEET (RULE 26) -NS0 2 -lower alkyl(C 3 -C 8 ), -NS0 2 -lower alkenvl(C 3 -C 8 ) I I R R. O II -NH-C-O-lower alkyl(C 3 -C 8 )straight or branched O II -NH-C-lower alkyl(C 3 -C 8 )straight or branched, O II -NH-C-O-lower alkenyl(C--C 8 )straight or branched, O II -NH-C-loweralkenyl(C 3 -C 8 )straightorbranched, wherein cycloalkyl is defined as C3 to C6 cycloalkyl, cyclohexenyl or cyclopentenyl; R a is hydrogen, CH3 , C2H5, oieites of the formulae: - (CH2) 2-C-lower alkyl (C1-C3) or -CH2CH2OH; q is one, two or three; Rb is hydrogen, -CH3 or -C2H5; and (b) a moiety cf the formula: -X-RlO; wherein Rio is lower alkyl (C3-C8) , lower alkenyl (C3-C8) , - ( CH2)p-cycloalkyl (C3-C6) , and p is zero to three: X is 0, S, NH, NCH3, C = O orabond / and R5 and R7 are as previously defined (c) a moiety of the formula: R b N-COJ wherein J is R a , lower alkyl (C3-C ) branched or unbranched, lower alkenyl (C3-C8) branched or unbranched, -O-lower alkyl (C3-C8) branched or unbranched, -O-lower alkenyl (C3-C8) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties or -CH2-K' wherein K' is halogen, -OH, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety: -N E \ / G=F wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C1-C3) lower alkyl, hydroxy, -CO-lower alkyl (C1-C3) , CHO, (C1-C3) lower alkoxy, -Cθ2-lower alkyl (C1-C3 ) , and R a and Rb are as hereinbefore defined; (d) a moiety selected from those cf the formulae: R I Λ -N-COCHAr' , R O II -O-C-lower alkyl (CJ-C-J) , -S-lower alkyl(C 1 -C 3 ) wherein R c is selected from halogen, (C1-C3) lower alkyl, -O-lower alkyl (C1-C ) and OH; Rb is as hereinbefore de ined; wherein Ar ' is selected from the group: -286- SUBSTΓΓUTE SHEET (RULE 26) Rg and R9 are independently hydrogen, lower alkyl (C1-C3), O-lower alkyl (C1-C3) , S-lower alkyl (C1-C3 ) , -CF3, -CN, -OH, -ΞCF3, -OCF3, halogen, NO2, amino, or -NH-lower alkyl (C1-C3) ; -N- [lower alkyl (C1-C3) ]2, -N ( Rb ) ( CH2 ) q-N ( Rb ) 2 ; R25 is selected from the moieties -287 - SUBSTΓΓUTE SHEET (RULE 26) W is selected from O, S, NH, N-lower alkyl (C1-C3) , -NCO-lower alkyl (C1-C3 ) , or NSO2-lower alkyl (C1-C3 ) ; and pharmaceutically acceptable salts thereof. 71. A compound selected from those of the formula: wherein Y i s 0 , S , NH and N- lowei alkyl ; and A-B is — CH,— N or N— CH — " Rl is hydrogen, halogen (chlorine, bromine, fluorine, iodine), OH, S-lower alkyl (C1-C3) , -SH, -SO-lower alkyl (C1-C3) , -Ξθ2"lower alkyl (Cl -C3) , -CO-lower alkyl (C1-C3 i , -CF3 , lower alkyl (C .1. -C3) , O-lower alkyl (C1-C3) , -NO2, -NH2, -NHCO lower alkyl (C1-C3) , -N- [lower alkyl (C1-C3 ) ]2, -SO2NH2 : -SO2NH lower alkyl (C1-C3 ) , cr -Sθ2N[lower alkyl (C1-C3) ] 2; P-2 is hydrogen, Cl, Br, F, I, -OH. lower alkyl (C1-C3 ) , O-lower alkyl (C1-C3 ) , or Ri and P taken together are methylenedioxy or ethylenedioxy; R3 is the moiety: O II -CAr wherein Ar is selected from moieties of the formula: R4 is selected from hydrogen, lower alkyl (C1-C3) , -CO-lower alkyl (C1-C3) R5 and R7 are selected from hydrogen(C1-C3) lower alkyl (C1-C3) lower alkoxy and halogen; R6 is selected from (a) moieties of the formula: -NSO.-lower alkyl(C-C-), -NSO.-lower alkenyl(C 3 -C 8 ) I R a R o -NH-C-O-lower alkyl(C 3 -C 8 )straight or branched O II -NH-C-lower alkyl(C,-C 8 )straight or branched, O II -NH-C-O-lower alkenyl(C 3 -C 8 )straight or branched, O II -NH-C-lower alkenyl(C--C 8 )straight or branched, wherein cycloalkyl is def ined as C3 to Cf, cycloalkyl , cyclohexenyl or cyclopentenyl ; R a i s hydrogen , CH3 , C2H5 , moieties of the formulae : -290- SUBSTΓΓUTE SHEET (RULE 26) - (CH2) 2θ-lower alkyl (C1-C3) or -CH2CH2OH; q is one, two or three; Rb is hydrogen, CH3 or -C2H5; (b) a moiety of the formula: -X-RlO; wherein Rio is lower alkyl (C3-C8) , lower alkenyl (C3-C8) , - (CH2)p-cycloalkyl (C3-C6) , and p is zero to three: X is 0, S, NH, NCH3, \ C= O ora bond / and P.5 and R7 are as previously defined (c) a moiety of the formula: R, N-COJ wherein J is R a , lower alkyl (C3-C5) branched or unbranched, lower alkenyl (C3-Cg) branched or unbranched, O-lower alkyl (C3-C8) branched cr unbranched, O-lower alkenyl (C3-C8) branched or unbrancned, tetrahydroguran, tetrahydrothiophene, the moieties cr -CH2-K' wherein K ' is halogen, -OH, tetrahydrofuran, tetrahydrothiophene or the heterocvclic ring moiety: -N E \ / G=F wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C1-C3) lower alkyl, hydroxy, -CO-lower alkyl (C1-C3 ) , CHO, (C1-C3) lower alkoxy, -Cθ2-lower alkyl (C1-C3) , and R a and Rb are as hereinbefore defined; (d) a moiety selected from those of the formulae: R I a - N- COCHAr' , O II -O-C-loweralkyl (C j -Cg) , -S-loweralkyl(C j -C 3 ) wherein R c is selected from halogen, (C1-C3) lower alkyl. -O-lower alkyl (C1-C3) and OH; Rb is as hereinbefore defined; wherein Ar ' is selected from the group: -293- SUBSTTTUTE SHEET (RULE 26) Rg and R9 are independently hydrogen, lower alkyl (C1-C3) , O-lower alkyl (C1-C3) , S-lower alkyl (C1-C3) , -CF3, -CN, -OH, -SCF3, -OCF3 , halogen, NO2, amino, or -NH-lower alkyl (C1-C3) ; -N- [lower alkyl (C1-C3) ]2, -N(Rb ) (CH2)q-N ( Rb ) 2 R25 is selected from the moieties W is selected from 0, S, NH, N-lower alkyl (C1-C3) , -NCO-lower alkyl (C1-C3 ) , or NS02-lower alkyl {C1-C3) ; and pharmaceutically acceptable salts thereof. -294- SUBSTΓΓUTE SHEET (RULE 26) 72. A compound selected from those of the formula: wherein Y is selected from 0, S, NH, and N-lower alkyl (C1-C3) ; Rl is hydrogen, halogen (chlorine, bromine, fluorine, iodine), OH, S-lower alkyl (C1-C3) , -SH, -SO-lower alkyl (C1-C3) , -S02~lower alkyl (C1-C3) , -CO-lower alkyl (C1-C3) , -CF3, lower alkyl (C1-C3) , O-lower alkyl (C1-C3) , -N02, -NH2, -NHCO lower alkyl (C1-C3) , - N- [lower alkyl(Cι-C3) ]2,-S02NH2; -SO2NH lower alkyl (Ci- C3) , or -S02N[lower alkyl (C1-C3) ]2; R2 is hydrogen, Cl, Br, F, I, -OH, lower alkyl (C1-C3) , O-lower alkyl (C1-C3) , or Ri and R2 taken together are methylenedioxy or ethyleneedioxy; R3 is the moiety: O II -CAr wherein Ar is selected from moieties of the formula: 0 R4 is selected from hydrogen, lower alkyl(Cι-3), -CO-lower alkyl(Cι-C3); R5 and R7 are selected from hydrogen(C]-C3) lower alkyl(Cι-C3) lower alkoxy and halogen R6 is selected from (a) moieties of the formula: -NS0 2 -lower alkyl(C 3 -C 8 ), -NSO.-lower alkenyl(C 3 -C 8 ) R R O II -NH-C-O-lower alkyl(C 3 -C 8 )straight or branched O II -NH-C-lower alkyl(C 3 -C 8 )straight or branched, O II -NH-C-O-lower alkenyl(C 3 -C 8 )straight or branched, O II -NH-C-lower alkenyl(C 3 -C 8 )straight or branched, wherein cycloalkyl is defined as C3 to C6 cycloalkyl, cyclohexenyl or cyclopentenyl; Ra is hydrogen, CH3, C2H5, moieites of the formulae: -(CH2)2-0-lower alkyl(Cι-C3) or -CH2CH2OH; q is one, two or three; R is hydrogen, -CH3 or -C2H5; and (b) a moiety of the formula: -X-RlO; wherein Rio is lower alkyl(C3-C8), lower alkenyl (C3-C8), -(CH2)p- cycloalkyl(C3-C6), and p is zero to three: X is O, S, NH, NCH3, C= O or a bond / and R5 and R7 are as previously defined (c) a moiety of the formula: R- - N- COJ wherein J is R a , lower alkyl(C3-Cδ) branched or unbranched, lower alkenyl(C3-Cδ) branched or unbranched, -O-lower alkyl(C3-Cδ) branched or unbranched, -O-lower alkenyl(C3-C8) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties or -CH2- ' wherein K' is halogen, -OH, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety: N E G=F wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C1-C3) lower alkyl, hydroxy, -CO-lower alkyl(Cι-C3), CHO, (Cι-C3)lower alkoxy, -Cθ2-lower alkyl(Cι-C3), and R a and Rb are as hereinbefore defined; (d) a moiety selected from those of the formulae: R - N- COCHAr R O II -O-C-lo er alkyl (C j -Cg) , -S-lower alkyl(C.-C 3 ) R_ - NHCH j Jq- N - 0- (CH . ) 2 - N χ wherein R c is selected from halogen, (Ci-C3)lower alkyl, -O-lower alkyl(Ci-C3) and OH; Rb is as hereinbefore defined; wherein Ar' is selected from the group: R8 and R9 are independently hydrogen, lower alkyl (C1-C3), O-lower alkyl(Cι-C3), S-lower alkyl(Cι-C3), -CF3, -CN, -OH, -SCF3, -OCF3, halogen, NO2, amino, or -NH-lower alkyl(C -C3);-N-[lower alkyl(Cι-C3)]2, -N(R )(CH 2 )q-N(Rb)2; R25 is selected from the moieties W is selected from O, S, NH, N-lower alkyl(Cι-C3), -NCO-lower alkyl(Cι- C3), or NSθ2-lower alkyl(Ci-C3); and pharmaceutically acceptable salts thereof. 73. A compound according to claim 72 wherein A-B is N- CH,- R, R3 is the moiety: o - CAr wherein Ar is selected from moieties of the formula: and Y, R a , Rb, Re Rl, 2. R3, 4, R5, Rό, 7, δ, 9, RlO, R25 are as previously defined in Claim 72. 74. A compound according to claim 72 wherein A-B is N- CH R, Y is O; and Ra, Rb, Re Rl, R2, R3, R4, R5, R6, R7, R8, R9, RlO, R25 are as previously defined in Claim 72. 75. A compound according to claim 72 wherein A-B is N- CI^- R, R3 is the moiety: O II - CAr wherein Ar is selected from moieties of the formula: Y is O; and Ra, Rb, Ro Rl, R2, R3, R4, R5, R6, R7, Rδ, R9, RlO, R25 are as previously defined in Claim 72. 76. A compound according to claim 72 wherein A-B is N- CH^- R. Y is NH; and Ra, Rb, Re Rl, R2, R3, R-4, R5, R6, R7, Rδ, R9, RlO, R25 are as previously defined in Claim 72. 77. A compound according to claim 72 wherein R. R3 is the moiety: o II - CAr wherein Ar is selected from moieties of the formula: and Y is NH; and, R a , Rb, e Rl, 2, R3, 4, 5, Rό, R7, Rδ, R9, RlO, 25 are as previously defined in Claim 72. 78. A compound selected from those of Formula I: Formula 1 wherein Y is selected from (CH2) n , O, S, NH, NCOCH3, N-lower alkyl (Q- C3), CH-lower alkyl(Cι-C3), CHNH-lower alkyl(Cι-C3), CHNH2, CHN[lower alkyl(Cι-C3)]2,CHO-lower alkyl(Ci-C3), CHS-lower alkyK - C3), wherein n is an integer from 0-2; A-B is wherein m is an integer from 1-2, provided that when Y is -(CH2)n- and n=2, m mav also be zero and when n is zero, m may also be three, provided also that when Y is -(CH2)n- and n is 2, m may not also be two; Rl is hydrogen, halogen (chlorine, bromine, fluorine, iodine), OH, -S- lower alkyl(Cι-C3), -SH, -SO lower alkyl(Cι-C3), -SO2 lower alkyl(Cι-C3), -CO-lower alkyl(Cι-C3), -CF3, lower alkyl(Cι-C3), O-lower alkyl(Cι-C3), -NO2, -NH2, -NHCO lower alkyl(Cι-C3), -N-[lower alkyl(Cι-C3)]2, -S02NH2, -SO2NH lower alkyl (C1-C3), or -Sθ2N[lower alkyl(Cι-C3)]2; R2 is hydrogen, Cl, Br, F, I, -OH, lower alkyl(Cι-C3), O-lower alkyl(Cι-C3), or Rl and R2 taken together are methylenedioxy or ethylenedioxy; R3 is the moiety O II - CAr wherein Ar is a moiety selected from the group and X is O, S, -NCH3 or -NH R4 is selected from hydrogen, lower alkyl(Cι-C3), -CO-lower alkyl(C -C3); R5 and R7 are selected from hydrogen, (C1-C3) lower alkyl, (Ci-C3)lower alkoxy and halogen R(, is selected from (a) moieties of the formula -NSO,-lower alkyl(C -3,-C-„8) / , -NSO--lower alkenvl(C 3 -C 8 I R R O II -NH-C-O-lower alkyl(C--C 8 )straight or branched O II -NH-C-lower alkyl(C--C 8 )straight or branched, O II -NH-C-O-lower alkenyl(C 3 -C 8 )straight or branched, O II -NH-C-lower alkenyl(C.-C 8 )straight or branched, wherein cycloalkyl is defined as C3 to C6 cycloalkyl, cyclohexenyl or cyclopentenyl; R a is hydrogen, CH3, C2H5, moieties of the formulae: -(CH2)2-0-lower alkyl(Ci-C3) or -CH2CH2OH; q is one, two or three; Rb is hydrogen, -CH3 or -C2H5;and (b) a moiety of the formula: -X-RlO, wherein Rio is lower alkyl(C3-Cδ), lower alkenyl(C3-Cs), -(CH2)p- cvcloalkvl(C3-C6), and p is zero to three; X is O, S, NH, NCH3, \ C= O or a bond / and R5 and Rγ are as previously defined, (c) a moietv of the formula: R b - N -COJ wherein J is R a , lower alkyl (C3-C8) branched or unbranched, lower alkenyl(C3-C8) branched or unbranched, -O-lower alkyl(C3-Cδ) branched or unbranched, -O-lower alkenyl(C3-Cδ) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties or -CH2-K ' wherein K ' is halogen, -OH, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety: — N E \ / G=F wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C1-C3) lower alkyl, hydroxy, -CO-lower alkyl(Cι-C3), CHO, (Cι-C3)lower alkoxy, -Cθ2-lower alkyl(Cι-C3), and Ra and R are as hereinbefore defined; (d) a moiety selected from those of the formulae: R - N- COCHAr' R O -O-C-lower alkyl (C j -Cg) , -S-lower alkyUC j -C 3) - S- - - N wherein R c is selected from halogen, (Ci-C3)lower alkyl, -O-lower alkyl(Ci-C3) and OH; R is as hereinbefore defined; wherein Ar' is selected from the group: Rδ and R9 are independently hydrogen, lower alkyl (C1-C3), O-lower alkyl(Cι-C3), S-lower alkyl(Ci-C3), -CF3, -CN, -OH, -SCF3, -OCF3, halogen, NO2, amino, or -NH-lower alkyl(Ci-C3); -N-[lower alkyl(Ci-C3)]2 , -N(Rb)(CH 2 ) q -N(R b )2; W is selected from O, S, NH, N-lower alkyl (C1-C3), -NCO-lower alkyK - C3), or NSθ2-lower alkyI(Cι-C3); 25 is selected from the moieties and the moiety Z O represents: a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, wherein the 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom is optionally substituted by (Cl-C3)lower alkyl, formyl, a moiety of the formula: - (CH-,) α N q \ halogen or (Cι-C3)lower alkoxy; and the pharmaceutically acceptable salts, esters and pro-drug forms thereof. 79. A compound selected from those of the formulae: wherein Y is selected from -(CH2)-, O, S, NH, NCOCH3, N-lower alkyl (Q- C3), CH-lower alkyl(Ci-C3), CHNH-lower alkyl(Cι-C3), CHNH2, CHN[lower alkyl(Cι-C3)]2,CHO-lower alkyl( -C3), CHS-lower alkyl(C_- C3); A-B is - (CH j J - N - or - N - (CH 2 ) — R 3 R 3 Rl is hydrogen, halogen (chlorine, bromine, fluorine, iodine), OH, S- lower alkyl(Cι-C3), -SH, -SO-lower alkyl(Cι-C3), -Sθ2-lower alkyl(Cι-C3), -CO-lower alkyl(Cι-C3), -CF3, lower alkyl(Cι-C3), O-lower alkyl(Cι-C3), -Nθ2, -NH2, -NHCO lower alkyl(Cι-C3), -N-[lower alkyl(Cι-C3)]2, -SO2NH2; -SO2NH lower alkyl (C1-C3), or -Sθ2N[lower alkyl(Cι -C3)]2; R2 is hydrogen, Cl, Br, F, I, -OH, lower alkyl(Cι-C3), O-lower alkyl(Cι-C3), or Ri and R2 taken together are methylenedioxy or ethylenedioxy; R3 is the moiety: O II - CAr wherein Ar is selected from moieties of the formula: R4 is selected from hydrogen, lower alkyl(Cι-C3), -CO-lower alkyl(Cι-C3); R5 and Rγ are selected from hydrogen(Cι-C3)lower alkyl(Cι-C3) lower alkoxy and halogen; 6 is selected from (a) moieties of the formula: -NSO.-lower alkyl(C 3 -C 8 ), -NSO.-lower alkenyl(C 3 -C 8 ) R R O II -NH-C-O-lower alkyl(C 3 -C 8 )straight or branched O II -NH-C-lower alkyl(C 3 -C 8 )straight or branched, O II -NH-C-O-lower alkenyl(C--C 8 )straight or branched, O II -NH-C-lower alkenyl(C--C 8 )straight or branched, wherein cycloalkyl is defined as C3 to Cβ cycloalkyl, cyclohexenyl or cyclopentenyl; R a is hydrogen, CH3, C2H5, moieties of the formulae: - (CH^- ^ (CH-)q- N C \ -(CH2)2"0-lower alkyl(Cι-C3) or -CH2CH2OH; q is one, two or three; Rb is hydrogen, -CH3 or -C2H5; and (b) a moiety of the formula: -X-RlO; wherein RlO is lower alkyl(C3-Cδ), lower alkenyl (C3-C8), -(CH2)p- cycloalkvl(C3-C6), and p is zero to three: X is O, S, NH, NCH3, \ C= O or a bond X and R5 and R7 are as previously defined (c) a moiety of the formula: - wherein J is Ra, lower alkyl(C3-Cδ) branched or unbranched, lower alkenyl(C3-Cδ) branched or unbranched, -O-lower alkyl(C3-Cδ) branched or unbranched, -O-lower alkenyl(C3-Cδ) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties or -CH2-K ' wherein K ' is halogen, -OH, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety: -N E \ / G=F wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (Ci- C3)lower alkyl, hydroxy, -CO-lower alkyl(Cι-C3), CHO, (Cι-C3)lower alkoxy, -Cθ2-lower alkyl(Cl-C3), and R a and R are as hereinbefore defined; (d) a moiety selected from those of the formulae: R - N- COCHAr' R O -O-C-lower alkyl (C j -Cg) , -S-lower alkylfC^C 3) NHCH,) α - N - 0- (CH . ) 2 - N χ wherein R is selected from halogen, (Ci-C3)lower alkyl, -O-lower alkyl(Ci-C3) and OH; Rb is as hereinbefore defined; wherein Ar' is selected from the group: Rδ and R9 are independently hydrogen, lower alkyl(Cι-C3), O-lower alkyl(Cι-C3), S-lower alkyl(Cι-C3), -CF3, -CN, -OH, -SCF3, -OCF3, halogen, NO2, amino, or -NH-lower alkyl(Ci-C3); - N-[lower alkyl(Cι-C3)]2, -N(Rb)(CH2)q-N(R b )2; R25 is selected from the moieties W is selected from O, S, NH, N-lower alkyl(Cι-C3), -NCO-lower alkyl(Cι- 3), or NSθ2-lower alkyl(Cι-C3); and pharmaceutically acceptable salts thereof. δO. A compound according to claim 79 wherein A-B is N- CH-r R_ R3 is the moiety: O - CAr wherein Ar is selected from moieties of the formula: and Y, R a , Rb, e Rl, R2. R3, R4, 5, Rό, R7, R8, R9, RlO, R25 are as previously defined in Claim 79. 81. A compound according to claim 79 wherein A-B is N- CH.- R_ Y is -(CH2)-; and Ra, Rb, Re Rl, R2, R3, R4, R5. Rό, R7, Rδ, R9, RlO, R25 are as previously defined in Claim 79. δ2. A compound according to claim 79 wherein A-B is N- CH,- R 3 Y is O; and Ra, Rb, Re Rl, R2, 3, R-4, R 5, ό, 7, δ, 9 , RlO, R25 are as previously defined in Claim 79. δ3. A compound according to claim 79 wherein A-B is N- Cr - R 3 Y is NH; and Ra, Rb, Re Rl, R2, R3. R4, 5, Rό, R , δ, R9. RlO, 25 are as previously defined in Claim 79. δ4. A compound according to claim 79 wherein A-B is N- CH-,- R, R3 is the moiety: O - CAr wherein Ar is selected from moieties of the formula: Y is -(CH2)-; and Ra, Rb, Re Rl, R 2, R3< Ri, R5, ό, R7, Rδ, R9, RlO, R25 are as previously defined in Claim 79. 85. A compound according to claim 79 wherein A-B is N- CH,- R, R3 is the moiety: O II - CAr wherein Ar is selected from moieties of the formula: Y is O; and Ra, Rb, Re Rl, R2, 3, R4, 5, Rό, R?, Rδ, 9 RlO, R25 are as previously defined in Claim 79. 66. A compound according to claim 79 wherein A-B is N- CH-- R, R3 is the moiety: O II ■ CAr wherein Ar is selected from moieties of the formula: Y is NH; and Ra, Rb, Re Rl, 2, R3, R-4, R5, Rό, R7, Rδ, R9, RlO, R25 are as previously defined in Claim 79. 87. A compound selected from those of Formula I Formula I wherein Y is selected from (CH2)n, 0, S, NH, NCOCH3, N- lower alkyl (C1-C3) , CH-lower alkyl (C1-C3) , CHNH-lower alkyl (C1-C3) , CHNH2, CHN[lower alkyl (C1-C3) ] 2 ,CHO-lowe- alkyl (C1-C3) , CHS-lower alkyl (C1-C3) , wherein n is an integer from 0-2; A-B is wherein m is an integer from 1-2, provided that when Y is ~(CH2)n~ an d n=2, m may also be zero and when n is zero, m may also be three, provided also that when Y is -(CH2)n- and n is 2, m may not also be two; Ri is hydrogen, halogen (chlorine, bromine, fluorine, iodine), OK, -S-lower alkyl (C1-C3) , -SH, -SO lower alkyl (C1-C3) , -SO2 lower alkyl (C1-C3) , -CO-lower alkyl (C1-C3) , -CF3, lower alkyl (C1-C3) , O-lower alkyl (C1-C3) , -NO2, -NH2, -NHCO lower alkyl (C1-C3) , -N- [lower alkyl (C1-C3) ] 2, -SO2 H2, -SO2NH lower alkyl (Cι-C3), or -SO2N[lower alkyl (C1-C3) ] 2; R2 is hydrogen, Cl, Br, F, I, -OH, lower alkyl (C1-C3) , O-lower alkyl (C1-C3) , cr Ri and R2 taken together are methylenedioκy or ethylenedioxy; R3 is the moiety and X is 0, S, -NCH3 or -NH R4 is selected from hydrogen, lower alkyl (C1-C3) , -CO- lower alkyl (C1-C3) ; R5 and F-7 are selected from hydrogen, (C1-C3) lower alkyl, (C1-C3) lower alkoxy and halogen R6 is selected from (a) moieties of the formula: -NS0 2 -lower alkvl(C 3 -C 8 ), -NSO.-lower alkenyl(C 3 -C 8 ) I R R o -NH-C-O-lower alkyl(C 3 -C 8 )straight or branched O II -NH-C-lower alkyl(C,-C 8 )straight or branched, O II -NH-C-O-lower alkenyl(C 3 -C 8 )straight or branched, O II -NH-C-lower alkenyl(C.-C 8 )straight or branched, wherein cycloalkyl is defined as C3 to Co cycloalkyl, cyclohexenyl or cyclopentenyl; Ra is hydrogen, CH3, C2H5, moieties of the formulae: (CH^-N - (CH^- N^? , \ A -(CH2)2"0-lower alkyl(Cι-C3) or -CH2CH2OH; q is one, two or three; Rb is hydrogen, -CH3 or -C2H5;and (b) a moiety of the formula: -X-RlO, wherein R10 is lower alkyl(C3-Cδ), lower alkenyl(C3-Cδ), -(CH2)p- cycloalkyl(C3-C6), and p is zero to three; X is O, S, NH, NCH3, \ C— O or a bond / and R5 and R7 are as previously defined, (c) a moiety of the formula: R- - N -COJ wherein J is R a , lower alkyl (C3-C ) branched or unbranched, lower alkenyl(C3-Cδ) branched or unbranched, -O-lower alkyl(C3-Cδ) branched or unbranched, -O-lower alkenyl(C3-Cδ) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties or -CH2-K' wherein K' is halogen, -OH, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety: G=F wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C1-C3) lower alkyl, hydroxy, -CO-lower alkyl(Cι-C3), CHO, (Cι-C3)lower alkoxy, -Cθ2-lower alkyl(Ci-C3), and R a and Rb are as hereinbefore defined; (d) a moiety selected from those of the formulae: R - N- COCHAr' R O II -O-C-lower alkyl (C C 3 ) , -S-lower alkyl(C - -C 3 ) S (CH.), - - NH(CH.) N - 0- (CH,) 2 - N \ R_ R.. wherein R c is selected from halogen, (Cι-C3)lower alkyl, -O-lower alkyl(Ci-C3) and OH; Rb is as hereinbefore defined; wherein Ar ' is selected from the group: Rδ and R<9 are independently hydrogen, lower alkyl (C1-C3), O-lower alkyl(Cι-C3), S-lower alkyl(Q-C3), -CF3, -CN, -OH, -SCF3, -OCF3, halogen, NO2, amino, or -NH-lower alkyl(Ci-C3); -N-[lower alkyl(Cι-C3)]2, -N(Rb)(CH 2 ) q -N(Rb)2; W" is selected from O, S, NH, N-lower alkyl (C1-C3), -NCO-lower alkyl(Cι- C3), or NSθ2-lower alkyl(Ci-C3) 25 is selected from the moieties R„ 20 25 and the moiety Z O represents: a 5-membered aromatic (unsaturated) heterocyclic ring having one S heteroatom wherein the 5 -membered aromatic (unsaturated) heterocyclic ring is optionally substituted by ( -C3)lower alkyl, formyl, a moiety of the formula: " (CH-) halogen or (Ci-C3)lower alkoxy; and the pharmaceutically acceptable salts, esters and pro-drug forms thereof. δδ. A compound selected from those of the formula: wherein Y is selected from -(CH2)-, O, S, NH, and N-lower alkyl(Cι-C3); I A-B is - CH.- N or N- CH-- Rl is hydrogen, halogen (chlorine, bromine, fluorine, iodine), OH, S- lower alkyl(Cι-C3). -SH, -SO-lower alkyl(Cι-C3), -Sθ2-lower alkyl(Cι-C3), -CO-lower alkyl(Ci-C3), -CF3, lower alkyl(Cι-C3), O-lower alkyl(Ci-C3), -Nθ2, -NH2, -NHCO lower alkyl(Cι-C3), -N-[lower alkyI(Cι-C3)]2,- SO2NH2; -SO2NH lower alkyl(Cι-C3), or -Sθ2N[lower alkyl(Cι-C3)]2; R2 is hydrogen, Cl, Br, F, 1, -OH, lower alkyl(Cι-C3), O-lower alkyl(Cι-C3), or Ri and R2 taken together are methylenedioxy or ethyleneedioxy; R3 is the moiety: O II - CAr wherein Ar is selected from moieties of the formula: NHZOR 2.5 o x χ - R , R- R4 is selected from hydrogen, lower alkyl(Cι-3), -CO-lower alkyl(Cι -C3); R5 and R7 are selected from hydrogen(Cι-C3) lower alkyl(Cι-C3) lower alkoxy and halogen Rό is selected from (a) moieties of the formula: -NS0 2 -lower alkyl(C 3 -C 8 ), -NS0 2 -lower alkenyl(C 3 -C 8 ) I R. R. O -NH-C-O-lower alkyl(C 3 -C 8 )straight or branched O II -NH-C-lower alkyl(C 3 -C 8 )straight or branched, O II -NH-C-O-lower alkenyl(C 3 -C 8 )straight or branched, O II -NH-C-lower alkenyl(C--C 8 )straight or branched, wherein cycloalkyl is defined as C3 to C cycloalkyl, cyclohexenyl or cyclopentenyl; Ra is hydrogen, CH3, C2H5, moieites of the formulae: -(CH2)2-0-lower alkyl(Cι-C3) or -CH2CH2OH, q is one, two or three; Rb is hydrogen, -CH3 or -C2H5; and (b) a moiety of the formula: -X-RlO; wherein Ri 0 is lower alkyl(C3-Cδ), lower alkenyl (C3-C ), -(CH2)p- cycloalkyl(C3-C6), and p is zero to three: X is O, S, NH, NCH3, \ C= O or a bond / and R5 and R7 are as previously defined (c) a moiety of the formula: R- - N- COJ wherein J is Ra, lower alkyl(C3-Cδ) branched or unbranched, lower alkenyl(C3-Cδ) branched or unbranched, -O-lower alkyl(C3-Cδ) branched or unbranched, -O-lower alkenyl(C3-Cδ) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties or -CH2-K' wherein K' is halogen, -OH, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety: -N E \ / G= F wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C1-C3) lower alkyl, hydroxy, -CO-lower alkyl(Cι-C3), CHO, (Cι-C3)lower alkoxy, -Cθ2-lower alkyl(Ci-C3), and R a and Rb are as hereinbefore defined; (d) a moiety selected from those of the formulae: R I a - N- COCHAr ' , R O -O-C-lower alkyl (C 1 -C 3 ) , -S-lower alkyKC j -Cg) - Nl-KC^) N wherein R is selected from halogen, (Cι-C3)lower alkyl, -O-lower alkyl(Ci-C3) and OH; Rb is as hereinbefore defined; wherein Ar' is selected from the group: Rδ and Rq are independently hydrogen, lower alkyl (C1-C3), O-lower alkyl(Cι-C3), S-lower alkyl(Cι-C3), -CF3, -CN, -OH, -SCF3, -OCF3, halogen, NO2, amino, or -NH-lower alkyl(Cι-C3);-N-[lower alkyl(Cι-C3)]2, -N(Rb)(CH 2 )q-N(Rb)2; R25 is selected from the moieties W is selected from O, S, NH, N-lower alkyl(Cι-C3), -NCO-lower alkyl(C]- C3), or NSθ2-lower alkyl(Cι-C3); and pharmaceutically acceptable salts thereof. 89. A compound according to claim 8δ wherein A-B is N- CH,- R, R3 is the moiety: o - CAr wherein Ar is selected from moieties of the formula: and Y, R a , Rb, Ro Rl, R2, R3, R4, &5, Rό, ?, Rδ, 9, RlO, R25 are as previously defined in Claim 88. 90. A compound according to claim 88 wherein A-B is N- CR,- R, Y is -(CH2)-; and R a , Rb, Re Rl, R2, R3, R4, R5, Rό, R7, Rδ, R9, RlO, R25 are as previousl y defined in Claim δδ. 91. A compound according to claim 68 wherein A-B is N- CH,- Y is O; and Ra, Rb, Re Rl, R2, R3, R4, R5, Rό, R7, Rδ, R9, RlO, R25 are as previously defined in Claim 88. 92. A compound according to claim 88 wherein A-B is N- CH-- *3 Y is NH; and Ra, Rb, Re Rl, R2, 3, R4, R5, Rό, R7, R8, R9, RlO, R25 are as previously defined in Claim 88. 93. A compound according to claim 88 wherein A-B is N- CI^- R. R3 is the moiety: O II - CAr wherein Ar is selected from moieties of the formula: Y is -(CH2)-; and R a , Rb, Re Rl, 2, R3, R4, R5, Rό, R7, Rδ, R9, RlO, R25 are as previously defined in Claim 88. 94 A compound according to claim 88 wherein R3 is the moiety O II - CAr wherein Ar is selected from moieties of the formula- Ra, Rb, Re, Rl, R2, 3, R4, R5, ό, R7, δ, R9, RlO, R25 are as previously defined in Claim 88 95 A compound according to claim 8δ wherein R3 is the moiety: O - CAr wherein Ar is selected from moieties of the formula: and Y is 0; Ra. Rb, Re, Rl, 2, R3, R4, R5. Rβ, R7, 8, R9, RlO, 25 are as previously defined in Claim 88. 96. The compound according to claim 1, N-[4- (dibenz [b, f] [1,4]oxazepin-10 (IIH) -ylcarbonyl) -phenyl]- [1,1'-biphenyl]-2-carboxamide. 97. The compound according to claim 1, N-[4- (dibenz [b, f] [1, 4]oxazepin-10 (IIH) -ylcarbonyl) -3-chloro- phenyl] [1,1'biphenyl]-2-carboxamide. 98. The compound according to claim 1, N-[5- (dibenz [b, f] [1, 4]oxazepin-10 (IIH) ylcarbonyl) -2- pyridinyl] -5-fluoro-2-methylbenzamide. 99. The compound according to claim 1, N-[5- (dibenz [b, f] [1, 4]oxazepin-10 (IIH) -ylcarbonyl) -2- pyridinyl] -2- (4-pyridinyl) enzamide. 100. The compound according to claim 1, N-[5- (pyrido [2, 3-b] [1, 5]benzoxazepin-6 (5H) -ylcarbonyl) -2- pyridinyl] [1, 1 'biphenyl]-2-carboxamide. 101. The compound according to claim 1, N-[5- (pyrido [2, 3-b] [1, 4]benzoxazeρin-5 (6H) -ylcarbonyl) -2- pyridinyl] [1,1 '-biphenyl]-2-carboxamide. 102. The compound according to claim 1, N-[4- (pyrido [2, 3-b] [1, 4]benzoxazepin-5 (6H) -ylcarbonyl) -3- chlorophenyl] [1,1'biphenyl] -2-carboxamide. 103. The compound according to claim 1, N- [4- (6, 11-dihydropyrido [2 , 3-b] [1,5]benzodiazepin-6 (5H) - ylcarbonyl) -phenyl] [1.1'-biphenyl]-2-carboxamide. 104. The compound according to claim 1, N-[4- (6, 11-dihydropyrido [2, 3-b] [1, 5]benzodiazepin-6 (5H)-yl¬ carbonyl) -3-chlorophenyl] [1,1'-biphen l]-2-carboxamide. 105. The compound according to claim 1, N-[4- (6, 11-dihydropyrido [2, 3-b] [1,5]benzodiazepin-6 (5H) -yl¬ carbonyl)phenyl] [1,1 '-biphenyl] -2-carboxamide, hydrochloride. 106. The compound according to claim 1, N-[4- [ (5, 11-dihydro-lOH-dibenz [b,e] [1, 4]diazepin-10-yl) - carbonyl] -3-chlorophenyl] [1, 1 '-biphenyl] -2-carboxamide. 107. The compound according to claim 1, N-[4- [ (5, li-di ydro-lOH-dibenz [b,e] [1, 4 ] iazepin-10-yl) - carbonyl] -phenyl] [1,1'-biphenyl] -2-carboxamide. 108. The compound according to claim 1, N-[4- [ (5, ll-dihydro-10H-dibenz[b,e] [1, 4]diazepin-10-yl) - carbonyl] -3-methylphenyl] [1,1'-biphenyl]-2-carboxamide. 109. The compound according to claim 1, N-[4- [ (5, 11-dihydro-lOH-dibenz [b,e] [1, 4]diazepin-10-yl) - carbonyl]-2-methylphenyl] [1,1'-biphenyl] -2-carboxamide. 110. The compound according to claim 1, N-[4- [ (5, 11-dihydro-lOH-dibenz [b,e] [1, ]diazepin-10-yl) - carbonyl] -2-chlorophenyl] [1,1'-biphenyl] -2-carboxamide. 111. The compound according to claim 1, N-[4- [ (6, ll-dihydro-5H-dibenz [b,e] azepin-5-yl) carbonyl] - pheny] [1, 1 '-biphenyl]-2-carboxamide. 112. The compound according to claim 1, N-[4- [ (6, ll-dihydro-5H-dibenz [b, e] azepin-5-yl) carbonyl] -3- chlorophenyl] [1,1'-biphenyl] -2-carboxamide. 113. The compound according to claim 1, N-[4- [ (6, ll-dihydro-5H-dibenz [b, e]azepin-5-yl) carbonyl] -3- methylpheny1] [1,1'-biphenyl] -2-carboxamide. 114. The compound according to claim 1, N-[4- [ (6, ll-dihydro-5H-dibenz [b,e] azepin-5-yl) carbonyl]-2- chlorophenyl] [1,1'-biphenyl] -2-carboxamide. 115. The compound according to claim 1, N-[5- [ (6, ll-dihydro-5H-pyrido[2, 3-b] [1, 4]benzodiazepin-5- yl) carbonyl]-2-pyridinyl] -5-fluoro-2-methylbenzamide. 116. The compound according to claim 1, N-[4- [ (6, ll-dihydro-5H-pyrido[2, 3-b] [1, 4]benzodiazepin-5-yl) - carbonyl]-3-chlorophenyl] [1,1'-biphenyl] -2-carboxamide. 117. The compound according to claim 1, N-[4- [ (6, ll-dihydro-5H-pyrido[2, 3-b] [1, 4]benzodiazepin-5-yl) - carbonyl]phenyl] [1,1 '-biphenyl] -2-carboxamide. 118. The compound according to claim 1, N-[4- [ (6, ll-dihydro-5H-pyrido [2 , 3-b] [1, 4]benzodiazepin-5-yl) - carbonyl] -3-methylphenyl] [1,1 '-biphenyl] -2-carboxamide. 119. The compound according to claim 1, N-[4- [ (4, 5-dihydropyrazolo [4, 3-d] [1]benzazepin-6 (1H) -yl) - carbonyl]phenyl] [1, 1 '-biphenyl] -2-carboxamide. 120. The compound according to claim 1, N-[4- [ (4, 5-dihydropyrazolo[4, 3-d] [l]benzazepin-6 (1H) -yl) - carbonyl] -3-chlorophenyl] [1,1 '-biphenyl]-2-carboxamide. 121. The compound according to claim 1, N-[5- [ (4, 5-dihydropyrazolo[4, 3-d] [l]benzazepin-6 (1H) -yl) - carbonyl]-2-pyridinyl] [1,1'-biphenyl] -2-carboxamide. 122. The compound according to claim 1, N-[5- [ (4, 5-dihydropyrazolo [4, 3-d] [l]benzazepin-6 (1H) -yl) - carbonyl] -2-pyridinyl] -5-fluoro-2-methylbenzamide. 123. The compound according to claim 1, N-[5- (4H-thieno[3,4-b] [1, 5]benzodiazepin-9(10H)-yl) -2- pyridinyl]-5-fluoro-2-methylbenzamide. 124. The compound according to claim 1, N-[4- (4H-thieno[3, 4-b] [1, 5]benzodiazepin-9 (10H) -yl) -phenyl]- [1,1'-biphenyl]-2-carboxamide. 125. The compound according to claim 1, N-[4- (4H-thieno [3, 4-b] [1, 5]benzodiazepin-9 (10H) -yl) -3-chloro- phenyl] [1,1 '-biphenyl]-2-carboxamide. 126. The compound according to claim 1, N-[5- (4H-thieno[3,4-b] [1, 5]benzodiazepin-9 (10H) -yl) -2- pyridinyl] [1,1*-biphenyl]-2-carboxamide. 127. The compound according to claim 1, 5,11- dihydro-10-[4- (2-thienyl)benzoyl]-lOH-dibenz [b,e] [1,4]- diazepine. 128. The compound according to claim 1, 5,11- dihydro-10- [4- (3-thienyl)benzoyl]-lOH-dibenz [b,e] [1,4]- diazepine. 129. A compound according to claim 79 wherein A-B is -Cr^-N ^ R3 is the moiety : O II ■ CAr wherein Ar is selected from moieties of the formula: and Y, R a , b, Re, Rl, 2, R3, R , 5, 6, 7, δ, R9, RlO, R 25 are a s previously defined in Claim 79. 130. A compound according to claim 79 wherein I A-Bis -CH.-N Y is - (CH2)-; and Ra, Rb, Re, Rl, R2, R3, R , R5, R6, 7, R8, R9, RlO, R25 are as previously defined in Claim 79. 131. A compound according to claim 79 wherein I A-Bis —CH-.—N Y is 0; and Ra, Rb, Re, Rl, R2, R3, R4, R5, R6, R7, 8, R9, RlO, R25 are as previously defined in Claim 79. 132. A compound according to claim 79 wherein A-B is -CK.- *3 Y is NH; and Ra, Rb, Re, Rl, R2, R3, R4, R5, Rδ, R7, R8, R9, RlO, R25 are as previously defined in Claim 79. 133. A compound according to claim 79 wherein A-B is ■ H.- N R3 is the moiety : O II -CAr wherein Ar is selected from moieties of the formula: Y is - (CH2 ) - ; and Ra, Rb, Re, Rl, 2, 3, 4, R5, Rδ, R7, R8, R9, RlO, R25 are as previously defined in Claim 79. 134. A compound according to claim 79 wherein I A-Bis —CH.-N *3 R3 is the moiety: O II -CAr wherein Ar is selected from moieties of the formula: Y is 0/ and Ra, Rb, Re, Rl, 2, R3, R , 5, δ, R7, R8, R9, RlO, R25 are as previously defined in Claim 79. 135. A compound according to claim 79 wherein I A-Bis —CH,—N *. R3 is the moiety: O II -CAr wherein Ar is selected from moieties of the formula: Y is NH; and Ra, Rb, Re, Rl, R2, 3, R , 5, 6, 7, Rδ, R9, RlO, R25 are as previously defined in Claim 79. 136. A compound according to claim 88 wherein I A-Bis —CH,,—N *3 R3 is the moiety: O II -CAr wherein Ar is selected from moieties of the formula: and Y, R a , Rb, Re, Rl, R2, R3, 4, 5, 6, 7, R8, R9, R 10, R25 are as previously defined in Claim 88. 137. A compound according to claim 88 wherein I A-Bis —CH-,—N Y is - (CH2) -; and Ra, Rb, Re, l, R2, R3, 4, R5, 6, R7, R8, R9, RlO, R25 are as previously defined in Claim 88. 138. A compound according to claim 88 wherein I A-Bis —CH,—N Y is 0; and Ra, Rb, Re, Rl, 2, R3, 4, R5, Rδ, R7, R8, R9, RlO, R25 are as previously defined in Claim 88. 139. A compound according to claim 88 wherein I A-B is — CH,— Y is NH; and Ra, Rb, Re, Rl, R2, 3, R4» R5, Rδ, R7, R8, 9, RlO, R25 are as previously defined in Claim 88. 140. A comDound according to claim 88 wherein I A-Bis _ CH,— N R3 is the moiety: O II -CAr wherein Ar is selected from moieties of the formula: Y is -(CH2)-; and Ra, Rb, Re, Rl, R2, 3, R , R5, R6, R7, Rδ, R9, RlO, R25 are as previously defined in Claim 88. 141. A compound according to claim 88 wherein A-Bis - r^-N R3 is the moiety: O II -CAr wherein Ar is selected from moieties of the formula and Y is NH; Ra, Rb, Re, Rl, R2, R3, R4, 5, Rδ, R7, Rδ, R9, RlO, R25 are as previously defined in Claim 88. 142. A compound according to claim 88 wherein I A-Bis —CH-.—N *3 R3 is the moiety: O II -CAr wherein Ar is selected from moieties of the formula: and Y is 0; Ra, Rb, Re, Rl, R2, 3, R , R5, δ, R7, 8, R9, RlO, R25 are as previously defined in Claim 88.

Inventors: ALBRIGHT JAY DONALD, DELOS SANTOS EFREN GUILLERMO, VENKATESAN ARANAPAKAM MUDUMBAI, ALBRIGHT, JAY, DONALD, DELOS SANTOS, EFREN, GUILLERMO, VENKATESAN, ARANAPAKAM, MUDUMBAI
Applicants: AMERICAN CYANAMID CO, AMERICAN CYANAMID COMPANY
Application year: 1996
Main classification: C07D223
IPC codes: A61K31, A61P13, A61P15, A61P43, C07D223, C07D243, C07D267, C07D401, C07D405, C07D409, C07D413, C07D471, C07D487, C07D495, C07D498, C07D513